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Chapter 1
Introduction: Protein Posttranslational Modification
(Portions of the text in this chapter were reprinted or adapted from: Senevirathne, C., Green, K.
D., and Pflum, M. K. H. (2009) Kinase-Catalyzed Biotinylation of Peptides, Proteins, and
Lysates, In Current Protocols in Chemical Biology, John Wiley & Sons, Inc. and Suwal, S.,
Senevirathne, C., Garre, S., and Pflum, M. K. (2012) Structural analysis of ATP analogues
compatible with kinase-catalyzed labeling, Bioconjugate chemistry 23, 2386-2391)
Proteins undergo diverse modifications to regulate their functions and stability.(1) Protein
modifications can occur after translation, and are commonly called posttranslational
modifications (PTMs). PTMs enhance the cellular diversity of roughly 30,000 human genes.
More than 100 PTMs have been recognized to date. Fifteen out of 20 amino acid residues have
been identified with various PTMs, which include acetylation, acylation, adenylation, ADPribosylation,

glycosylation,

methylation,

phosphopantetheinylation,

phosphorylation,

prenylation, sulfation, transglutamination, etc.(2) These PTMs influence various cellular
processes, functions and disease formation. With a major role in biological systems,
characterizing PTMs is important to understanding cell biology and disease formation.

1.1 Protein Phosphorylation
Protein phosphorylation was identified more than 100 years ago;(3) enzyme-mediated
reversible phosphorylation was reported in 1954.(4) Kinase-catalyzed protein phosphorylation is
an important PTM occurring in cells.(5) Phosphorylation is involved in a variety of biological
processes including cell signaling, diseases, cancer, and immunosuppression.(6) Proteins kinases
are the enzymes that are responsible for protein phosphorylation, and protein phosphatases are
the enzymes that are involved in dephosphorylation.(5,

7)

In phosphorylation, adenosine 5’-

triphosphate (ATP) acts as a universal phosphate donor and the protein kinase assists in the
transfer of a phosphate group from the γ position of ATP.(8) In eukaryote, phosphorylation
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occurs on the hydroxyl group of serine, threonine, and tyrosine (Scheme 1.1).(9) In addition,
histidine, arginine, and lysine phosphorylation (N-phosphorylation)(10) is possible in procaryote.
When the neutral hydroxyl group is replaced with a negatively charged phosphate group, the
activity of the protein may change, which influences cell biology.(1) At any given time, 30% of
proteins are phosphorylated at serine, threonine, and tyrosine.(5)

Scheme 1.1: Reversible Protein Phosphorylation of Amino Acids Containing Hydroxyl Side
Chains
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1.2 Phosphorylation and Protein Functions
Phosphorylation influences protein activity through a variety of mechanisms. Protein
binding is enhanced upon phosphorylation. For example, p53 is a tumor suppressor
transcriptional activator, which is stabilized after phosphorylation (Figure 1.1).(11) There are 22
phosphorylation sites identified on p53, which influence its stability.(11, 12) Stress signals such as
UV radiation, DNA damage, etc, activate various kinases to phosphorylate p53.(13) This
phosphorylation occurs sequentially, as phosphorylation of serine-15 leads to phosphorylation of
additional sites.(14, 15) Upon phosphorylation, p53 is stabilized and dissociated from its inhibitor
MDM2,(13) and binds to transcriptional activator p300.(16) p53 binding to DNA enhances gene
transcription to protect the cell from stress condition.(17)

Figure 1.1: Stabilization of p53 with Phosphorylation. Stress signals stimulate several kinases
to phosphorylate p53. Upon phosphorylation, p53 is stabilized, translocated to the nucleus, and
bound to DNA, which activates transcription of different genes.
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Another example of protein-protein interactions that are dependent on phosphorylation
involves CREB (cyclic adenosine 3’, 5’-monophosphate responsive element binding) protein and
CBP (CREB binding protein) (Figure 1.2).(18, 19) Upon phosphorylation, the neutral serine-133 on
CREB becomes a negatively charged phosphoserine, which alters its hydrogen bond donor
ability into a hydrogen bond acceptor. Once phosphorylated at serine-133, a hydrogen bond can
form between CREB S-133 and Y-658 on CBP. Phosphorylation at S-133 is critical for
interaction of two proteins, CREB and CBP.(18) The transcriptional activity of CREB is greatly
enhanced upon CBP binding.

Figure 1.2: Phosphorylation of CREB Facilitates Interactions with CBP. Structure of CREB
bound to CBP highlighting phosphoserine 133 (pS133) in red interacting with tyrosine 658
(Y658) in green.
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Kinase-catalyzed phosphorylation also influences cell growth, arrest and apoptosis, by
mediating cell signaling cascades.(20) For example, signaling pathways depend on
phosphorylation to begin neuronal cell growth (Figure 1.3).(21) Binding of neuronal growth factor
(NGF) to TrkA leads to autophosphorylation of tyrosine on TrkA (Neurotrophic tyrosine kinase
receptor type 1).(21) The phosphotyrosine of TrkA then binds to Grb (Growth factor receptorbound protein), which binds to Sos (Son of sevenless). The Ras (protein kinase produced by the
ras gene)/Raf (protein kinase produced by the raf gene)/MEK (Mitogen activated or extracellular
signal regulated protein kinase) pathway is activated by Sos. Activation of the Ras/Raf/MEK
pathway promotes phosphorylation of MAPK (Mitogen activated protein kinase).(22)
Phosphorylated MARK leads to phosphorylation of ELK-1 (E-26 like protein 1) which then
activates the transcriptional machinery for cell growth. MARK can also stimulate p21CIP, which
is responsible for growth arrest. Additionally, the activity of RhoA (Ras homolog gene family,
member A) can increase via activated Ras. Activated RhoA can stop growth arrest by inhibiting
MARK activity toward p21CIP.(21) Although only one example, this kinase signaling pathway
demonstrates the fundamental role of phosphorylation in cell biology. The next section focuses
on the involvement of phosphorylation in disease formation.
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Figure 1.3: Signaling Cascade of Phosphorylation Dependent Cell Growth. NGF binding to
TrkA leads to TrkA autophosphorylation. This phosphorylation results in interaction of the
receptor with various kinases and activation of the Ras/Raf/Mek pathway. Phosphorylated
MAPK initiates phosphorylation of ELK-1, which results in cell growth.
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1.3 Protein Phosphorylation in Disease
A number of kinases and phosphorylation pathways are associated with diseases.
Aberrant phosphorylation levels and elevated kinase activities are responsible for disease
formation, and are highlighted here. As one example, translocation of chromosome 9 and 22
leads to fusion of the Abelson kinase (Abl) gene with the BCR (break point cluster) gene to
produce the Bcr-Abl gene fusion.(23) The Bcr-Abl protein product of this gene fusion has higher
kinase activity than regular Abl kinase, which leads to formation of chronic myelogenous
leukemia (CML).(23-27) Gleevec, an Abl kinase inhibitor and an FDA approved drug, is used to
treat CML.(28)
Additionally, several other kinases are linked with cancer formation, such as casein
kinase 2 (CK2),(29) phosphoinositide 3-OH kinase (PI3K),(30) cellular Src (c-Src),(31) protein
kinase B (PKB),(32) and epithelial growth factor receptor (EGFR).(33) Various other signaling
pathways influenced by kinases are also linked to cancer, including PI3K/PKB, Ras-Raf-ERK,
JAK-signal transducer and activator of transcription (STAT) pathways.(34, 35)

1.4 Kinase inhibitors
Protein phosphorylation and kinase enzymes play critical roles in disease formation.
Hence many pharmaceutical drugs have developed to target kinases (Table 1.1 and Figure 1.4).
A number of FDA approved kinase inhibitors are used to treat a wide range of diseases,
including diabetes, rheumatoid arthritis, cancer, and immunosupression.(6) However cancer is the
most targeted disease. Rapamycin and Everolimus are two natural products that have the same
core structure, and are used to treatment of immunosupression by targeting mTOR.
Staurosporine is a natural product, used as a general kinase inhibitor used in laboratory research
only. Fasudil inhibits ROCK and is used for the treatment of cerebral vasospasms. However, this
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sulphonamide is approved only in Japan. Iressa and tarceva both target EGFR kinase for
treatment of cancer. Nexavar targets Raf-1 for cancer treatment. Axitinib and Sunitinib target
multiple kinases such as VEGFR-1, 2, 3 and PDGFR. Some approved drugs bind to more than
one kinase, which may lead to unnecessary side effects.(6)
The main drawback of kinase inhibitors is their non-specific binding to many kinases.
Because of the highly conserved active sites of kinases, drugs do not generally differentiate
between members of the kinase family. Hence, it is extremely difficult to synthesize molecules
that selectively inhibit a single kinase. Gleevec (Imatinib) which selectively inhibited tyrosine
kinase Bcr-Abl was the first selective kinase inhibitor. Other examples of selective kinase
inhibitors are DRB (5,6-Dichloro-1-β-D-ribofuranosyl benzimidazole) and H8 (N-[2(methylamino) ethyl]-5-isoquinolonesulfonamide), which selectively inhibit CK2 and PKA,
respectively.
Kinase inhibitors show diverse structural features, including riboses, glucoses,
polyketides, sulfonamide, piperazines, and heterocyclic derivatives. With the interest of kinases
as drug targets, understanding their function and structure has been useful.
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Table 1.1: List of FDA Approved Kinase Inhibitors Found in Market (6, 36)

Inhibitor

Kinase
Targeted

Disease

Company

Rapamycin

m-TOR

Immunosuppression Wyeth-Ayerst

Gleevec

Bcr-Abl

Cancer

Novartis

Iressa

EGFR

Cancer

Astra-Zeneca

Tarceva

EGFR

Cancer

OSI Pharm.

Nexavar

Cancer

Bayer

Sunitinib

Raf-1
VEGFR,
PDGFR

Cancer

Pfizer

Crizotinib

ALK, ROS-1

Cancer

Pfizer

Vemurafenib BRAF
VEGFR,
Axitinib
PDGFR

Cancer

Roche

Cancer

Pfizer

Bosutinib

Bcr-Abl, Src

Cancer

Fasudil

ROCK

Pfizer
Asahi Chem.
Cerebral vasospasm Ind

Status
FDA approved
(1999)
FDA approved
(2001)
FDA approved
(2003)
FDA approved
(2004)
FDA approved
(2005)
FDA approved
(2006)
FDA approved
(2011)
FDA approved
(2011)
FDA approved
(2012)
FDA approved
(2012)
Japan approved
(1995)
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Figure 1.4: Structural Diversity of Kinase Inhibitors. Structure of some kinase inhibitors are
shown here. Sturosporine, H8, and DRB are used only in laboratory research. All others are used
in treatment of various diseases (see Table 1.1).
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1.5 Protein Kinases: Family, Structure, and Enzymatic Mechanism
Kinase enzymes catalyze protein phosphorylation. There are over 500 human kinases
known.(37) Protein kinases are classified into two different groups-the serine/threonine protein
kinases (SPK) and tyrosine protein kinases (TPK).(38) These classifications are based on each
enzymes preferred amino acid substrate. There is a third class of kinases that phosphorylate both
serine/threonine and tyrosine side chains, but they not well characterized. One kinase enzyme
can act upon multiple protein substrates.(39) Human kinases are divided into 7 major groups
according to sequence similarities in their catalytic sites (Figure1.5).(37)

Figure 1.5: Main Groups of Human Kinases. Human kinases are mainly divided into 7 major
groups including; aAGC: Containing PKA, PKG, PKC families; CAMK: Calcium/calmodulindependent protein kinase; CK1: Casein kinase 1; CMGC: Containing CDK, MAPK, GSK3,
CLK families; STE: Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases; TK: Tyrosine
kinase; TKL: Tyrosine kinase-like. Other: other kinases not belong to above groups.
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Scheme 1.2: Mechanism of Protein Phosphorylation Illustrated with a Serine Residue

As mentioned in section 1.1, ATP acts as a phosphate donor and binds to the active site
of kinases.(8) The catalytic sites of protein kinases display very similar primary structures.(40)
Generally there are nine conserved amino acids found in kinase catalytic sites,(41) including G52,
K72, Q91, D166, N171, D184, G186, Q208, and R280. Six of these residues stabilize the
triphosphate and three of them interact with the adenine base portion. Within the kinase family,
this core active site structure is conserved.(38) The kinases consist of two domains, which contain
α-helical and β-sheets. The linker portion between the α-helical and β-sheet domains generates
the binding region for the ATP molecule.(42) The α-helical domain contains the substrate binding
site. The substrate binds to the active site of the kinase through interactions with specific amino
acids in the substrate binding site (Figure 1.6).(38) ATP binding to the active site occurs in such a
way that adenine portion points inside the conserved site and its phosphates point away from the
pocket. ATP binding brings the α-helical and β-sheet domains in close proximity to facilitate
tight binding of ATP as well as binding of the protein substrate to the kinase.(43) Hence, the
protein kinase forms a ternary complex with its protein substrate and ATP cosubstrate in close
proximity to achieve enzymatic phosphorylation.(8) ATP cosubstrate binding is stabilized by two
divalent metal ions, either Mg2+ or Mn2+, which chelate with charged amino acid residues within
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the catalytic site (Figure 1.6).(38) D166 acts as a base during the kinase reaction by removing
hydrogen from the hydroxyl group on the protein substrate, to making it nucleophilic.(38) The
interactions between the metal ion and oxygen atoms in the phosphoryl group hold the ATP
appropriately for nucleophilic attack of the γ-phosphate by the substrate hydroxyl. This produces
a phosphorylated substrate and ADP as a byproduct (Scheme 1.2).
The enzymatic phosphorylation mechanism has two possibilities (Figure 1.7).(44, 45) First,
an associative mechanism was proposed,(46) which is similar to an SN2 (bimolecular nucleophilic
substitution) type mechanism. In the associative transition state, bonds between the nucleophilic
oxygen of the substrate and the γ-phosphate of ATP are formed simultaneously with the ADP
leaving group still connected (Figure 1.7 A). Interestingly, recent experimental evidence has
been more consistent with a dissociative type transition state for phosphorylation,(44,45,47) similar
to SN1(unimolecular nucleophilic substitution) type reaction. In the dissociative transition state,
the ADP leaving group departs in advance of nucleophilic oxygen attack on the electrophilic γphosphate of ATP (Figure 1.7 B). Currently, the dissociative mechanism is considered the most
appropriate for many kinases.(44, 45, 47)
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A

B

Figure 1.6: Crystal Structure of PKA with Amino Acid Residues. (A) Crystal structure of
PKA with peptide substrate inhibitor and Solvent expose ATP. (B) Kinase-catalyzed
phosphorylation mechanism showing the major interaction of PKA enzyme with protein
substrate, ATP and metal ions with side chains (GenBank ID 6755076, PDB 1ATP).
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Figure 1.7: Proposed Associative vs Dissociative Phosphorylation Mechanism. (A) The
leaving group and incoming nucleophile remain attached to the reactive center in an associative
mechanism. (B) The leaving group departs in advance of nucleophile attack at the reactive center
in a dissociative mechanism.

The peptide or protein substrate must contain a consensus sequence that can be
recognized by a specific kinase.(38) Phosphorylation occurs when the consensus sequence of the
substrate is recognized by the appropriate protein kinase, which directs phosphorylation of the
serine, threonine, or tyrosine within the consensus sequence. Generally, the amino acids
immediately surrounding the phosphorylated residue are critical for kinase recognition.
Consensus sequences for many kinases are known and indicate that specific kinases can
recognize basic, acidic, hydrophobic or proline residues to direct phosphorylation (Table 1.2).
For example, Abl protein kinase is a tyrosine kinase with a hydrophobic consensus sequence of
I/V/L-Y-X-X-P/F (X represents any amino acid).(48) Casein Kinase II (CK2) is a serine/threonine
kinase with an acidic consensus sequence of S/T-X-X-D/E.(49) Another serine/threonine kinase,
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c-AMP dependent protein kinase (PKA) prefers to phosphorylate peptides having a basic amino
acid consensus site of R-R/K-X-S/T.(50)
Table 1.2: Consensus Sequence of Selected Protein Kinases
Kinase
Abl
AKT1
Aurora-A
CDK 1
CHK 1
CK2
ERK 1
GRK 5
GSK 3
PKA
SRC

Consensus sequence(51)
I/V/L-Y-X-X-P/F
R-X-R-XX-S/T
R/K/N-R-X-S/T-B
S/T-P-X-R/K
R-X-X-S/T
S/T-X-X-D/E
P-X-S/T-P
D/En-S/T-X-X-X
X-S/T-X-X-X-Sp
R-R-X-S/T-Y
E-E-I-Y-E/G-X-F

1.6 Kinase cosubstrate promiscuity
1.6.1: ATP-γS
Many PTM enzymes show cosubstrate promiscuity.(52-73) Indeed, kinases also show
cosubstrate promiscuity with different ATP analogs. The first reported kinase cosubstrate analog
was adenosine 5’-[γ-thio]-triphosphate (ATP-γS).(74, 75) ATP-γS is an analog of ATP where O is
replaced by S at the γ-phosphate. ATP-γS acts as a cosubstrate for many kinases, making a
thiophosphorylated product (Figure 1.8). The reactivity of thiol on phosphate is used for identify
and purify of thiophosphorylated products. A similar phosphorylation mechanism to ATP occurs
with ATP-γS, with hydroxyl attack on the γ-phosphate group producing a thiophosphorylated
product and the byproduct ADP. However, kinetic analysis with ATP-γS showed low catalytic
efficiency compared to ATP,(76-79) known as the thio effect.
efficiency, ATP-γS is widely used in the proteomic field,(76,

Despite the poorer catalytic
80-83)

due to the stability of
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thiophosphorylated proteins towards phosphatases,(74,

84-86)

which can lead to identification of

low abundance proteins.

Figure 1.8: Kinase-Catalyzed Phosphorylation with ATP-γS. Serine, threonine, or tyrosine
hydroxyl groups on proteins attack the γ-thiophosphate group on ATP-γS to label proteins with a
thiophosphoryl group.

In addition to the ATP-γS analog, another class of ATP analogs was synthesized for
selective phosphorylation with specific kinases (Figure 1.9).(82, 83) In this case, the ATP analog is
modified at both the γ-phosphate group and the adenine base. Kinases were mutated to
selectively bind the base modified ATP analogs. This method was used for specific purification
of substrates for MS analysis (more details discussed in chapter 4).(87) This method was
developed by Shokat and coworkers,(82,

83)

and was used to identify substrates for a specific

kinases. The method has been applied to various engineered kinases to identify their substrates.

As a significant extension of the ATP-γS analog, the Pflum lab was interested in adding
large groups at the γ-phosphate ATP for kinase transfer. The crystal structures of many protein
kinases have been reported, such as those for PKA, CK2 and Abl(88-90). Analyses of crystal
structures of protein kinase active sites showed that the γ-phosphate of ATP is solvent-exposed
(Figure 1.6). With this analysis, we hypothesized that other γ-phosphate modified ATP analogs
should act as kinase cosubstrates. In fact, our group showed that several γ-phosphate modified
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ATP analogs act as cosubstrates for kinase-catalyzed phosphorylation,(91-93) as discussed bellow.
These analogs can be used to understand and characterize cell signaling pathways leading to
disease.

Figure 1.9: Phosphorylation of modified ATP-γS with Mutant Kinase. Cell lysates were
incubated with mutant kinases and modified N6-Benzyl-ATP-γS. Substrates for the mutant
kinase were labeled as thiophosphorylated products. Thiophosphorylated products were purified
and identified by MS analysis (more details discussed in chapter 4).
1.6.2: ATP-biotin
To initially validate the cosubstrate tolerance of kinase, we performed kinase-catalyzed
biotinylation with an ATP-biotin analog, along with recombinant kinases and peptide substrates
(Figure 1.10).(91) Establishing that a kinase of interest is compatible with ATP-biotin was
necessary before visualizing phosphoproteins from a complex cellular mixture. Commercially
available ATP-biotin was incubated with three synthetic peptides containing either serine
(LRRASLG),

threonine

corresponding kinase

(RRREEETEEE),

PKA, CK2,

or

and Abl,

tyrosine

(EAIYAAPFAKKK)

respectively. Similar to

and

the

biotinylation,

phosphorylation was performed with ATP as a control reaction. To determine the success of the
biotinylation reaction with the peptide substrates, a quantitative mass spectrometric (MS)
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analysis method was performed. The relative conversion percentages were calculated, assuming
reactions with ATP to be 100% complete (Table 1.3). This initial experiment provided evidence
for the cosubstrate promiscuity of kinases.(91, 94)

Figure 1.10: Kinase-Catalyzed Biotinylation. Peptides or proteins modified with a
phosphorylbiotin group upon biotinylation with ATP-biotin in the presence of kinases. See Table
1.3 for the structure of ATP-biotin.

With the success of peptide labeling using ATP-biotin, the tolerance of kinases to ATPbiotin was further tested with full length protein substrates. Kinase-catalyzed biotinylation was
performed with ATP-biotin, CK2 and a full-length protein substrate (β-casein). Biotinylation of
full-length protein substrates was analyzed using gel electrophoresis followed by visualizing the
biotin tag using an SA-HRP (Streptavidin-horseradish peroxidase) conjugate. The biotinylation
reaction was validated by observing biotin on the protein product after gel analysis.(91) In
addition to labeling known substrates of a specific kinase in vitro, the labeling of substrates in
mammalian cell lysates provides a physiologically relevant means of monitoring kinase activity.
We found that ATP-biotin collaborates with cellular kinases to biotinylate endogenous substrates
in HeLa cell lysates.

(91)

The results suggest that kinase-catalyzed biotinylation is generally

successful using mammalian cell lysates to probe endogenous cellular kinases and substrates.
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Table 1.3: Kinase-catalyzed labeling with previously reported ATP analogs (91-93)

1.6.3: ATP-dansyl
With the success of kinase-catalyzed biotinylation, we were interested in testing the
compatibility of kinases with other γ-phosphate modified ATP analogs. To test additional analog
compatibility, commercially available ATP-dansyl was employed (Figure 1.11).(92) Like ATPbiotin, ATP-dansyl was incubated with peptides in the presence of their corresponding kinase
PKA, CK2 and Abl, respectively. Quantitative MS analysis was used to analyze the efficiency of
dansylation compared to phosphorylation (Table 1.3). These data indicated that ATP-dansyl was
also successfully used as a cosubstrate for kinase-catalyzed phosphorylation.(92)
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Figure 1.11: Kinase-Catalyzed Dansylation. Peptides modified with a phosphoryldansyl group
upon dansylation with ATP-dansyl in the presence of kinases. See Table 1.3 for structure of
ATP-dansyl.

With the success of the kinase-catalyzed dansylation of peptides, we further characterized
the reaction by conducting kinetics measurements. Using an absorbance assay, (95,

96)

measurements with PKA were taken in the presence of ATP vs. ATP-dansyl as cosubstrates.
ATP-dansyl maintained a similar KM value of 23 μM, compared to 24 μM KM of ATP, indicating
γ-phosphate modification did not alter the active site binding. In terms of kcat, ATP-dansyl had a
9-fold reduced value compared to ATP, indicating that dansylation is slower than
phosphorylation.(92) These results indicate that kinases permissively accept ATP analogs
containing different functional probes, opening the door for the use of multiple γ-phosphate
modified ATP analogs in kinase-catalyzed phosphoprotein labeling reactions.
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1.6.4: ATP-arylazide
Kinase-catalyzed biotinylation and dansylation demonstrated the promiscuity of kinases
towards the γ-phosphate modified ATP analogs. To increase the applicability of γ-phosphate
modified ATP analogs as a biological tool, we created an ATP analog containing a
photocrosslinking group attached at the phosphate (ATP-ArN3) to covalently link
phosphoproteins to kinases in a phosphorylation-dependent manner (Figure 1.12).(93) To
understand the compatibility of this photocrosslinker, the kinase reaction was performed with
synthetic peptides as describe earlier. As was observed with ATP-biotin and ATP-dansyl, ATPArN3 served as a kinase cosubstrate with high conversion percentages (Table 1.3).(93)

Figure 1.12: Kinase-Substrate Crosslinking with ATP-arylazide. Protein substrates are
crosslinked with enzymes upon phosphorylation with ATP-arylazide under UV irradiation. See
the Table 1.3 for structure of ATP-arylazide.
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To test if the analog would promote crosslinking of the kinase to substrate, we used
phosphorylation of casein by CK2 as a model system. SDS-PAGE and western blot analysis
were used to identify the kinase-substrate complex. Upon UV irradiation, photocrosslinking with
ATP-ArN3 resulted in the appearance of higher molecular weight species consistent with
crosslinked complexes of kinase and substrate.(93) In contrast, no higher molecular weight spots
were observed with ATP under the same conditions. To assure that the higher molecular weight
species was phosphorylation dependent, the phosphoramidate bond connecting the substrate and
kinase was cleaved using acid treatment. As expected, the higher molecular weight species was
reduced after TFA cleavage.(93) In addition, an antibody specific to the catalytic subunit of CK2
recognized the higher molecular weight species indicated the presence of CK2.(93) All these
observations support the formation of kinase substrate crosslinked products via kinase dependent
phosphorylation with ATP-ArN3.(93)
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Figure 1.13: Diversity of γ-Phosphate Modified ATP Analogs. Structures of ATP analogs
containing various detection tags are shown here. Applications of all these individual compounds
were discussed in the text.
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1.6.5: ATP-BODIPY
In addition to the ATP analogs studied in the Pflum lab, recently different types of γphosphate modified ATP analogs were reported (Figure 1.13). ATP-BODIPY, γ-phosphate
modified ATP, was used to label protein in an activity-dependent manner.(97) In this specific
case, histidine residues on histidine kinase were autophosporylated with extracellular signal.
Then the aspartic acid of response regulator protein attacked phosphate group of histidine kinase.
Hence the detection of phosphorylation event is important to understand the activity of histidine
kinases. However the phosphoamidate bond on phosphor-histidine is much more labile with very
short half-life.(98) Therefore a fluorophore was attached to the ATP using a sulfur atom instead
nitrogen (Figure 1.14),(97) which formed a more stable intermediate. This ATP-BODIPY showed
competitive binding with ATP, and was applied to measure the activity of histidine kinase
catalyzed phosphorylation (Figure 1. 14).(97)

Figure 1.14: Autophosphorylation of Histidine Kinase with ATP-BODIPY. Histidine kinase
undergoes autophosphorylation with ATP-BODIPY (See Figure 1.13 for structure) to label the
histidine residue with fluorescent modification upon stimulation, with subsequent transfer of the
modification to the aspartic acid of response regulator.
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1.6.6: ATP-ferrocene
ATP-ferrocene was also successfully used in phosphorylation reactions to transfer the
ferrocene-phosphate group to peptide or protein substrates (Figure 1.15).(99) This modification
was detected electrochemically and with anti-ferrocene antibodies. Additionally, γ-phosphate
modified ATP analogs were shown to compete with ATP for kinase binding.This analog was
used to monitor the activity of kinases and identification of kinase inhibitors.(99)

Figure 1.15: Kinase-Catalyzed Phosphorylation by ATP-ferrocene. Peptides or proteins were
labeled with ferrocene-phosphate modification upon phosphorylation with kinase and ATPferrocene (See Figure 1.13 for structure). The ferrocene-phosphate modification can be identified
by antiferrocene antibodies.
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1.6.7: ATP-acyl-biotin
Beyond substrate labeling, γ-phosphate modified ATP analogs were also used to label
and identify kinases in complex mixtures.(100, 101) This method is based on ATP binding to the
active site of kinases. With few exceptions, protein kinases have two conserved lysine residues
near the active site.(37,

90, 102)

One can be found in the ATP binding region, while the other is

found near the C-terminus. In addition, co-crystal structures of kinases indicated that these lysine
residues are close to the γ- and β-phosphates of ATP.(90) Hence this method was able to identify
most protein kinases. Once ATP-acyl-biotin is bound to the kinase, the acyl-phosphate group is
positioned towards a conserved lysine residue in the active site, allowing the amine on lysine to
attack the acyl group to release ATP. The reaction forms a covalent bond between kinase and
biotin tag through an amide bond (Figure 1.16).(100, 101) Then the proteins were digested, purified
with streptavidin beads, and identified by MS/MS analysis. This method was also used to
identify kinase inhibitors.(101)

Figure 1.16: Strategy of Kinase Labeling by ATP-Acyl-Biotin. The modified ATP analog
binds to the kinase active site and a conserved lysine residue in the kinase attacks the acyl group,
leading to labeling the kinase with biotin.
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1.7 Significant and Highlight of the Projects
During phosphorylation, the neutral hydroxyl group is replaced by a negatively charged
phosphate group, which strongly influences protein activity within cells.(20) Hence
characterization of the phosphorylation events and phosphorylated amino acids is useful to study
protein function in vivo. This posttranslational modification affects various processes in cell
biology including, protein shape, function, activity, protein-protein interaction, and cell signaling
cascades.(1, 37, 103) With a significant role in biochemical functions, it is important to understand
phosphorylation. Techniques to understand and monitor phosphorylation involve radiolabel with
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P,(104) immobilizing metal affinity chromatography,(105) covalent modifications of the

phosphate,(106) phosphate staining, such as with Pro-Q diamond stain,(107) and visualization using
specific antibodies.(108) Besides these methods, the Pflum lab has developed the use of γmodified ATP analogues as tools for studying phosphorylation.(91-93) These methods are
discussed further in chapters 2 and 4.
Based on kinase cosubstrate promiscuity, several kinase-catalyzed labeling methods have
been reported. We aim here to characterize the kinase-catalyzed labeling as a biological tool in
proteomic research. First, we explored the generality of kinase cosubstrate promiscuity by testing
biotinylation with 26 kinases throughout the kinome phylogenetic tree. Using the ADP-Glo assay
with peptide and protein substrates (Promega), all kinases maintained reasonable conversions
with ATP-biotin, with most displaying only modestly reduced catalytic efficiencies (kcat/KM)
compared to ATP (Chapter 2). To characterize the scope and limitations of the biotinylation
reaction, we probed the sensitivity of biotinylated phosphoproteins to phosphatases. Our goal
was to ultimately apply the biotinylation reaction to phosphoproteomics, making an
understanding of phosphobiotin stability in lysates critical. We found that the modification is
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resistant to both Ser/Thr and Tyr phosphatases (Chapter 3). These results argue that the stable
biotin tag will facilitate identification of low abundance phosphoproteins. Given the generality of
kinase-catalyzed biotinylation and stability to phosphatases, finally, we applied kinase-catalyzed
biotinylation to phosphoprotein identification using MS analysis. We compared avidin
purification to the widely used titanium oxide (TiO2) affinity chromatography. In addition,
kinase-catalyzed biotinylation captured full-length phosphoproteins, which is not possible with
TiO2 chromatography. The significant conclusion is that kinase-catalyzed biotinylation is well
suited for low abundance phosphoprotein detection and complements existing methods to
provide a more complete view of the phosphoproteome (Chapter 4).
The enzymatic reactions with ATP-biotin, ATP-danzyl, ATP-ArN3, and other analogs
established that kinases promiscuously accept γ-phosphate modified ATP analogs as
cosubstrates. By studying both kinases and phosphatases, kinase-catalyzed labeling experiments
will build a more detailed and complete picture of the complex cell signaling pathways
governing disease. In total, the chemical tools established with different ATP analogs will
provide innovative and unprecedented approaches to monitor the role of phosphorylation in
biology.
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Chapter 2
The Generality of ATP-biotin as Kinase Cosubstrate
(Portions of the text in this chapter were reprinted or adapted from: Senevirathne, C., Green, K.
D., and Pflum, M. K. H. (2009) Kinase-Catalyzed Biotinylation of Peptides, Proteins, and
Lysates, In Current Protocols in Chemical Biology, John Wiley & Sons, Inc. and Senevirathne,
C., and Pflum, M. K. (2013) Biotinylated Phosphoproteins from Kinase-Catalyzed Biotinylation
are Stable to Phosphatases: Implications for Phosphoproteomics, Chembiochem: a European
journal of chemical biology 14, 381-387)
In this chapter we focus on a systematic study of the labeling of substrates with ATPbiotin in a kinase dependent manner. The Pflum lab recently discovered the utility of γ-modified
ATP analogues as tools for studying phosphorylation.(91-93) We found that kinases promiscuously
accept γ-modified ATP analogs as cosubstrates (Chapter 1). Here we explore the generality of
ATP-biotin with a variety of recombinant kinases, showing that 26 kinases accept ATP-biotin as
cosubstrate and can be used for protein labeling. The kinetic data indicate that kinase-catalyzed
biotinylation occurs with catalytic efficiency appropriate for phosphoproteomics application. A
summary of phosphoprotein detection and identification methods is also discussed in this
chapter.

2.1 Current Methods Used to Identify Phosphopeptides and Phosphoproteins
Historically, 2-D gel analysis has been used to detect phosphoproteins. In this method,
proteins are separated by their isoelectric points (pI), followed by their molecular weight (Figure
2.1). Differences in the pI and size of the proteins are seen between phosphorylated and
unphosphorylated proteins. Due to these differences, the shifted proteins can be isolated and
characterized.(109, 110) However, 2-D analysis is challenging with proteins that are highly acidic,
basic, too large, too small, highly hydrophobic or additionally modified (other posttranslational
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modification, e.g. sulfation), which can cause a non-phosphorylation dependent shift in pI and
molecular weight. (111, 112)

Figure 2.1: Theory of Two-Dimensional Gel Electrophoresis. Proteins are separated by
isoelectric point followed by molecular weight. Treated protein sample (top) is compared to
untreated sample (bottom). The shifted proteins in the treated sample (red circled) are digested
and analyzed by MS/MS analysis.
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Another classic method to identify protein phosphorylation involves radioactive labeling
with

32

P-labeled ATP with subsequent visualizing of the

32

P labeled phosphoproteins by

autoradiography.(104, 113) With the in vivo method, radiolabelled inorganic phosphate (32Pi) is used
to metabolically incorporate into ATP, which undergoes phosphorylation to label
phosphoproteins. ATP-γ32P is directly used with lysates to label phosphoproteins. The method is
not efficient since the

32

P labeled ATP competes with the natural ATP. In addition, large

amounts of radioactive material are required, making the method hazardous. Hence, less
hazardous ATP-γ35S has become popular with phosphoproteins labeling.(83)
Phosphoprotein-specific

detection

using

Pro-Q

Diamond

phosphoprotein

stain

(Invitrogen)(107) and western blotting (108) are also used widely. Pro-Q is a fluorescent stain which
detects phosphate groups at serine, threonine and tyrosine within SDS-polyacrylamide gels.
Generally, Pro-Q stain is coupled with total protein detection using SYPRO Ruby stain for better
quantification. Pro-Q Diamond phosphoproteins detection does not required any antibody or
hazardous radioactive material. In additon, Pro-Q Diamond is compatible with MS analysis,
which is an advantage of this phosphoproteins detection.(114) Western blotting requires generation
of specific antibody reagents for each phosphoprotein of interest, making it less appropriate for
visualizing all phosphoproteins in a complex mixture.(110,

115)

For phosphoproteomics

applications, antibodies recognizing a single phosphotyrosine amino acid have been used
successfully, while the poor binding affinity of antibodies recognizing phosphoserine or
phosphothreonine has limited their use.(110, 115)
Mass spectrometric (MS) analysis is also widely used to identify protein
phosphorylation.(116-118) In MS analysis, a phosphorylated peptide within 80 Da greater mass
would be expected, which facilitates its identification.(119) MS analysis can be coupled with

33

different separation systems and mass analyzers to increase sensitivity and accuracy.(120,

121)

Despite many improvements, MS has limitations. For example, the ion suppression of charged
phosphates in MS analysis results in difficulty detecting phosphopeptides in complex
mixtures.(122) To minimize the influence of ion suppression, unphosphosphorylated peptides are
often removed from the mixtures prior to MS analysis. As a result, multiple phosphopeptide
purification methods have been developed to enhance phosphoproteomics analysis (see Chapter
4 for more details).
2.2 Kinase-Catalyzed Biotinylation
While a variety of methods are available to visualize phosphoproteins in complex
mixtures, each method has its strengths and weaknesses, making the development of alternate
strategies of interest. To provide an alternative, the Pflum lab has reported use of γ-modified
ATP analogues as tools for studying phosphorylation. In particular, we demonstrated that an
ATP analogue with biotin attached to the γ-phosphate (ATP-biotin) acts as a cosubstrate for
kinases and transfers biotin along with the phosphate group onto peptides and proteins (Figure
2.2).(91) The biotinylation reaction was successful with synthetic peptides and full-length protein
substrates. Importantly, kinase-catalyzed biotinylation was successfully applied to cell lysates.
The availability of a facile means of biotin-labeling phosphoproteins and phosphopeptides in
complex mixtures using kinases as the catalyst represents a useful method to detect
phosphoproteins. In this chapter, we focus on the systematic study of the generality of ATPbiotin with recombinant kinases.
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Figure 2.2: Kinase-catalyzed biotinylation. (A) Chemical structure of ATP 1 and γ-modified
ATP analogues ATP-biotin 2 are shown. (B) Peptides or proteins (3) undergo biotinylation with
a kinase and ATP-biotin (2) to create biotinylated phosphopeptide (4), which can be subjected to
avidin purification. The phosphoamidate bond is cleaved with acid to yield phosphopeptides or
phosphoproteins (5).
To characterize the generality of ATP-biotin for future applications, a diverse set of
kinase substrate pairs were selected from the human kinome. There are over 500 human kinases
are known up to date. These protein kinases are divided into different groups, families and
subfamilies according to the sequence similarity (Figure 1.5).(37,

102)

Kinases are mainly

categorized into seven groups and oriented as a kinome tree (Figure 2. 3),(37) which represents
the catalytic domain sequence similarity between kinases. Deviation of the sequence of two
kinases is represented by the distance within the branches. Twenty-six kinases were selected to
maximize kinome representation, as it is impossible to test all human kinases. Depending on the
availability of kinase substrate pair, at least one kinase from each group was selected (Figure 2.3
and Table 2.1). Twenty-six kinases were selected from different places on kinome tree to
increase the diversity and kinase representation (Figure 2.3 and Table 2.1). Different ranges of
substrates were selected including, peptides, poly-peptides, and proteins (Table 2.4). Hence
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selected kinases and their substrates display the diversity of enzyme-substrate pairs and better
human kinase illustration.

Figure 2.3: Human Kinome Tree. Selected Kinase for labeling and kinetic analysis in the
human kinome is highlighted in red. The figure is obtained from Manning et al. 2002, Sci, 298,
5600. Illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com).
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Table 2.1: Selected Protein Kinase from Human Kinome Tree for Study with ATP-biotin
Type
Groupa
Abl
Tyrosine
TK
AKT1
Serine/Threonine
AGC
ASK1
Serine/Threonine
STE
Aurora A
Serine/Threonine
Other
CAMK4
Serine/Threonine
CAMK
CDK1
Serine/Threonine
CMGC
CHK1
Serine/Threonine
CAMK
CK1
Serine/Threonine
CK1
CK2
Serine/Threonine
CMGC
DAPK1
Serine/Threonine
CAMK
ERK1
Serine/Threonine
CMGC
FLT1
Tyrosine
TK
GRK5
Serine/Threonine
AGC
GSK3β
Serine/Threonine
CMGC
HIPK1
Serine/Threonine
CMGC
JAK3
Tyrosine
TK
MARK1
Serine/Threonine
CAMK
MLK1
Serine/Threonine
TKL
MST1
Serine/Threonine
STE
NEK 2
Serine/Threonine
Other
PAK1
Serine/Threonine
STE
PKA
Serine/Threonine
AGC
RSK1
Serine/Threonine
AGC
SRC
Tyrosine
TK
TGFβR2
Serine/Threonine
TKL
TRKA
Tyrosine
TK
a
AGC: Containing PKA, PKG, PKC families; CAMK: Calcium/calmodulin-dependent protein
kinase; CK1: Casein kinase 1; CMGC: Containing CDK, MAPK, GSK3, CLK families; Other:
other kinases; STE: Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases; TK: Tyrosine
kinase; TKL: Tyrosine kinase-like.
Kinase
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In this chapter, we focus on the general use of ATP-biotin with variety of recombinant
kinases. However, a systematic study of ATP-biotin with kinases has not reported yet.
Phosphoprotein labeling and monitoring using promiscuous kinase-catalyzed biotinylation will
advance the proteomic field.

2.2.1 Synthesis of ATP-biotin
Initially the Pflum lab used commercially available ATP-biotin for biotinylation studies
(Chapter 1, section 1.7.2). To study the generality of kinase-catalyzed biotinylation, we
synthesized ATP-biotin 2 (Scheme 2.1) using a similar strategy as previously published.(93)
Commercially available biotin 6 was activated by TBTU, and then treated with 4, 7, 10-trioxa-113-tridecanediamine 7 to yield biotin amine 8. Biotin amine 8 was then coupled with the
disodium salt of ATP using EDCI in water while maintaining the pH between 5.6-5.8 to give
ATP-biotin 2. Intermediate biotin amine 8 and the final ATP-biotin 2 were characterized by
HRMS, 1H, 13C and 31P NMR (Figures A 2.1-2.9). The synthesized ATP-biotin analog has two
extra methylene in linker compared to the commercially available ATP-biotin analogue used in
previous work.(91)
Scheme 2.1: Synthesis of ATP-biotin
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2.2.2 Labeling of Peptides with ATP-biotin
From previous studies, we have shown that three different recombinant kinases (PKA,
CK2 and Abl) successfully utilized different γ-modified ATP analogs (ATP-biotin, ATP-danzyl,
and ATP-arylazide).(91-93) However no analog has been tested with additional kinases. With the
ability to label and purify with avidin, the ATP-biotin analog was selected for systematic
analysis with various kinases. Kinase-catalyzed biotinylation was studied with commercially
available peptides containing either serine, threonine, or tyrosine along with 10 different
recombinant kinases, AKT1, CAMK4, CHK1, FLT1, GSK3β, MARK1, MST1, PAK1, RSK1
and SRC (Table 2.1). Biotinylated phosphopeptides were created by incubating ATP-biotin with
AKT1

and

AKT(PKB)

substrate

(CKRPRAASFAE),

CAMK4

and

Autocamtide

(KKALRRQETVDAL-amide), CHK1 and CHKtide (KKKVSRSGLYRSPSMPENLNRPR),
FLT1 and IGF1Rtide (KKKSPGEYVNIEFG), GSK3β and GSK3 peptide substrate
(YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE),

MARK1

and

CHKtide

(KKKVSRSGLYRSPSMPENLNRPR), MST1 and Axltide (KKSRGDYMTMQIG), PAK1 and
PAKtide (RRRLSFAEPG), RSK1 and S6K substrate (KRRRLASLR), or SRC and SRC
substrate (KVEKIGEGTYGVVYK-amide) in the manufacturer provide buffer (1X, Promega).
As a control, the phosphorylation reaction with ATP was also performed. To unambiguously
show that biotinylation is kinase-dependent, at the same time ATP-biotin was also incubated
with peptide substrates without kinase. The reaction products were separated with 16% Tristricine peptide gels (Biorad) and transferred to PVDF membrane. Peptides were visualized with
coomassie stain, which indicated equal loading of peptides in each lane (Figure 2.4, top gels for
each kinase). Biotinylated peptides were visualized with SA-Cy5 conjugate (Figure 2.4, bottom
gels for each kinase). The results indicate that all ten kinases successfully transferred the
phosphorylbiotin group to the peptide substrates (Figure 2.4, bottom gels, lane 3). As expected,
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no biotin labeling was observed in the absence of kinases (Figure 2.4, bottom gels, lane 1)
indicating that biotinylation occurred through a kinase-catalyzed pathway. These data
demonstrate that ATP-biotin is compatible with several kinases and their corresponding peptide
substrates.

Figure 2.4: Labeling of Peptides using ATP-biotin. Peptides were subjected to kinasecatalyzed biotinylation. The reactions were separated on 16% Tris-tricine gel and visualized by
Coomassie Stain (top gel images for each kinase) and SA-Cy5 (bottom gel images for each
kinase). Reaction contents are indicated above the lanes. Full gel images can be found in
appendix Figure A 2.10.
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2.2.3 Labeling of Proteins with ATP-biotin
With successful peptide labeling with ATP-biotin and various kinases, our next goal was
to label full-length proteins with additional kinases. Previously, Dr. Green used β-casein and
CREB full-length protein substrate with CK2 and PKA enzymes in successful biotinylation
reactions. In our systematic study of ATP-biotin with kinases, we used 16 additional kinases and
their corresponding protein substrates. Phosphorylated proteins or biotinylated phosphoproteins
were created by incubating ATP or ATP-biotin with Abl, ASK1, Aurora A, DAPK1, ERK1,
HIPK1, MLK1, or TGFβR2 with Myelin basic protein (MBP), CDK1 with Histone H1 protein,
CK1 with dephosphorylated Casein protein, CK2 and GRK5 with β-Casein protein, and JAK3,
and TRKA with poly (Glu4, Tyr1) peptide substrate in the manufacturer provide buffer (1X,
Promega). To verify that labeling is kinase-catalyzed, ATP-biotin was incubated with protein
substrate only. Crude reaction mixtures were separated by 16% SDS-PAGE and transferred to a
PVDF membrane. Proteins were visualized with Sypro Ruby Stain (Figure 2.5, top gels for each
kinase) and biotinylated proteins with SA-Cy5 conjugate (Figure 2.5, bottom gels for each
kinase).
The results are shown in Figure 2.5 and Figure 3.5, and indicate that all the 16 kinases
were compatible with ATP-biotin as a cosubstrate. Similar to the peptide labeling, protein
labeling with ATP-biotin was observed in the presence of kinase (Figure 2.5, bottom gels, lane
3). Incubating ATP-biotin with full-length proteins in the absence of kinases did not show biotin
labeling with SA-Cy5 (Figure 2.5, bottom gels, lane 1), indicating no kinase-independent
reaction between ATP-biotin and protein substrates, confirming that the labeling is kinasemediated. The conclusion of the labeling experiments is that kinases promiscuously accept ATPbiotin as a cosubstrate. This study used peptides, poly-peptides, and proteins as cosubstrates with
26 different kinase enzymes, which represent the human kinome. The data indicated that the all
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the 26 kinases tested here were able to accommodate ATP-biotin in kinase-dependent
phosphorylation and labeled their corresponding peptide, polypeptide, and protein substrates.

Figure 2.5: Labeling of Proteins using ATP-biotin. Proteins are subjected to kinase-catalyzed
biotinylation with ATP-biotin and 16 recombinant kinases. The reactions are separated on 16%
SDS-PAGE and visualized by Sypro Ruby Stain (top gels) and SA-Cy5 (bottom gels). Reaction
contents are indicated above the lanes. Gel images for Abl, CK2, and PKA can be found in
Figure 3.5. Full gel images can be found in appendix Figure A 2.11 and Figures A 3.4, 3.5, 3.6.
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2.2.4 Quantification of Biotinylation-HPLC Analysis
The results of the previous sections indicate that many kinases can utilize ATP-biotin and
can be used to label peptides, poly-peptides, and proteins. Next we were interested in
determining the efficiency of these biotinylation reactions compared to phosphorylation. In prior
work, quantitative MS analysis was used to determine the efficiency of biotinylation with
peptides and proteins.(91-93) However this time we quantified the reaction using HPLC analysis
with peptides and gel analysis with proteins (discussed in section 2.2.5). Phosphorylated peptides
or biotinylated phosphopeptides were created by incubating ATP or ATP-biotin with Abl and
Abl

peptide

substrate

(EAIYAAPFAKKK),

AKT1

and

AKT(PKB)

substrate

(CKRPRAASFAE), CAMK4 and Autocamtide (KKALRRQETVDAL-amide), CK2 and CK2
peptide (RRREEETEEE), FLT1 and IGF1Rtide (KKKSPGEYVNIEFG), GSK3β and GSK3
substrate (YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE), PAK1 and PAKtide (RRRLSFAEPG),
PKA and kemptide (LRRASLG), RSK1 and S6K substrate (KRRRLASLR), or SRC and SRC
substrate (KVEKIGEGTYGVVYK-amide) in the manufacturer provide buffer (1X, Promega).
After each kinase reaction, the crude mixtures were analyzed by HPLC (Figure 2.6 and
Appendix A, section 2.4). As the HPLC buffer was acidic (~pH=2), the phosphoamidate bond
was broken to yield a phosphopeptide after the biotinylation reaction. This bond cleavage is
possible as the reaction mixture was heated to denature the kinase (95 °C, 1 min) and
equilibrated with the acidic HPLC buffer prior to injection. However, without heat deactivation
or acidic pre-equilibration, unreacted ATP-biotin was seen without loss of the phosphoamidate
bond breaking (retention time 10.3 min, Figure A 2.49, top).On the other hand phosphoamidate
bond cleavage was still observed with the peptides, yielding a phosphopeptide product (Figure A
2.49, bottom). The biotin-amine, cleaved product was also observed (retention time 12.6 min,
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Figure A 2.4 and 2.7). Cleavage of phosphoamidate bond on peptides is more facile and can be
explained by mechanism through neighboring group participating (Figure A 2.50).
HPLC analysis indicated that peptide substrates were efficiently phosphorylated with
ATP (Figure 2.6). In the reaction with Abl, CAMK4, PAK1, and PKA phosphorylation was
100% with all the three trials, indicating all the peptides were converted onto phosphopeptides.
With other kinases tested, with peptide substrates showed phosphorylation conversion ranging
from 26% to 94%. Specifically, 94(±6)% (AKT1), 91(±6)% (CK2), 35(±1)% (FLT1), 26(±2)%
(GSK3β), 94(±6)% (RSK1), and 63(±5)% (SRC) conversion was observed. A similar trend in
conversion efficiencies was observed with ATP-biotin. Kinase-mediated biotinylation indicated
that the conversion was 85(±6)% with Abl, 49(±2)% with AKT1, 62(±3)% with CAMK4,
46(±2)% with CK2, 30(±6)% with FLT1, 11(±2)% with GSK3β, 67(±1)% with PAK1, 61(±6)%
with PKA, 74(±1)% with RSK1, and 59(±1)% with SRC. As some kinases do not show 100%
conversion with phosphorylation, overall conversion efficiency of the biotinylation was
calculated compared to ATP phosphorylation. This showed overall biotinylation efficiencies
were 85(±6)% with Abl, 53(±2)% with AKT1, 62(±3)% with CAMK4, 51(±3)% with CK2,
86(±13)% with FLT1, 42(±5)% with GSK3β, 67(±1)% with PAK1, 61(±6)% with PKA,
79(±5)% with RSK1, and 94(±4)% with SRC. The data indicated that the percent conversion of
biotinylation with peptide substrates ranged from 42% to 94% compared to ATP phosphorylation
(Table 2.2). Thus, kinase-catalyzed biotinylation is occurring with comparable efficiency to the
ATP phosphorylation.
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Figure 2.6: Quantification of Biotinylation with Petides. (1) HPLC analysis of unmodified
peptides (Abl peptide at ~13.8 min; AKT1 peptide at ~13.0 min; CAMK4 peptide at ~12.1 min;
CK2 peptide at ~7.5 min; FLT1 peptide at ~15.8 min; GSK3β peptide at ~11.5 min; PAK1
peptide at ~13.6 min; PKA peptide at ~10.9 min; RSK1 peptide at ~11.4 min; SRC peptide at
~14.2 min). (2) HPLC analysis of ATP-phosphorylated peptides (Abl phosphopeptide at ~13.1
min; AKT1 phosphopeptide at ~11.5 min; CAMK4 phosphopeptide at ~11.2 min; CK2
phosphopeptide at ~7.1 min; FLT1 phosphopeptide at ~15.5 min; GSK3β phosphopeptide at
~10.8 min; PAK1 phosphopeptide at ~13.3 min; PKA phosphopeptide at ~10.3 min; RSK1
phosphopeptide at ~11.8 min; SRC phosphopeptide at ~13.1 min). (3) HPLC analysis of ATPbiotin phosphopeptides (Abl phosphopeptide at ~13.0 min; AKT1 phosphopeptide at ~11.6 min;
CAMK4 phosphopeptide at ~11.5 min; CK2 phosphopeptide at ~7.1 min; FLT1 phosphopeptide
at ~15.5 min; GSK3β phosphopeptide at ~10.9 min; PAK1 phosphopeptide at ~13.3 min; PKA
phosphopeptide at ~10.3 min; RSK1 phosphopeptide at ~11.8 min; SRC phosphopeptide at
~13.0 min). The peaks at ~12.7 min with AKT1 and GSK3β are from biotin-amine due to
phosphoamidate cleavage. The complete HPLC traces are shown in section A 2.4, Figure A
2.12- A 2.21.

2.2.5 Quantification of Biotinylation-Gel Analysis
To determine the efficiency of biotinylation with the remaining 16 kinases, gel analysis
was performed. Phosphorylated proteins or biotinylated phosphoproteins were created by
incubating ATP or ATP-biotin with ASK1 and MBP, Aurora A and MBP, CHK1 and MBP,
CDK1 and Histone H1 protein, CK1 and dephosphorylated casein protein, DAPK1 and MBP,
ERK1 and MBP, GRK5 and β-Casein protein, HIPK1 and MBP, JAK3 and poly (Glu4, Tyr1)
peptide substrate, MARK1 and MBP, MLK1 and MBP, MST1 and MBP, NEK2 and MBP,
TGFβR2 and MBP, or TRKA and poly (Glu4, Tyr1) peptide substrate in the manufacturer
provide buffer (1X, Promega). As a control only full-length protein substrate was loaded to
assess the initial phosphorylation state of the proteins. As phosphorylation produces
phosphoproteins and biotinylation produces phosphorylbiotin products, direct quantification with
Pro-Q was not appropriate here. However, the phosphoamidate bond can be easily cleaved under
acidic conditions to yield phosphoproteins that are the same product obtained with the ATP
reaction. After kinase reaction, ATP and ATP-biotin reaction products were treated with 50%
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TFA to obtain phosphoproteins for direct comparison of biotin reactions. Crude reaction
mixtures were separated by 16% SDS-PAGE. Total proteins were visualized with Sypro Ruby
Stain (Figure 2.7, top gels) and phosphoproteins were observed with Pro-Q Diamond Stain
(Figure 2.7, bottom gels). We used Pro-Q Diamond Stain for quantification of kinase conversion
with ATP and ATP-biotin reactions. Sypro Ruby Stain provided evidence for equal protein
loading for each lane.
Myelin basic protein (MBP) displayed no or minimum phosphorylation before the kinase
reaction, depending on the batch used in each particular reaction. The MBP that was used with
AST1, Aurora A, DAPK1, ERK1, and HIPK1 was completely dephosphorylated (Figure 2.7,
lane 1, bottom gels), whereas MBP used with CHK1, MARK1, MLK1, MST1, NEK2, and
TGFβR2 displayed minimal initial phosphorylation on the proteins (Figure 2.7, lane 1, bottom
gels). Poly-(Glu4, Tyr1) peptide substrate used with JAK3 and TRKA and β-casein used with
GRK5 also showed minimum phosphorylation of purchased material (Figure 2.7, lane 1, bottom
gels). Finally, purchased dephosphorylated casein protein used with CK1 does not indicate any
phosphorylation before the kinase reaction. For the quantification, Pro-Q signal with untreated
substrate was subtracted from the signal after the kinase-dependent phosphorylation or
biotinylation.
Pro-Q gel analysis indicated that kinase-catalyzed phosphorylation gave an intense signal
on the gel (Figure 2.7, lane 2) compared to the untreated protein substrate only (Figure 2.7, lane
1). Similarly, biotinylated proteins also gave high signal (Figure 2.7, lane 3) compared to the
unreacted substrates (Figure 2.7, lane 1). For the quantification, ATP phosphorylation was
assumed to be 100% conversion and biotinylation efficiency was calculated relative to ATP
reaction. Reactions with Aurora A, ERK1, JAK3, NEK2, and TGFβR2 showed over 90%
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conversion with biotinylation compared to phosphorylation. Other kinases also indicated good
conversions with ATP-biotin, from 44% to 82%. The data from the quantitative analyses
indicated that the biotinylation occurred to a reasonable extent compared to phosphorylation.
To compare the HPLC and gel analysis methods, CAMK4 was tested with both peptide
substrate and protein substrate. The percent conversion of biotinylation with CAMK4 was 62%
with peptide (HPLC analysis, Figure 2.6) and 41% with protein (gel analysis, Figure A 2.22 gel
C).

Figure 2.7: Quantification of Biotinylation with Proteins. Proteins were subjected to kinasecatalyzed phosphorylation or biotinylation. Both phosphorylated and biotinylated samples were
incubated with 50% TFA for 15 minutes. The reactions were separated by 16% SDS-PAGE and
visualized by Sypro Ruby Stain (top) and Pro-Q Diamond Stain (bottom). Reaction contents are
indicated above the lanes. Full gel images can be found in appendix Figure A 2.22.
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Table 2.2: Efficiency of Kinase-Catalyzed Biotinylation with 26 Kinases

Kinase
ABL
AKT1
ASK1
Aurora A
CAMK4
CDK1
CHK1
CK1
CK2
DAPK1
ERK1
FLT1
GRK5
GSK3β
HIPK1
JAK3
MARK1
MLK1
MST1
NEK2
PAK1
PKA
RSK1
SRC
TGFβR2
TRKA

Method
HPLC
HPLC
Gel
Gel
HPLC (Gel)
Gel
Gel
Gel
HPLC
Gel
Gel
HPLC
Gel
HPLC
Gel
Gel
Gel
Gel
Gel
Gel
HPLC
HPLC
HPLC
HPLC
Gel
Gel

% Conversion
85 ± 6
53 ± 2
76 ± 6
96 ± 1
62 ± 3 (41 ± 2)
77 ± 2
47 ± 4
82 ± 9
51 ± 2
63 ± 4
91 ± 6
86 ± 13
53 ± 9
42 ± 5
44 ± 5
91 ± 3
65 ± 10
78 ± 6
55 ± 2
94 ± 3
67 ± 1
61 ± 6
79 ± 5
94 ± 4
91 ± 5
66 ± 12
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2.3 ADP-Glo Assay-Theory and Control Reactions
The efficiency of the biotinylation reaction was further characterized by a kinetic analysis
using the ADP-Glo assay (Promega). The assay was performed as follows (Figure 2.8). The
kinase reactions were performed at 30 °C for 30 minutes. Then an equal amount of ADP-Glo
reagent was added to the mixture and incubated for 40 minutes at room temperature in the dark,
which terminated the kinase reaction and degraded the unreacted ATP. Then an equal amount of
kinase detection reagent (KDR) was added to the reaction mixture and allowed to react 60
minutes at room temperature, which converted ADP into ATP. At the same time, the
luciferase/luciferin reaction took place with the newly formed ATP. This luciferase/luciferin
reaction produced a luminescence signal to measure the amount of formed ATP. Hence the
signal corresponded to the amount of ADP produced in kinase reaction and the activity of the
kinase reaction. Signal was determined with a micro plate luminescence reader (Tecan).
Because the ATP-Glo assay was developed for ATP reactions, several control reactions
were performed to characterize the ADP-Glo assay with ATP-biotin (Figure 2.9). First,
experiments were done without performing a kinase reaction (Figure 2.9 A). Blank reactions not
containing any ATP or ATP-biotin gave only background signal (Figure 2.9 A, lane 1). No
significant signal was observed with ATP alone (Figure 2.9 A, lane 2) or ATP-biotin alone
(Figure 2.9 A, lane 3), indicating that both were degraded by the ADP-Glo reagent.
Luminescence signal was observed when ADP was treated with ADP-Glo reagent and kinase
detection reagent itself (Figure 2.9 A, lane 4) or in the presence of ATP (Figure 2.9 A, lane 5) or
ATP-biotin (Figure 2.9 A, lane 6). These ADP reactions indicate luminescence was produced
with newly formed ATP from ADP.
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Figure 2.8: Theory of ADP-Glo the Assay. Kinase reactions with ATP or ATP analog
produced ADP as a byproduct. Addition of ADP-Glo reagent inhibited the kinase reaction and
degraded remaining ATP or ATP analog. Kinase detection reagent converted ADP into ATP and
this newly formed ATP was used in a luciferase reaction to produce light.
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Next, the same components were tested with kinase detection reagent only. When ATP
(Figure 2.9 A, lane 7) or ADP (Figure 2.9 A, lane 8) was treated with only the kinase detection
reagent, the signal intensity was the same as when ADP was treated with ADP-Glo reagent and
KDR (Figure 2.9 A, compare lane 4 and 8). In contrast, the ATP-biotin reaction produced only
back ground signal (Figure 2.9 A, lane 9). Also, addition of ATP-biotin to ATP or ADP did not
significantly affect the luminescence signal (Figure 2.9 A, lane 10 and 11). As expected, a
combination of the ATP and ADP almost doubled the signal compared to itself (Figure 2.9 A,
compare lane 12 with lane 7 and 8). These reactions indicate that the ATP-biotin does not
produced signal with KDR.

Then we performed controls including the kinase reaction (Figure 2.9 B). After the kinase
reaction, luminescence signal was observed in reactions containing ATP (Figure 2.9 B, lane 8) or
ATP-biotin (Figure 2.9 B lane 9) as cosubstrates. However in the absence of kinase, ATP (Figure
2.9 B, lane 6) or ATP-biotin (Figure 2.9 B, lane 7) did not show any significant signal with
peptide substrate. Additionally, incubation of kinase with ATP (Figure 2.9 B, lane 4) or ATPbiotin (Figure 2.9 B, lane 5) without peptide substrate did not give any luminescence. Similarly,
kinase alone (Figure 2.9 B, lane 2) or peptide alone (Figure 2.9 B, lane 3) gave only background
signal (Figure 2.9 B, lane 1). These results indicated that ADP-Glo assay works with ATP-biotin
similar to ATP, and ATP-biotin does not interfere with assay reagent and can be used for further
analysis.

52

Figure 2.9: Control Experiments with ADP-Glo Assay. Several control experiments were
carried out to validate the ADP-Glo assay with ATP-biotin. (A) ADP-Glo assay performed
without a kinase reaction. Lanes 1-6 included both ADP-Glo reagent and kinase detection
reagent. Lanes 7-12 used kinase detection reagent only. (B) ATP and ATP-biotin controls with
kinase reaction. Lanes 1-9 included both ADP-Glo reagent and kinase detection reagent. Lane 8
and 9 represent the kinase reaction with peptide substrate and, ATP and ATP-biotin respectively.

53

Next we were interested in finding the degraded product of ATP or ATP-biotin with the
ADP-Glo reagent. Graduate student Maheeka Embogama performed the following control
experiment. If ATP-biotin was not degraded by the ADP-Glo reagent, would it could be used by
luciferase to produce signal. However, the above luminescence data indicated that ATP-biotin is
either degraded or not used by ADP-Glo reagent (Figure 2.9 A, lane 3) and not used by
luciferase/luciferin reaction to enhance the luminescence signal (Figure 2.9 A, lane 5,6, 9, 10 and
11). To determine the fate of ATP-biotin in the ADP-Glo assay, HPLC analysis was performed
with ATP vs.-7- ATP-biotin with the ADP-Glo reagent (Figure 2.10) and kinase detection
reagent (Figure 2.11). The data indicate that ADP-Glo reagent converts ATP (Figure 2.10, tR=42.
2 min) to an unidentified substance (Figure 2.10, tR=12.5 min), this reagent has no effect on ADP
(Figure A 2.51, tR=38.2 min), AMP (Figure A 2.51, tR=32.6 min), adenosine (Figure A 2.51,
tR=7.3 min), or adenine (Figure A 2.51, tR=6.9 min). Interestingly, ATP-biotin (Figure 2.10,
tR=27.9 min) does not convert to any of these products indicating that the ATP-biotin is not a
substrate for ADP-Glo reagent. As expected, reaction of ATP with kinase detection reagent
produced AMP (Figure 2.11, tR=32.8 min), which is a byproduct in luciferase/luciferin reaction.
Similarly, ATP-biotin also produced AMP (Figure 2.11, tR=32.8 min) with kinase detection
reagent, indicating that the ATP-biotin is a substrate for luciferase. However, this conversion was
around 60% compared to 100% with ATP, and luminescence produced by this hydrolysis did not
show significant luminescence signal, from previous analysis (Figure 2.9 A, lane 9). To further
clarify, ATP or ATP-biotin was incubated with kinase detection reagent and luminescence signal
was measured every 2.5 minutes (Figure A 2.52) for a one hour period time. The data indicated
that the amount of signal produced by ATP-biotin is 10-fold less compared to the signal
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produced by ATP. These control reaction data indicate that ATP-biotin is compatible with the
ADP-Glo assay for the kinetic analysis.

ATP only

ATP incubated with ADP-Glo reagent

ATP-biotin only

ATP-biotin incubated with ADP-Glo reagent

Figure 2.10: Control Experiments with ADP-Glo Assay using HPLC. ATP (tR=42.2) min or
ATP-biotin (tR=27.9 min) incubated with ADP-Glo reagent and separated with HPLC. ATP
(tR=42.3 min) is degraded to an unidentified substance (tR=12.5 min) whereas ATP-biotin
(tR=27.9 min) remained intact.
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ATP only

ATP incubated with KDR

ATP-biotin only

ATP-biotin incubated with KDR

Figure 2.11: Control Experiments with ADP-Glo Assay using HPLC. ATP (tR=42.2) min or
ATP-biotin (tR=27.9 min) incubated with kinase detection reagent and separated with HPLC.
ATP (tR=42.3 min) was fully degraded to AMP (tR=32.8 min), whereas ATP-biotin (tR=28.1
min) was only partially degraded to AMP (tR=32.8 min).
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2.4 ADP-Glo Assay- Kinetic Analysis
The efficiency of the biotinylation reaction was further characterized using the ADP-Glo
assay. Unlike the widely used enzyme-coupled assay,

(95, 96)

the ADP-Glo assay is an end point

assay. Thus kinetic measurements were obtained by performing the reaction with different
substrate concentrations (1, 3, 10, 30, and 100 µM) and time points (5, 10, 20, 30, and 40 min).
We screened all 26 kinases and determined kinetic parameters such as KM, kcat and kcat/KM.
With the kinetic analysis, ATP-biotin displayed similar KM values compared to ATP for
tested kinases, ranging from 0.6-fold to 2.9-fold increased values (Table 2.3). ATP-biotin
showed a higher KM for 22 kinases and lower KM for 4 kinases (GRK5, NEK2, PAK and PKA),
when compared to ATP. In addition, ATP-biotin showed only 2-fold higher KM for 4 enzymes
(DAPK, GSK3β, HIPK and TGFβR2). This data suggested that the γ-phosphate modification
does not affect significantly ATP analog kinase binding efficiency.
To assess the efficiency of phosphoamidate transfer using ATP-biotin, kcat values were
compared to those of phosphate transfer. ATP-biotin showed similar kcat (1-1.5 fold reduced
values) compared to ATP for 8 kinases. In contrast, the analog displayed reduced kcat relative to
ATP (ranging from 2 to 53-fold) for the remaining 16 kinases. Significantly, ATP-biotin showed
19-fold and 53-fold reduced kcat compared to ATP with ASK1 and GSK3β, respectively.
Altogether, the reduced kcat demonstrated that unnatural phosphorylbiotin transfer with ATPbiotin is slower than natural phosphate transfer with ATP. We also assessed the catalytic
efficiencies (kcat/KM) for biotinylation and phosphorylation reactions. As expected, ATP-biotin
showed lower catalytic efficiencies compared to ATP ranging from 1.1 to 135-fold reduced.
These data indicated that ATP-biotin is an efficient substrate for some kinases and less efficient
substrate for other kinases, compared to the natural ATP substrate.
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There is no direct correlation between catalytic efficiencies and the earlier percent
conversion data. For example, kinases demonstrating low catalytic efficiencies, such as ASK1
and GSK3β (Table 2.3) have reasonable ATP-biotin conversion under equilibrium condition
(76% ASK1 and 42% GSK3β, Table 2.2). In addition, ATP-biotin showed similar catalytic
efficiencies as ATP with NEK2 and PAK1 (Table 2.3), but 94% and 67% conversions,
respectively. However, the remaining 22 kinases showed 2to7 fold reduced catalytic efficiencies
for biotinylation compared to phosphorylation. These numbers are comparable to the catalytic
efficiencies of ATP-γS, which is widely used compound for protein labeling.(81-83, 87) One report
indicated that ATP-γS shows an 8-fold reduced kcat/KM compared to ATP. The data suggested
that most kinases utilize ATP-biotin with good catalytic efficiencies and can be used for
phosphoproteomics analysis.
Table 2.3: Kinetic constant for Enzymes
Kinase
ABL
AKT1
ASK1
Aurora
CAMK4
CDK1
CHK1
CK1
CK2
DAPK1
ERK1
FLT1
GRK5
GSK3β
HIPK1
JAK3
MARK1
MLK1
MST1
NEK2
PAK1
PKA
RSK1
SRC
TGFβR2
TRKA

KM (µM)
ATP
8.8 ± 1.6
20.5 ± 2.1
12.4 ± 2.3
23.8 ± 1.3
13.1 ± 0.6
19.5 ± 1.2
15.0 ± 1.9
4.3 ± 0.9
5.8 ± 1.8
3.9 ± 0.9
41.8 ± 3.0
33.3 ± 2.5
9.2 ± 1.6
4.7 ± 0.6
5.2 ± 0.4
10.4 ± 1.3
10.2 ± 0.7
24.3 ± 3.0
17.2 ± 2.9
25.0 ± 4.0
23.3 ± 3.0
24.4 ± 1.5
25.3 ± 1.9
15.3 ± 2.5
1.4 ± 0.3
28.6 ± 2.1

ATP-biotin
12.0 ± 1.1
23.7 ± 2.8
16.0 ± 2.6
36.4 ± 2.5
14.0 ± 2.5
27.8 ± 3.0
19.2 ± 2.8
7.3 ± 0.5
8.9 ± 1.9
11.5 ± 1.4
47.1 ± 3.9
36.6 ± 3.8
9.1 ± 1.0
11.4 ± 1.8
14.6 ± 2.5
15.4 ± 1.6
12.7 ± 1.3
27.7 ± 2.7
24.9 ± 3.7
20.9 ± 2.9
20.7 ± 2.3
15.0 ± 2.3
35.8 ± 4.0
16.2 ± 1.8
4.1 ± 0.9
28.2 ± 2.0

Ratio
1.4
1.2
1.3
1.5
1.1
1.4
1.3
1.7
1.5
2.9
1.1
1.1
1.0
2.4
2.8
1.5
1.2
1.1
1.4
0.8
0.9
0.6
1.4
1.1
2.9
1.0

kcat (s-1)
ATP
1.27 ± 0.06
1.99 ± 0.01
0.95 ± 0.05
2.49 ± 0.05
0.37 ± 0.006
6.90 ± 0.14
1.60 ± 0.06
0.12 ± 0.006
1.36 ± 0.11
0.18 ± 0.01
0.65 ± 0.02
0.14 ± 0.004
0.02 ± 0.001
0.53 ± 0.02
1.30 ± 0.03
0.99 ± 0.04
2.21 ± 0.04
1.12 ± 0.05
0.37 ± 0.02
0.58 ± 0.03
0.04 ± 0.002
3.03 ± 0.07
3.40 ± 0.10
0.83 ± 0.04
0.03 ± 0.001
1.12 ± 0.03

ATP-biotin
0.27 ± 0.008
0.39 ± 0.02
0.05 ± 0.003
1.53 ± 0.04
0.12 ± 0.006
3.88 ± 0.16
0.96 ± 0.05
0.10 ± 0.002
0.63 ± 0.04
0.17 ± 0.01
0.22 ± 0.01
0.06 ± 0.002
0.01 ± 0.0002
0.01 ± 0.0004
1.06 ± 0.06
0.89 ± 0.03
1.32 ± 0.04
0.28 ± 0.01
0.22 ± 0.01
0.42 ± 0.02
0.03 ± 0.001
0.41 ± 0.02
1.90 ± 0.09
0.55 ± 0.02
0.02 ± 0.001
0.56 ± 0.02

Ratio
4.7
5
19
1.6
3.1
1.8
1.7
1.2
2.1
1.0
2.9
2.4
2.6
53
1.2
1.1
1.7
4.0
1.7
1.4
1.3
7
1.8
1.5
1.2
2.0

kcat/KM (mM S)-1
ATPATP
biotin
143.8
22.3
96.8
16.3
76.5
3.2
104.8
41.9
28.5
8.6
354.7
139.6
104.8
49.7
27.3
13.6
233.8
71.2
45.6
15.1
115.5
4.8
4.2
1.6
1.9
0.8
113.6
0.8
251.8
73.1
95.1
58.1
217.1
104.0
46.2
10.2
21.6
8.7
23.3
20.0
1.8
1.6
124.0
28.0
132.7
52.4
54.4
33.8
20.0
5.9
41.9
19.8

Ratio
7
6
24
2.5
3.3
2.5
2.1
2.0
3.3
3.0
3.3
2.7
2.4
135
3.4
1.6
2.1
4.5
2.5
1.2
1.1
4.4
2.5
1.6
3.4
2.1
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2.5 Conclusion and Future Direction
Analysis of ATP-biotin with 26 selected kinases indicated that peptide, poly-peptide, or
protein substrates were labeled in a kinase-dependent manner (section 2.2.2 and 2.2.3). Previous
work done by our group(91-93) and others with different ATP analogs such as, ATP-γS,(81) ATPferrocene(99) and ATP-BODIPY(97) also successfully labeled the corresponding substrates in
invitro assay. Specially, ATP-γS is used for substrate labeling.(81-83,

87)

Interestingly,

commercially available ATP-biotin, which is two carbons shorter in the linker, was also used to
label peptides and lysates with gel analysis.(123) Additionally, the ATP-acyl-biotin derivative was
used to identify over 200 kinases in ATP binding manner.(100, 101) These data indicate the ability
of ATP analogs to bind to a variety of kinases in complex mixture.
In addition, the efficiency of biotinylation was measured with an end point assay (section
2.2.4 and 2.2.5) and kinetic analyses (section 2.4). The end point analysis was performed using
HPLC (for peptides) or gel electrophoresis (for poly-peptides and proteins), and indicated that
conversion efficiencies ranged from 41% to 96%. This data suggest that under equilibrium
conditions (higher concentration and longer reaction time) the kinases utilize ATP-biotin more
efficiently to transfer the phosphorylbiotin group. The percent conversion of CAMK4 was tested
with both HPLC (peptide, 62%) and gel (protein, 42%) methods, indicating that the efficiency of
biotinylation with substrate and the method of analysis.
As mentioned earlier ATP-γS is widely used for protein labeling and shows higher KM
(10-fold) compared to ATP.(76) Interestingly, opposite results were observed with kcat, indicating
1.5-fold higher value and 18 to 137-fold lower numbers.(76-79, 124) This variation can be due to the
quality of enzymes, which depends on source and purification.(95, 125) The kinetic constants of
ATP-γS indicate that modification on γ-phosphate with electronically different and large atoms
effects binding and catalytic mechanism.(76-78, 124) The biotinylation reaction was characterized
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using the ADP-Glo assay. ATP-biotin showed similar KM and decreased kcat compared to ATP.
However the biotinylation displayed similar catalytic efficiency (kcat/KM) as thiophosphorylation.
Biotinylation demonstrated a catalytic efficiency (kcat/KM) ranging from 1.1- to 135-fold reduced
compared to natural phosphorylation, indicating that some kinases can utilize ATP-biotin nearly
as well as ATP. Altogether, kinases accept ATP-biotin as a cosubstrate at a level useful for
phosphoproteomic research.
In the future, we will use ATP-biotin to test its generality with other kinase such as lipid
kinase, sugar kinase, nucleotide kinase etc. We would also like to discover the labeling with
kinase and to find correlation between kinase active site properties and binding of ATP analogs.
Cell permeable version of ATP-biotin analog will help to understand the phosphorylation event
within the cellular content. We also hope to use biotinylation to study kinase inhibitors and
kinase substrate pairs. In addition, we will test other ATP analogs containing different
functionalities.
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2.6 Experimental
2.6.1 Materials
Biotin, triethylamine, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(EDCI), 4, 7, 10-trioxa-1, 13-tridecanediamine, diisopropylethylamine (DIPEA), N, Ndimethylformamide (DMF), and pyrrolidine were purchased from Acros. Adenosine 5’triphosphate (ATP), glycerol, sodium hydroxide (NaOH), potassium chloride (KCl), magnesium
chloride (MgCl2), sodium chloride (NaCl), sodium dodecyl sulfate (SDS), glacial acetic acid,
acetonitrile, and SA-Cy5 conjugate were purchased from Fisher. HPLC grade trifluoroacetic acid
(TFA) and acetonitrile were obtained from VWR and EM Millipore, respectively. D2O and
CD3OD were obtained from Cambridge Isotope Labs. Ammonium bicarbonate, β-casein was
bought from Sigma. PKA, CK2, Abl, enzymes, sodium fluoride, sodium orthovanadate and Abl
peptide were purchased from New England Biolabs. All other kinases (AKT1, ASK1, Aurora A,
CAMK4, CDK1, CHK1,CK1, DAPK1, ERK1, FLT1, GRK5, GSK3β, HIPK1, JAK3, MARK1,
MLK1, MST1, NEK2, PAK1, RSK1, SRC, TGFβR2, and TRKA), AKT(PKB) substrate,
Autocamtide, CHKtide, IGF1Rtide, GSK3, Axltide, PAKtide, S6K substrate, SRC peptide
substrate, Kemptide, CK2 peptide peptide, poly (Glu4, Tyr1) peptide substrate, Myelin Basic
Protein (MBP), dephosphorylated Casein protein, Histone H1 protein and ADP-Glo assay were
obtained from Promega. Triton X-100 was purchased from Fluka. Coomassie Briliant Blue was
obtained from NuSep. Immobilion P and Psq PVDF membrane were purchased from Millipore.
Sypro Ruby and Pro-Q diamond stain was obtained from Invitrogen. Ready Gel 16% Tris-tricine
was purchased from Bio-Rad.
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2.6.2 Instrumentation
1

H NMR,

13

C NMR and

31

P NMR were recorded on a Varian Mercury (400 MHz)

spectrometer. The peaks appearing at δ 4.78 and δ 5.12 in 1H NMR are due to D2O. The signals
appearing at δ 1.58 and δ 3.52 in the 1H NMR and δ 8.2 and δ 46.4 in the 13C NMR are due to the
triethylamine counter ion. IR spectra were carried out in CHCl3 on FT/IR-460 plus (JASCO Co.
Ltd.) spectrometer. High resolution mass spectra (HRMS) were obtained on LCT Premier XT
(Waters). HP 8452A Diode array UV-Vis spectrophotometer was used to measure absorbance of
ATP-biotin. The purified final product was lyophilized using VirTis BT 3.3 EL Benchtop
lyophilizer. A SPD131 DDA ThermoSavant speed vac was used to evaporate solvents in vacuo.
The luminescence values for the ADP-Glo assay were measured with a fluorimeter (GENios Plus
Tecan). The SDS-PAGE apparatus was purchased from BioRad (Protean III) and a mini-gel
setup was used. Western blotting was carried out using the Mini-Transblot Electrophoretic
Transfer Cell apparatus from Bio-Rad. Peptides were analyzed using a Waters 1525 binary
HPLC pump and Waters 2998 photodiode array detector. A reverse phase C-18 column (YMC
America, INC 250×4.6 mm, 4µm, 8 nm) was used to separate peptide mixtures. After SOS –
Page separation proteins were visualized using a Typhoon 9210 scanner (Amersham
Biosciences).

2.6.3 Synthesis of biotin-PEG amine (8)
Biotin 6 (977.24 mg, 4 mmol) was dissolved in DMF (5 mL). TBTU (1.5412 g, 4.8
mmol) and DIPEA (0.836 mL, 4.8 mmol) were added and the mixture was stirred at room
temperature for 30 min. The mixture was added dropwise to a solution of 4, 7, 10-trioxa-1-13tridecanediamine 7 (2.2 mL, 10 mmol) in DCM (250 mL) at 4 ºC. After addition was complete,
the reaction mixture was stirred overnight at room temperature. The reaction progress was
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monitored by TLC (3:1:0.5 EtOH: DCM: NH4OH, Rf =0.60). The solvent was removed in vacuo.
The product was purified by flash chromatography on silica gel with EtOH/DCM (1:1→3:1 v/v)
to yield 82% of biotin-PEG-amine 8 as dark brown solid (1.463 g, 3.28 mmol). Figures A 2.12.4; IR (CHCl3, cm-1): 724, 798, 847, 1129, 1184, 1434, 1658, 2939, 3052, 3206, 3457. 1H NMR
(400 MHz, D2O): δ 1.19-1.27 (m, 2H), 1.36-1.65 (m, 8H), 2.08 (t, J=7.2 Hz, 2H), 2.56 (t, J=6.8
Hz, 2H), 2.82 (dd, J=12.8 and 4.8 Hz, 2H), 3.09 (t, J=6.4 Hz, 2H), 3.12-3.18 (m, 1H), 3.40 (t,
J=6.0 Hz, 2H), 3.43 (t, J=6.4 Hz, 2H), 3.51 (s, 8H), 4.25 (dd, J=8 and 4.4 Hz, 1H), 4.43 (dd,
J=8.0 and 4.8 Hz, 1H). 13C NMR (100 MHz, D2O): δ 25.1, 27.6, 27.9 28.2, 30.7, 35.4, 36.2, 37.6,
39.6, 55.3, 60.1, 61.9, 68.3, 68.8, 69.2, 69.3 69.5, 165.1, 176.5. HRMS (ESI): m/z calculated for
C20H39N4O5S [M+H] + 447.2641, observed 447.2633.

2.6.4 Synthesis of ATP-biotin (2)
Adenosine 5’- triphosphate disodium salt (27.5 mg, 0.05 mmol) was dissolved in water (5
mL) and the pH of the solution was raised to 7.0 by adding 1M sodium hydroxide. 1-(3Dimethylaminpropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 383.42 mg, 2 mmol) dissolved
in water (1 mL) was added to the reaction mixture. The pH of the solution was adjusted to 5.6
with 1 M hydrochloric acid and a pH range between 5.6-5.8 was maintained throughout the
reaction. Biotin-PEG-amine 8 (894.44 mg, 2 mmol) was added to the ATP solution and progress
of the reaction was monitored by TLC (6:3:1 iPrOH: NH4OH: H2O Rf =0.69). The reaction was
stirred for 4 hours and then treated with triethylamine (TEA) to reach pH 8.0. The product was
purified on DEAE Sephadex-A25 anion exchange column. The column was run with flow rate of
4 mL/min. A stepwise elution using 5%, 10%, 25%, 37.5%, 50%, 75% and 100%
triethylammonium bicarbonate buffer (TEAB) was applied. The product eluted between 37.550% TEAB. Purified product was lyophilized to yield 20% of ATP-biotin 2 as a white TEA salt
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(10.2 mg, 0.01 mmol). Figures A 2.5-2.9; UV (MeOH): λ 259 nm. 1H NMR (400 MHz, D2O): δ
1.68-2,16 (m, 8H), 2.57 (t, J=7.2 Hz, 2H), 3.24-3.46 (m, 6H), 3.58-3.64 (m, 4H), 3,84-4.01 (m,
12H), 4.57-4.59 (m, 2H), 4.72-4.74 (m, 2H), 4.89-4.92 (m, 2H), 6.48 (t, J=6.0 Hz, 1H), 8.63 (s,
1H), 8.92 (s, 1H).

13

C NMR (100 MHz, D2O): δ 25.1, 26.4, 27.8, 28.0, 36.2, 37.5, 38.5, 39.6,

42.1, 55.2, 60.1, 61.9, 65.1, 66.6, 68.2, 68.7, 69.2, 69.3, 69.4, 70.3, 74.2, 84.0, 86.6, 110.8, 118.5,
140.0, 149.1, 152.3, 164.1, 176.6. 31P NMR (400 MHz, D2O): δ -0.06 (d, γ-P), -10.35 (d, α-P), 21.78 (t, β-P). HRMS (ESI): m/z calculated for C30H51N9O17P3S [M-H]- 934.2337, observed
934.2329.

2.6.5 Storage of ATP-biotin (2)
The quality of the ATP-biotin is very important for biotinylation reaction. Like any
triphosphate, ATP-biotin is prone to hydrolyze to ATP or ADP. Degraded ATP will compete
with ATP-biotin in the kinase reaction. Therefore, lyophilized product (section 2.6.4) of ATPbiotin was dissolved in the storage buffer (Tris-base, 25 mM, pH 7.5) and stored at -80 °C as
single use aliquots. In addition, it is critical that freeze thaw cycles be avoided with ATP-biotin.
However, ATP-biotin will degrade over time and should be used within 3 months.

2.6.6 Kinase-Catalyzed Phosphorylation and Biotinylation
Phosphorylated or biotinylated peptides were created by incubating ATP or ATP-biotin
(2 mM) with a kinase enzyme (Table 2.4) and its corresponding peptide substrate (0.25 mM) in
the manufacturer provide buffer (1X). As a control, reactions were performed without kinases.
The final volume of the reactions was 25 µL. The reaction mixtures were incubated at 30 ºC for
2 hours without shaking. After reaction, the mixtures were heated at 95 ºC for 1 minute to
denature the kinase activity. Crude sample was separated on a 16% Tris-tricine gel (section
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2.6.7) and transferred to Immobilion PSQ PVDF membrane, and visualized with Coomassie stain
and SA-Cy5 conjugate as described in sections 2.6.11 and 2.6.10. For HPLC quantification,
crude samples were pre-equilibrate in 50 µL HPLC buffer A (99.9% water with 0.1%
trifluoroacetic acid) for 10-15 minutes and used directly for HPLC analysis, as described in
section 2.6.9.
Phosphorylated proteins or biotinylated phosphoproteins were generated as described
above. In this case, after heat denaturation, the crude sample was separated by 16% SDS-PAGE
and transferred to Immobilion P PVDF membrane, and visualized with Sypro Ruby Stain and
SA-Cy5 conjugate as described in sections 2.6.10 and 2.6.12. For quantification experiments, 25
μL of TFA (50% TFA final concentration) was added to both phosphorylated and biotinylated
samples and incubated for 15 minutes to cleave the biotin tag. Then the samples were evaporated
to dryness using a speed vac and subsequently neutralized with 1.5 M Tris-base (pH 12). Then
crude samples were used in SDS-PAGE separation, and gel imaging with Sypro Ruby Stain
(section 2.6.12) and Pro-Q Diamond Stain (section 2.6.13).
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Table 2.4: Enzymes and substrates used for labeling and quantification
Kinase

Kinase
Concentration (nM)

Substrate

ABL
AKT1
ASK1
Aurora A
CAMK4
CDK1
CHK1
CK1
CK2
DAPK1
ERK1
FLT1
GRK5
GSK3β
HIPK1
JAK3
MARK1
MLK1
MST1
NEK2
PAK1
PKA
RSK1
SRC
TGFβR2
TRKA

125
94
133
112
101
102
98
129
165
113
182
85
70
110
113
125
64
104
96
105
88
150
74
96
0.118
0.121

MBP, (EAIYAAPFAKKK)a
CKRPRAASFAE
Myelin Basic Protein
Myelin Basic Protein
KKALRRQETVDAL-amide
Histone-H1
KKKVSRSGLYRSPSMPENLNRPR, (MBP)a
Casein Protein (dephospho)
Casein Protein, (RRREEETEEE)a
Myelin Basic Protein
Myelin Basic Protein
KKKSPGEYVNIEFG
Casein Protein
YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE
Myelin Basic Protein
Poly (4:1 Glu, Tyr) Peptides
KKKVSRSGLYRSPSMPENLNRPR, (MBP)a
Myelin Basic Protein
KKSRGDYMTMQIG, (MBP)a
Myelin Basic Protein
RRRLSFAEPG
MBP, (LRRASLG)a
KRRRLASLR
KVEKIGEGTYGVVYK-amide
Myelin Basic Protein
Poly (4:1 Glu, Tyr) Peptides

a= In some case different substrates were used in biotinylation and quantification experiments.
Substrates in paranthesis were used for quantification experiments. Abl, CK2, PKA, and Abl
substrates were purchased from New England Biolab. All other enzymes and substrates were
purchased from Promega.
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2.6.7 Tris-Tricine Gel Electrophoresis
The tris-tricine gels were either purchased from Bio-Rad (cat no: 4563063) or prepared as
follows. The tris-tricine gel was prepared in two layers, an upper “stacking” layer and a lower
“separating” layer, as described in Nature Protocols.(126) A 16% separating layer was prepared
consisting of a 10 mL of 3X Gel buffer (0.3% w/v SDS, 3 M Tris, brought to pH 8.45 with HCl),
10 mL of 40% v/v 29:1 acrylamide:bisacrylamide, and 3 mL of glycerol, which was diluted to 30
mL with distilled water. Polymerization was initiated by the addition of 100 µL of 10%
ammonium persulfate, followed by 10µL of TEMED. After addition to the gel setup, distilled
water was added on top of the separating layer to ensure a smooth edge and removed before
adding the stacking layer. The upper stacking layer was composed of 4 mL of 3X gel buffer
(0.3% w/v SDS, 3 M Tris, brought to pH 8.45 with HCl), and 1 mL of 40% v/v 29:1
acrylamide:bisacrylamide, which was diluted to 12 mL by addion of distilled water.
Polymerization was initiated by the addition of 90 µL of 10% ammonium persulfate followed by
9 µL of TEMED, before loading on top of the separating layer. The gel running chamber was
filled with a 1X Tris-Tricine-SDS running buffer, which was composed of 0.1% SDS, 100 mM
Tris, and 100 mM tricine (at pH 8.3). A protein molecular weight marker (5 µL, Spectra
Multicolor Low Range Protein Marker, Thermo Scientific) was used as a standard. The gel was
run at a constant 100 V for 2 hours.

2.6.8 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
The polyacrylamide gel was prepared in two layers, an upper “stacking” layer and a
lower “separating” layer (as described in Molecular Cloning, Appendix 8.40-8.45).(127) The
lower layer contained approximately 4 mL of a 16% separating layer consisting of 1 mL of 4X
Tris/SDS separating buffer (0.4% w/v SDS, 1.5 M Tris, brought to pH 8.8 with HCl), 1.6 mL of
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40% w/v 37:1 acrylamide:bisacrylamide, 1.38 mL of distilled water, and 10% ammonium
persulfate. Polymerization was initiated by the addition of 4 μL of TEMED. After addition to the
gel setup, methanol was added on top of the separating layer to ensure a smooth edge and
removed before adding the stacking layer. The upper stacking layer was composed of 0.5 mL of
4X Tris/SDS stacking buffer (0.4% w/v SDS, 1.5 Tris, brought to pH 6.8 with HCl), 0.25 mL of
40% w/v 37:1 acrylamide: bisacrylamide, 1.24 mL of distilled water, and 10 μL of 10%
ammonium persulfate. Polymerization was initiated by the addition of 2 µL of TEMED. The gel
running chamber was filled with a 1X SDS running buffer, which was composed of 0.1% SDS,
0.025M Tris, and 0.25 M glycine (at pH 8.3). A protein molecular weight marker (5uL, EZ-RUN
Pre-Stained Protein Marker, Fisher) was loaded onto the gel as a standard. The gel was run at a
constant 200 V for 1 hour.

2.6.9 HPLC Analysis
For HPLC analysis, peptide reactions (25 µL) were incubated in Buffer A (50 µL; 99.9%
water with 0.1% trifluoroacetic acid) for atleast 15 min at room temperature to pre-equilibrate.
Reverse phase chromatographic separation of peptides was performed using a C18 column
(YMC America INC; 250×4.6 mm, 4µm, 8 nm) and Waters 1525 binary HPLC pump. The
elution gradient used started at 95% Buffer A in Buffer B (99.9% acetonitrile with 0.1%
trifluoroacetic acid), and decreased to 70% Buffer A over 15 min. The flow rate was 1 mL/min
and the peptide absorbance was detected at 214 nm. The percentage of phosphopeptide was
calculated by dividing the area under the phosphopeptide peak by the total area under both the
phosphopeptide and unmodified peptide peaks.
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2.6.10 Biotin Visualization
Proteins separated by gel were transferred to a polyvinyldene fluoride (PVDF) membrane
(Immobilon P or PSQ, Millipore). The membrane was pre-wet with methanol and proteins were
transferred using the Mini-Transblot Electrophoretic Transfer Cell apparatus from BioRad, with
CAPS/methanol buffer (0.01M CAPS [N-cyclohexyl-3-aminopropanesulfonic acid] at pH 10.5,
and 10% methanol) used to fill the transfer chamber. The transfer was carried out at 90 V for 1
hour. After the transfer was complete, the membrane was incubated overnight in a blocking
solution of 5-10% (w/v) non-fat dry milk in PBST (0.1% Tween-20 in 1X PBS buffer: 137mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4). The membrane was washed with
PBST and then incubated in a 1:500 dilution of SA-Cy5 for one hour (longer time incubation can
lead to non-specific labeling). The membrane was rinsed with PBST for 5 minutes, thrice, to
remove the excess antibody, and visualized using the Typhoon scanner at an excitation
wavelength of 633 nm and an emission at 670 nm.

2.6.11 Coomassie Stain
The tris-tricine gel was fixed in 50 mL of fixing solution (50% methanol and 10% acetic
acid in water) and incubated with gentle rocking at room temperature for 30 minutes. The used
fix solution was removed and 50 mL of undiluted Coomassie Brilliant Blue stain (NuSep) was
added. The gel was incubated in the staining solution at room temperature overnight, with gentle
rocking. The gel was then transferred to another clean container containing 100 mL of the
destaining solution (6% acetic acid), and incubated at room temperature for 10-12 hours. The
coomassie stained gel was imaged using a commercial scanner (HP Scanjet G4010).
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2.6.12 Sypro Ruby Stain
The polyacrylamide gel was submerged in 50 mL of fixing solution (50% methanol and
7% acetic acid in water) and incubated with gentle rocking at room temperature for 30 minutes.
The used fix solution was removed and the process was repeated. The used fix solution was
poured off and 50 mL of undiluted Sypro Ruby gel stain (Invitrogen) was added. In this and
subsequent steps, the gel was protected from light by covering the container with aluminum foil.
The gel was incubated in the staining solution at room temperature overnight, with gentle
rocking. The gel was then transferred to another clean container containing a sufficient volume
of the washing solution (10% methanol and 7% acetic acid in water), and incubated at room
temperature for 30 minutes. The washing solution was discarded and the gel was rinsed with
distilled H2O for 5 minutes to remove excess acid to prevent corrosive damage to the instrument
used for visualization. The Sypro Ruby stained gel was imaged using the Typhoon scanner at an
excitation wavelength of 450 nm and an emission of 610 nm.

2.6.13 Pro-Q Staining
The gel (independent gel from same crude reaction) was incubated in 50 mL of fixing
solution (50% methanol and 10% acetic acid in water) overnight, and then the solution was
discarded. The gel was rinsed with distilled water for 30 minutes, three times. Then 50 mL of
undiluted Pro-Q Diamond gel stain (Invitrogen) was added. In this and subsequent steps, the gel
was protected from light by covering the container with aluminum foil. The gel was incubated in
the staining solution at room temperature for 60-90 minutes, with gentle rocking. The gel was
then transferred to another clean container containing 100 mL of the washing solution (20%
acetonitrile, 50 mM sodium acetate pH 4), and incubated at room temperature for 90 minutes,
three times. The washing solution was discarded and the gel was rinsed with distilled water for 5
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minutes to wash off excess acid to prevent corrosive damage to the instrument used for
visualization. The Pro-Q stained gel was imaged using the Typhoon scanner at an excitation
wavelength of 532 nm and an emission of 555 nm.

2.6.14 Gel Image Quantification
Gel bands were quantified using ImageQuant 5.1 by drawing the same size rectangular
shape around comparable bands. The background correction was calculated by substracting the
untreated protein signal from kinase reaction signal. The percentage of phosphoproteins or
biotinylated phosphoproteins observed after kinase reaction was calculated by dividing the
protein signal with ATP-biotin treatment to the protein signal with ATP treatment. The
percentages displayed in Figure 2.7 are average percentages and standard error of observed
phosphoprotein or biotinylated phosphoprotein from three independent trials.

2.6.15 Kinetics analysis
Kinase kinetic analysis was performed using the ADP-Glo kinase assay (Promega). All
kinase assays were performed in white, flat-bottom 96-well half-area micro plates (Corning). For
kinase reactions, ATP or ATP-biotin (1, 3, 10, 30, and 100 µM final concentrations) were
incubated with corresponding peptide (0.2 µg/μL final concentration) or protein (0.1 µg/μL final
concentration) substrates and manufacture’s provided buffer (Table 2.5). The kinase reaction was
initiated by adding protein kinase (manufacture’s recommended amount; see Table 2.5). The
final volume of the reactions was 20 µL. The reaction mixtures were incubated at 30 °C for 5,
10, 20, 30, and 40 minutes for each concentration. After the incubation period, an equal amount
of ADP-Glo reagent (20 µL) was added to the mixture and incubated for 40 minutes at room
temperature. Then, an equal amount of kinase detection reagent (40 µL) was added to the
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reaction mixture and allowed to react 60 minutes at room temperature. Finally, luminescence
signal was determined with a micro plate luminescence reader (GENios Plus Tecan). The
concentration of ADP produced during the reaction was determined using a standard curve. Then
the concentration of ADP produced in the reaction was plotted with the time. The initial rates of
the reactions were obtained from the slope of the linear portion of the plots. The experimental
results (rate vs concentration) were fitted by non-linear regression using Kaleidagraph
(“Michaelis-Menten-Kinetic” model was used, V=Vmax*[S] / (KM + [S]), V=rate of the reaction
and [S]= substrate concentration) to obtain the KM and Vmax, and Vmax was divided by the
concentration of enzyme (Table 2.5) to obtain the kcat value. The fold change of the relevant
kinetic constants were calculated by dividing the the kinetic constants with ATP-biotin reaction
by the kinetic constants with the ATP reaction.
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Table 2.5: Enzymes and substrates used for ADP-Glo assay
Kinase
ABL
AKT1
ASK1
Aurora
CAMK4
CDK1
CHK1
CK1
CK2
DAPK
ERK1
FLT1
GRK5
GSK3
HIPK
JAK3
MARK1
MLK1
MST1
NEK2
PAK1
PKA
RSK1
SRC
TGFβR2
TRKA

Kinase
Concentration
(nM)
15.0
5.9
4.2
1.4
1.3
0.7
3.1
16.1
10.0
2.1
4.6
13.3
10.0
3.4
1.4
1.6
0.4
3.9
3.0
3.3
10.5
12.0
0.7
1.2
18.4
0.8

Substrate
EAIYAAPFAKKK
CKRPRAASFAE
Myelin Basic Protein
Myelin Basic Protein
KKALRRQETVDAL-amide
Histone-H1
KKKVSRSGLYRSPSMPENLNRPR
Casein Protein (dephospho)
RRREEETEEE
Myelin Basic Protein
Myelin Basic Protein
KKKSPGEYVNIEFG
Casein Protein
YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE
Myelin Basic Protein
Poly (4:1 Glu, Tyr) Peptides
KKKVSRSGLYRSPSMPENLNRPR
Myelin Basic Protein
KKSRGDYMTMQIG
Myelin Basic Protein
RRRLSFAEPG
LRRASLG
KRRRLASLR
KVEKIGEGTYGVVYK-amide
Myelin Basic Protein
Poly (4:1 Glu, Tyr) Peptides

Substrate
Concentration
µg/µL
0.2
0.2
0.1
0.1
0.2
0.1
0.2
0.1
0.2
0.1
0.1
0.2
0.1
0.2
0.1
0.1
0.2
0.1
0.2
0.1
0.2
0.2
0.2
0.2
0.1
0.1

Footnote: Figure 2.3 in this chapter were reprinted with permission from Cell Signaling
Technology, Inc. (www.cellsignal.com). Request ID 315230.
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Chapter 3
Stability of Biotinylated Phosphoproteins from Kinase-Catalyzed Biotinylation
(Portions of the text in this chapter were reprinted or adapted with permission from:
Senevirathne, C., and Pflum, M. K. (2013) Biotinylated Phosphoproteins from Kinase-Catalyzed
Biotinylation are Stable to Phosphatases: Implications for Phosphoproteomics, Chembiochem: a
European journal of chemical biology 14, 381-387.)
Previous data indicated that many recombinant kinases and cellular kinases accept ATPbiotin as a cosubstrate. However the dynamics of the modified reaction were not characterized.
Given that phosphorylation is a reversible process, we were interesting in testing the dynamics of
biotinylation in a cellular contex. If the modification is sensitive to the phosphatases in lysates,
biotinylation can be used to monitor dynamic of phosphorylation. Or if the modification is stable
to phosphatases, the method would be great tool for identifying low abundance phosphoprotein
in complex mixture. This chapter is focused on studying the phosphatase stability of the
phosphorylbiotin group towards the use of kinase-catalyzed biotinylation for phosphoproteomics.

3.1 Phosphatase Activity with Phosphoryl Biotin Tag
Recently we reported use of γ-phosphate modified ATP analogs for studying
phosphorylation.(91-94) In particular, we demonstrated that an ATP analog with biotin attached to
the γ-phosphate (ATP-biotin (2), Figure 3.1) acts as a cosubstrate for kinases and transfers a
phosphorylbiotin group to peptides and proteins (Figure 3.1).(94) With these successes, kinasecatalyzed biotinylation has application towards characterizing the complete phosphoproteome.
However, cellular experiments are complicated by the presence of protein phosphatases, which
could alter the biotinylation state of the labeled phosphoproteins (Figure 3.1). To assess the
suitability of kinase-catalyzed biotinylation for phosphoproteomics applications, the sensitivity
of the phosphorylbiotin tag to phosphatase activity must be characterized.
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Figure 3.1: Protein Phosphorylation, Biotinylation and Dephosphorylation. Biotinylation
with kinases and ATP-biotin gives biotinylated phosphopeptide products (5). The sensitivity of
biotinylated phosphopeptides to phosphatases is studied in this chapter.

3.2 Protein Dephosphorylation: Phosphatases, Structure and Enzymatic Mechanism
Many biological processes involve kinases and phosphatases, including cell signaling,
and cancer formation, for examples.(6, 128) In contrast to kinases (over 500), a fewer number of
phosphatases (over 150) are known.
serine/threonine

phosphatases(129)

Phosphatases are divided into two major classes-(7)
and

tyrosine

phosphatases,(130)

which

hydrolyze

phosphoserine/threonine or phosphotyrosine, respectively. Unlike kinases, phosphatases have
differing active sites and mechanisms depending on their substrate.(10,

130-134)

Serine/threonine

phosphatases have an active site that utilizes catalytic metals (Mn, Fe, Zn) to bind the
phosphate(135-137) and activates water for phosphate ester hydrolysis (Figure 3.2 A).(138) In
contrast, tyrosine phosphatases hydrolyze the phosphate ester by employing a nucleophillic
cysteine (Figure 3.2 B).(130, 139, 140) To characterize the compatibility of the two active sites with
phosphoryl biotin degradation, we tested two serine/threonine phosphatases (protein phosphatase
1 (PP1) and calf intestinal phosphatase (CIP)) and one tyrosine phosphatase (T-cell protein
tyrosine phosphatase (TCPTP)).
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Figure 3.2: Mechanism of the Dephosphorylation by Protein Phosphatases. (A) Protein
serine/threonine phosphatases employ two metal ions which activate a water molecule to attack
the phosphate group during dephosphorylation. (B) Protein tyrosine phosphatases employ an
amino acid cysteine to attack the phosphate group during dephosphorylation.

3.3 Stability of Modifications on Phosphate towards Phosphatases
Kinases utilize γ-thio-ATP (ATP-γS (6), Figure 3.3) to generate thiophosphorylated
proteins. Prior work revealed that the thiophosphoryl group is insensitive to phosphatases(74, 86,
141)

and provided the foundation for use of ATP-γS and thiophosphorylation in

phosphoproteomics applications.(80, 81, 87, 124, 142) With this precedent, we examined whether the
phosphorylbiotin modification is similarly insensitive to phosphatases. If the biotin tag is stable
under cellular conditions, then kinase-catalyzed biotinylation would be an excellent tool to
visualize and purify phosphorylated proteins in lysates, with the ability to monitor low
abundance phosphoproteins.

76

Figure 3.3: Irreversible Kinase-Catalyzed Thiophosphorylation. (A) Chemical structure of
ATP-γS (6). (B) Peptides or proteins (3) undergo thiophosphorylation with kinases and ATP-γS
to give thiophosphopeptides or thiophosphoproteins products (7), which cannot be removed by
phosphatases. The insensitivity of thiophosphopeptides and thiophosphoproteins to phosphatases
is well documented.

Here we test the susceptibility of the phosphorylbiotin tag of kinase-catalyzed
biotinylation towards protein phosphatases.

We found that the phosphorylbiotin group on

peptide and protein substrates was relatively insensitive to protein phosphatases. To understand
how phosphatase stability would impact phosphoproteomics research applications, kinasecatalyzed biotinylation of cell lysates was performed in the presence of kinase or phosphatase
inhibitors. We found that biotinylation with ATP-biotin was sensitive to inhibitors, although
with variable effects compared to ATP phosphorylation.

The results suggest that kinase-

catalyzed biotinylation is well suited for phosphoproteomics studies, with particular utility
towards monitoring low abundance phosphoproteins or characterizing the influence of inhibitor
drugs on protein phosphorylation.
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3.4 Phosphatase Activity with Biotinylated Phosphopeptides
Two steps were employed to assess the phosphatase sensitivity of biotinylated
phosphopeptides. First, biotinylphosphopeptides were prepared by incubating ATP-biotin with
peptide/kinase pairs: PKA (Protein Kinase A) and serine-containing substrate (LRRASLG), CK2
(Casein Kinase 2) and a threonine-containing substrate (RRREEETEEE), and Abl (Abl Protein
Tyrosine Kinase) and a tyrosine-containing substrate (EAIYAAPFAKKK). After generating the
biotinylphosphopeptides, the second step involved heat denaturation of the kinase, followed by
incubation with PP1, CIP, or TCPTP. As a control, identical experiments were carried out with
ATP as a cosubstrate. All reactions were analyzed using high performance liquid
chromatography (HPLC). In the presence of acidic HPLC Buffer A (0.1% TFA in water, pH ~2),
the phosphoramidate bond of the biotinylphosphopeptide was cleaved to remove the biotin group
and yield a phosphopeptide product (see chapter 2, section 2.2.4 for more information).(143)
Therefore, ATP and ATP-biotin reactions produced HPLC traces containing identical
unmodified (Figure 3.4 A) or phosphorylated peptide products (Figure 3.4 B and C).
Under conditions where ATP control reactions demonstrated 90% to 100% kinase
conversion to phosphopeptide products (Figure 3.4 B, top), the ATP-biotin reactions
demonstrated 46-85% conversion (Figure 3.4 C, top). The efficiencies of the kinase reactions
with ATP-biotin were comparable to the quantitative mass spectrometric analysis reported
previously (56-80%),(91) demonstrating the reliability of the HPLC analysis. After phosphatase
treatment, ATP phosphorylated peptides were almost completely hydrolyzed; only 0-11%
phosphopeptides remained by HPLC (Figure 3.4 B, bottom), indicating that the phosphatase
maintains 89-100% activity.
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Figure 3.4: HPLC analysis and quantification of phosphorylated and biotinylated peptides
before and after phosphatase treatment (A) HPLC analysis of unmodified peptides (PKA
peptide at ~8.3 min; CK2 peptide at ~7.5 min; Abl peptide at ~13.8 min). (B) HPLC analysis of
ATP-phosphorylated peptides (top; PKA phosphopeptide at ~7.5 min; CK2 phosphopeptide at
~7.1 min; Abl peptide at ~13.2 min) after phosphatase treatment (bottom). (C) HPLC analysis of
ATP-biotin phosphopeptides (top; PKA phosphopeptide at ~7.5 min; CK2 phosphopeptide at
~7.1 min; Abl phosphopeptide at ~12.9 min) after phosphatase treatment (bottom). The
percentages in B and C represent the average percentage phosphopeptide observed from 3
independent trials with standard error. The complete HPLC traces are shown in Figure A 3.1, A
3.2, and A 3.3.
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In contrast, a significant amount of biotinylated phosphopeptide products were observed
after phosphatase treatment; 34-49% phosphopeptides were still observed after phosphatase
reaction (Figure 3.4 C, bottom). Comparing the percentage of biotinylated product before and
after phosphatase incubation (Figure 3.4 C, bottom versus top) revealed that 59% (PP1), 74%
(CIP), and 58% (TCPTP) of the modification remained intact. Therefore, while phosphatases
maintained 89-100% activity with phosphopeptide substrates, only 26-42% activity was seen
against biotinylated phosphopeptides. Of the three phosphatases tested, CIP was the least active
(26%) with PP1 and TCPTP maintaining similar activities (41% and 42%). These studies
indicate that the phosphorylbiotin modification is less susceptible to phosphatase hydrolysis than
a phosphate modification.

3.5 Phosphatase Activity with Biotinylated Phosphoproteins
Our next goal was to study the sensitivity of full-length biotinylated phosphoproteins to
phosphatase activity. While the kinase/phosphatase pairing was the same as with the peptides
experiments, the full-length substrates used were myelin basic protein (MBP) with PKA and Abl
and β-casein with CK2 (Figure 3.5). Similar to the peptide experiments, a two-step reaction
series was employed with kinase reaction first, followed by phosphatase incubation. In this case,
the crude products were analyzed by gel methods.
Control reactions with ATP demonstrated the sensitivity of phosphoproteins to
degradation by phosphatases; only 6-7% of total phosphoproteins were observed by Pro-Q
staining (Figure 3.5, lanes 2, 6, and 10, Pro-Q), indicating that phosphatases maintain 93-94%
activity at removing phosphates. In contrast, a significant amount of biotinylated
phosphoproteins was still detected after phosphatase treatment; 72-83% of total biotinylated
phosphoproteins were observed (Figure 3.5, lanes 4, 8, and 12, SA-Cy5), indicating that the
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phosphatases demonstrated only 17-28% activity at removing the biotin tag. Consistent with the
stability of the biotin tag to phosphatases, 37-66% biotinylated phosphoproteins were detected
after phosphatase incubation using Pro-Q staining (Figure 3.5, lanes 4, 8, and 12, Pro-Q).
Comparing the percentage of Pro-Q-visualized biotinylphosphoproteins after and before
phosphatase incubation (Figure 3.5, lanes 4 vs 3, 8 vs 7, and 12 vs 11, Pro-Q) revealed that 85%
(PP1), 66% (CIP), and 90% (TCPTP) of the modification remained intact. The Pro-Q analysis
indicated that phosphatases maintained 10-34% activity against biotinylated phosphopeptides.
The differences in activity comparing biotin (17-28%) and phosphate (10-34%) detection (Figure
3.5, SA-Cy5 versus Pro-Q) may be due to the presence of phosphorylation sites on the substrates
prior to kinase reaction, which would skew the Pro-Q staining data.

Figure 3.5: Gel analysis and quantification of phosphorylated and biotinylated proteins
before and after phosphatase treatment. The contents of each reaction are indicated below
each lane. Pro-Q staining visualizes phosphoproteins, SA-Cy5 staining detects biotin-labeled
proteins, and Syproruby stains for total protein content. The percentages of phosphorylated (ProQ) or biotinylated (SA-Cy5) proteins were calculated relative to lanes 1, 5, or 9 (Pro-Q, 100%)
or lanes 3, 7, or 11 (SA-Cy5, 100%). The full gel images, along with additional control reactions,
are shown in Figure A 3.4, A 3.5, and A 3.6 of appendix.
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A comparison of the activity data suggests that full-length biotinylated proteins are less
sensitive to phosphatases than biotinylated peptides (17-28% versus 26-42%). The protein data
represents the aggregate reactivities of all phosphorylation sites in the protein to phosphatases.
As a result, the data suggest that the majority of phosphorylation sites on full length proteins are
less susceptible to phosphatase hydrolysis than in isolated peptides. The steric bulk of fulllength proteins may prevent phosphatase binding and catalysis. The significant conclusion from
the experiments is that the phosphorylbiotin group, particularly on full length proteins, shows
significant stability to phosphatase degradation.
3.6 Inhibitor Studies in Cell Lysates
With an eye towards future phosphoproteomics applications, we were interested in
probing how the phosphatase stability of the phosphorylbiotin tag would impact lysate labelling.
Because cell lysates naturally contain phosphatases, typical phosphoproteomics experiments
include phosphatase inhibitors in the cell lysates to stabilize phosphorylation.(144, 145) With the
stability of the phosphorylbiotin tag, we hypothesized that robust kinase-catalyzed labeling will
occur in lysates without the need for phosphatase inhibitor treatment. In addition, we wondered
how phosphatase inhibitors would impact kinase-catalyzed labeling. Given the interest in kinases
and phosphatase inhibitors as drug targets,(146-149) inhibitor experiments would also establish the
utility of kinase-catalyzed labelling as a drug characterization tool.
3.6.1 Phosphatase Inhibitors
In contrast to kinase inhibitors (chapter 1.4), there are few inhibitors designed to target
protein phosphatases (Figure 3.6). However, a handful of phosphatase inhibitors are used to
treatment of diseases, such as diabetes, obesity and cancer.(128, 150, 151) Sodium stibogluconate is
the FDA approved phosphatase inhibitor used to treat for cutaneous leishmaniasis.(148,

152)

In
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addition, suramin, phenylarsine oxide, aplidin, alendronate, vanadate, etidronate, and gallium
nitrate are used as drugs.(153) Interestingly, finding new phosphatase inhibitor drugs has become
actively investigated recently.(148, 150) However, it is challenging to find selective inhibitors due to
similarities in the active sites of protein phosphatases and poor cell permeability of hydrophilic
inhibitors.

Figure 3.6: Structures of Common Phosphatase Inhibitors. Structures of widely used
phosphatase inhibitor molecules are shown here including: Sodium stibogluconate, FDA
approved drug; suramin, phenylarsine oxide, aplidin, alendronate, etidronate, and gallium nitrate,
used in clinical trials; Vanadate, fluoride and okadaic acid are used in primary laboratory
research.
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3.6.2 Inhibitor Studies in Cell Lysates: 1-D Gel Analysis
HeLa cell lysates were incubated with ATP-biotin in the presence of a kinase inhibitor
(staurosporine) or phosphatase inhibitors (sodium vanadate and sodium fluoride). As a control,
inhibitor experiments were also performed with ATP incubation. As expected, reactions
performed in the presence of kinase inhibitors showed only trace levels of phosphorylated
(Figure 3.7, lane 3, Pro-Q,) and biotinylated (Figure 3.7, lane 6, SA-Cy5) proteins.
Quantification and comparison between kinase inhibitor treated and untreated lanes revealed that
only 18 2% of phosphorylated (Figure 3.7, lanes 3 versus 2, Pro-Q) and 27 5% of biotinylated
(Figure 3.7, lanes 6 versus 5, SA-Cy5) proteins were visible (Figure A 3.8). The slightly elevated
level of biotinylation remaining with kinase inhibition may be due to the natural presence of
biotinylated proteins in cell lysates. These experiments indicate that kinase inhibitors similarly
reduce phosphorylation or biotinylation. Because monitoring changes in phosphorylation after
inhibitor treatment has been used as a drug characterization tool,(154-156) a future direction is use
of ATP-biotin labeling to characterize kinase inhibitor activities.
In contrast to the kinase inhibitor experiments, phosphatase inhibitors had differing
effects on phosphorylation and biotinylation. As expected with ATP phosphorylation, reactions
containing phosphatase inhibitors showed robust phosphoprotein signal (Figure 3.7, lane 4, ProQ). Comparison of the phosphatase treated and untreated reaction lanes showed that the
phosphoprotein signal was elevated to 118 9% (Figure 3.7, lane 4 versus 2, Pro-Q). These
results are consistent with the use of phosphatase inhibitors to augment phosphorylation levels in
phosphoproteomics applications.(144, 145) In the case of the ATP-biotin reactions, a biotin signal
was also observed in phosphatase inhibitor treated reactions (Figure 3.7, lane 7, SA-Cy5).
However, comparison of the treated and untreated reaction lanes revealed that the biotin signal
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was reduced to 81 6% (Figure 3.7, lanes 7 versus 5, SA-Cy5, Figure A 3.8). The decrease in
biotinylation can be rationalized considering the kinase/phosphatase equilibrium in lysates.
Because phosphorylated amino acids will be unavailable for ATP-biotin labeling, active
phosphatases are needed to remove phosphoryl groups and promote kinase-catalyzed
biotinylation. If phosphatase activity is reduced by inhibitors, ATP-biotin labeling will not occur
on already phosphorylated sites, reducing the level of biotinylation.

Therefore, these

experiments are consistent with the hypothesis that active phosphatases are critical for robust
kinase-catalyzed labeling in lysates.

Figure 3.7: Inhibitor Studies with 1-D Gel Analysis: Gel analysis of phosphoproteins (ProQ,
top) or biotinylated phosphoproteins (SA-Cy5, bottom) from HeLa cell lysates incubated with
ATP or ATP-biotin in the absence or presence of kinase or phosphatase inhibitors. The contents
of each reaction are indicated below each lane. Additional trials are shown in Figure A 3.7.
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3.6.3 Inhibitor Studies in Cell Lysates: 2-D Gel Analysis
To further test the sensitivity of biotinylation to phosphatase inhibitors, two dimensional
(2-D) gel analysis was performed (Figure 3.8). 2-D gel analysis is a classical method that offers
visualization of many more proteins in lysates than 1-D methods.(157,

158)

In addition, 2-D gel

methods have been used widely in phosphoproteomics analysis.(159, 160) HeLa cell lysates were
incubated with either ATP or ATP-biotin in the absence or presence of phosphatase inhibitors
(sodium vanadate and sodium fluoride). After reaction, proteins were separated by their
isoelectric points (pI) in the first dimension, followed by molecular weight in the second
dimension. As expected, ATP-labeled lysates treated with phosphatase inhibitors contained more
phosphoproteins compared to untreated reactions (Figure 3.8 A, see boxed area). In contrast,
ATP-biotin-labeled lysates showed a greater number of biotinylated proteins in the untreated
reaction than the phosphatase inhibitor-treated reaction (Figure 3.8 B, see boxed area). The
reduction in ATP-biotin labeling upon phosphatase inhibitor treatment is consistent with the 1-D
gel analysis (Figure 3.7), which provide further evidence for the hypothesis that active
phosphatases are needed for robust kinase-catalyzed biotinylation.
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Figure 3.8: Inhibitor Studies with 2-D Gel Analysis (A) Reactions of HeLa cell lysates and
ATP without (untreated) or with phosphatase inhibitors (phosphatase inhibitor treated). Proteins
were visualized with Pro-Q diamond phosphoprotein stain. (B) Reactions of HeLa cell lysates
and ATP-biotin without (untreated) or with phosphatase inhibitors (phosphatase inhibitor
treated). Biotinylated proteins were visualized with SA-Cy5. The boxed region of the images
highlights changes due to inhibitor treatment.
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A comparison of the boxed areas within the 2-D gel images shows that the phosphatase
inhibitor-treated ATP labeling (Figure 3.8 A, right) and untreated ATP-biotin labeling (Figure
3.8 B, left) showed similarities.

We note that the differences in charge state of the

phosphorylated and biotinylated proteins (see Figure 3.1) likely influence migration in the gels,
making direct comparison of ATP and ATP-biotin labeled reactions difficult by 2-D methods.
The comparison is further complicated by the use of different visualization methods (Pro-Q
versus SA-Cy5). However, the combined data from 1-D and 2-D methods is consistent with the
hypothesis that robust kinase-catalyzed biotinylation occurs without the need for phosphatase
inhibitor

treatment.

Therefore,

kinase-catalyzed

biotinylation

is

appropriate

for

phosphoproteomics application using untreated lysates.

3.7 Conclusion and Future Work
We have shown that the phosphorylbiotin product of kinase-catalyzed biotinylation is
stable to phosphatases. In vitro experiments suggest that both Ser/Thr and Tyr phosphatase are
similarly ineffective at phosphorylbiotin hydrolysis. These results are consistent with prior work
documenting that the product of ATP-γS labeling, a thiophosphorylated protein, is also
insensitive to phosphatase degradation.(74,

85, 86, 141)

The combined results suggest that

phosphoproteins containing a phosphate modification will generally display phosphatase
insensitivity. ATP-γS has been used for phosphoprotein labeling and detection directly in lysates,
without the need for phosphatase inhibitors.(80,

81, 87, 124, 142)

The use of untreated lysates

combined with the added functionality of the biotin group makes ATP-biotin labeling attractive
for phosphoproteomics applications. In particular, the likelihood of detecting low abundance
phosphoproteins is enhanced due to the stability of the biotin tag to phosphatases and the ability
to purify labeled proteins directly. Use of kinase-catalyzed biotinylation for detection of low
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abundance phosphoproteins is currently under investigation. In addition, the sensitivity of ATPbiotin labeling to both kinase and phosphatase inhibitors indicates that kinase-catalyzed labeling
has future application to phosphoproteomic-based drug characterization efforts. In conclusion,
the stability of the phosphorylbiotin product of ATP-biotin labeling to phosphatases suggests that
kinase-catalyzed biotinylation will be an excellent tool for phosphoproteomics research.
In future work, we hope to monitor phosphatase activity using kinase-catalyzed labeling.
For that first, phosphatase knock down cell line will be generated. The strategy would involve
labeling of untreated versus phosphatase knock down lysates with ATP-biotin. This method is
based on the fact that phosphatase activity is required for robust biotinylation, by removing
phosphates that generates sites for biotin labeling. After gel purification, those proteins that are
substrates to the knocked down phosphatase would be identifiable to due to a reduction of biotin
label compared to the untreated sample. This analysis will be coupled with MS-based protein
characterization to provide a simple method to identify substrates. Hence, kinase-catalyzed
labeling could lead to the identification of phosphatase substrates, which is a key step to
characterizing phosphatase biology and cell signaling.
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3.8 Experimental

3.8.1 Materials
ATP-biotin was synthesized as explained in Chapter 2, section 2.6.3 and 2.6.4. Adenosine
5’-triphosphate disodium (ATP), glycerol, sodium hydroxide (NaOH), potassium chloride (KCl),
magnesium chloride (MgCl2), sodium chloride (NaCl), sodium dodecyl sulfate (SDS), glacial
acetic, acetonitrile, staurosporine and SA-Cy5 conjugate were purchased from Fisher. HPLC
grade trifluoroacetic acid (TFA) and acetonitrile were obtained from VWR and EM Millipore,
respectively. N, N-dimethylformamide (DMF) was purchased from Acros Organics. D2O and
CD3OD were obtained from Cambridge Isotope Labs. Ammonium bicarbonate, β-casein and
myelin basic protein (MBP) were bought from Sigma. PKA, CK2, Abl, CIP, PP1, TC PTP
enzymes, sodium fluoride, sodium orthovanadate and Abl peptide were purchased from New
England Biolabs. Kemptide and CK2 peptides were bought from Promega. Triton X-100 was
purchased from Fluka. HeLa cells were obtained from the National Cell Culture Center
(www.nccc.org). Protease inhibitor cocktail V was purchased from Calbiochem, and Bovine
serum albumin (BSA) was obtained from Santa Cruz Biotechnology. Immobilion P PVDF
membrane was purchased from Millipore. Sypro Ruby and Pro-Q diamond stain was obtained
from Invitrogen. 2-D gel starter kit, rehydration/equilibration trays, ReadyStrip IPG strip (pH 310), and Ready Gel Tris-HCl Gel were purchased from Bio-Rad.

3.8.2 Instrumentation
The absorbance values for Bradford assay were measured with a fluorimeter (GENios
Plus Tecan). The SDS-PAGE apparatus was purchased from BioRad (Protean III) and a mini-gel
setup was used. Western blotting was carried out using the Mini-Transblot Electrophoretic
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Transfer Cell apparatus from BioRad. Protein IEF cell (Bio-Rad, used with permission from
Honn lab) was used for 2-D gel analysis. The peptides were analyzed using a Waters 1525 binary
HPLC pump and Waters 2998 photodiode array detector. Reverse phase C-18 column (YMC
America, INC 250*4.6 mm, 4μm, 8 nm) was used to separate peptide mixtures. The separated
proteins were visualized using a Typhoon 9210 scanner (Amersham Biosciences).

3.8.3 Kinase-Catalyzed Phosphorylation and Biotinylation
Phosphorylated peptides or biotinylated phosphopeptides were created by incubating
ATP or ATP-biotin (2 mM) with PKA (20 units/µL) and Kemptide peptide substrate (400 μM,
LRRASLG), CK2 (20 units/μL) and CK2 peptide substrate (400 µM, RRREEETEEE), or Abl
(20 units/µL) with Abl peptide substrate (400 μM, EAIYAAPFAKKK). The final volume of the
reactions was 20 µL and the manufacturer-supplied buffers were used at a 1X concentration
(NEB). The reaction mixtures were incubated at 30 ºC for 2 hours. After reaction, the mixtures
were heated at 95ºC for 1 minute to denature the kinase. The reactions were split into two 10 µL
portions. One 10 μL sample was used directly for HPLC analysis, as described below, while the
second 10 μL sample was treated with phosphatase, as described below.
Phosphorylated or biotinylated proteins were created by incubating ATP or ATP-biotin (2
mM) with PKA (25 units/µL) and myelin basic protein (MBP, 0.2 mM), CK2 (5 units/µL) and βcasein (0.2 mM), or Abl (5 units/µL) and MBP (0.2 mM) in the manufacturer-provided buffer
(1X, NEB). As a control, reactions were performed without kinases. The final volume of the
reactions was 10 µL. The reaction mixtures were incubated at 30˚C for 2 hours. After the
reaction, the mixture was heated at 95 ºC for 1 minute to denature the kinase. Only with CK2
reactions, ATP or ATP-biotin was removed using a 10 kDa Centriprep spin column (Millipore);
we found that ATP or ATP-biotin interfered with subsequent treatment with CIP. The reactions
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were split into two 5 µL portions. One 5 μL sample was diluted up to 20 μL and used for SDSPAGE analysis, as described below, while the second 5 μL sample was treated with phosphatase,
as described below.

3.8.4 Phosphatase-Catalyzed Dephosphorylation
Protein or peptide phosphorylation and biotinylation were performed as described in
section 3.8.3. Then phosphatases were added to the appropriate reaction mixtures. For PKA
reactions, PP1 (1.0 units/μL, final concentration) in the manufacturer-provided buffer (1X, NEB)
was added and the reaction mixture was incubated at 30˚C for 2 hours. For CK2 reactions, CIP
(2.5 units/μL, final concentration) in the manufacturer-provided buffer (1X, NEB) was added and
the reaction was incubated at 37 ºC for 2 hours. For Abl reactions, TCPTP (2.5 units/μL, final
concentration) in the manufacturer-provided buffer (1X, NEB) was added and the reaction was
incubated at 30˚C for 2 hours. The final volume of the reaction mixtures was 20 µL. The crude
protein products were analyzed by SDS-PAGE with subsequent gel imaging, as described below,
while the peptide reactions were analyzed by HPLC analysis, as described below.

3.8.5 HPLC Analysis
For HPLC analysis, peptides were pre-equilibrated in Buffer A (50 µL; 99.9% water with
0.1% trifluoroacetic acid). Reverse phase chromatographic separation of peptides was performed
using a C18 column (YMC America INC; 250×4.6 mm, 4µm, 8 nm). The elution gradient started
with 95% Buffer A in Buffer B (99.9% acetonitrile with 0.1% trifluoroacetic acid), and
decreased to 70% Buffer A over 15 min. Due to overlap of several peaks, the PKA/PP1 reaction
used a different gradient starting at 90% Buffer A in Buffer B, and decreasing to 70% Buffer A
over 15 min. The flow rate was 1 mL/min and the peptide absorbance was detected at 214 nm.
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The percentage of observed phosphopeptide was calculated by dividing the area under the
phosphopeptide peak by the total area under both the phosphopeptide and unmodified peptide
peaks. Figure 3.4 B and 3.4 C show the average percentage and standard error of observed
phosphopeptide from three independent trials (Figures A 3.1-3.3).

3.8.6 Starting a New Cell Culture
The strain of HeLa cells used was HeLa S3 obtained from ATCC (American Type
Culture Collection). These cells were stored into aliquots (1.0 mL, 10 × 106 cells) in cryogenic
vials and stored in a liquid nitrogen storage tank upon receipt. When starting a new cell culture,
an aliquot was removed from the liquid nitrogen tank and thawed quickly in a 37 °C water bath.
The solution of cells was then transferred to a 15 mL centrifuge tube and centrifuged at 1000
rpm for approximately 5 minutes. The supernatant was carefully discarded and the pellet of cells
was resuspended into 5 mL of Ham’s F-12 media (F-12 Nutrient Mixture, Invitrogen) containing
10% v/v fetal bovine serum (FBS, Invitrogen). The cells were grown in a 37°C incubator under a
5% CO2 environment with 95% relative humidity. The cell concentration during growth was
maintained between 0.5-1.0 × 106 cells per mL.

3.8.7 Long Term Cell Storage
Cells near confluency (approximately 1 × 106 cells per mL) were collected by
centrifugation at 1000 rpm for 5 minutes. The cell pellet (approximately 10 × 106 cells) was
resuspended in 1.5mL of fresh Ham’s F-12 media with 10% v/v FBS containing a final
concentration of 10% v/v DMSO. The cells were slowly cooled in a cryogenic vial (Corning) and
then stored in a liquid nitrogen storage tank (Thermolyne).
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3.8.8 Collection of Cells for Experiment
To HeLa cells at confluency, triple express (5-10 mL) was added to the flask to cover the
surface and incubated at 37 °C for 10 minutes. The released cells (make sure cells were lifted and
floating) were transferred to a centrifuge tube and centrifuged at 1000 rpm for 5 minutes. The
supernatant was discarded and cells were gently washed with 1X PBS (phosphate buffered
saline) consisting of 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4. The
cell pellet was stored at -80 °C until needed, or used immediately.

3.8.9 Large-Scale HeLa Cell Lysis Procedure
Frozen HeLa cells (National Cell Culture Center, 10 × 109 cells) were thawed and kept on
ice. HeLa cells were lysed in lysis buffer (10 mL; 50 mM Tris, pH 8.0, 150 mM NaCl, 10%
glycerol, 0.5% Triton X-100 and 1X protease inhibitor cocktail V). Cells were incubated with
rotation at 4 °C for 10 minutes. The soluble fraction was separated from the cell debris by
spinning at 12,000 rpm at 4 °C for 15 minutes. The supernatant was collected and the
concentration of total protein in the lysate was determined via a Bradford assay (generally 5-6
mg/mL total protein). The lysate supernatant was stored at -80 °C.

3.8.10 Bradford Assay
The Bradford reagent dye (Bio-Rad Protein Assay, manufactured by Bio-Rad
Laboratories) was prepared by diluting 1 part dye reagent concentrate with 4 parts of ddH2O and
filtering through a 0.22µm pore size filter (Millex-GP, Millipore) to remove particles. To create a
standard curve, several dilutions of bovine serum albumin (BSA, Fisher Scientific) ranging from
0.5 to 5.0 mg/mL were prepared in H2O, which were within the linear range of this assay.
Several dilutions of the lysate were also prepared, typically around 1/50 of the original
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concentration of the unknown to ensure the resulting concentration fell within the linear range of
the assay. Each standard solution (10 µL) and each unknown dilution (10 µL) was pipetted into
separate wells of a flat-bottom transparent 96-well microtiter plate (Assay Plate, Costar). The
diluted Bradford reagent dye (200µL) was added to each well and the plate was incubated at
room temperature for at least 5 minutes. The absorbance was measured with a fluorimeter
(GENios Plus) at a wavelength of 595 nm. A standard curve was generated from the known
concentrations of the BSA standards using Microsoft Excel to plot the known concentrations of
the standards against the corresponding measured absorbance values. A best-fit linear equation
was generated each time the assay was run in order to minimize any errors that may have
resulted from fluctuations in the instrument over time. To determine the concentration of the
unknown sample, the observed absorbance value of the unknown dilution was used with the
equation of the best-fit line to calculate the concentration of the diluted lysate. The resulting
concentration of the diluted sample was then multiplied by the dilution factor to obtain the
concentration of the original lysate.

3.8.11 Kinase and Phosphatase Inhibitor Studies
For the lysate reactions, HeLa cell lysates (100 μg of total protein) were incubated with
either ATP or ATP-biotin (2 mM) in the presence kinase inhibitor (Staurosporine, 0.10 mM) or
phosphatase inhibitors (sodium fluoride and sodium orthovanadate, 0.10 mM each) in the
manufacturer-provided buffer for PKA (1X, NEB) for 2 hours at 30 °C. The final volume of the
reactions was 25 µL. The products were analyzed by SDS-PAGE (Chapter 2, section 2.6.9) with
subsequent gel imaging (Chapter 2, section 2.6.10 and 2.6.13) and quantification of the entire
lane (Chapter 2, section 2.6.14). The percentage of phosphoproteins or biotinylated
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phosphoproteins observed after inhibitor treatment was calculated by dividing the protein signal
after treatment to the protein signal before treatment.

3.8.12 Two-Dimentional Gel Analysis
The reactions with lysates with or without phosphatase inhibitors were performed as
described in section 3.8.11. Protein sample after reaction (100 µg) was mixed with 125 µL of
manufacturer (Bio-Rad) provided rehydration/sample buffer (2% CHAPS, 8 M urea, 50 mM
DTT, 0.2% (w/v) Bio-Lyte 3/10 ampholytes and trace Bromophenol Blue). Then the mixture was
loaded into the rehydration/equilibration tray channel, except for 1 cm at each end. The process
was repeated for remaining samples, taking care not to introduce any air bubbles. ReadyStrip
IPG strip (pH 3-10) was peeled from the coversheet and the strip was gently placed onto the
sample (gel side down, taking care not to introduce any air bubbles). The IPG strip was left to
rehydrate for one hour. Then 2 mL of mineral oil was overlaid to prevent evaporation. The
rehydration/equilibration tray was covered with the plastic lid and left overnight (12-16 hours) to
rehydrate the strips and maximize sample absorption. The next day, a paper wick was placed at
both ends of the IEF focusing tray channels covering the wire electrode and the paper wick was
wetted with 10 μL of nanopure water (Bio-Rad). The cover was removed from
rehydration/equilibration tray and the strip was held vertically for 10 seconds to drain the mineral
oil. Then the IPG strip was transferred to the focusing tray (gel side down) and the strip was
covered with 2 mL of mineral oil. The focusing tray was placed into the PROTEIN IEF cell and
focusing was performed (250 V for 20 min, 4000 V for 2 hours and at 4000 V for 10 000
Vhours, 50 μA per strip and temperature maintain at 20 ˚C). After electrophoresis was
completed, the IPG strip was removed from the focusing tray and the strip was held vertically for
10 seconds to drain the mineral oil. Then the strip was transferred into a new
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rehydration/equilibration tray (gel side up) and equilibrated for 10 minutes in buffer 1 containing
0.375 M Tris-HCl (pH 8.8), 6 M urea, 30% (v/v) glycerol, 2% (w/v) SDS and 2% (w/v) DTT.
Next, the strip was incubated with buffer 2 containing 0.375 M Tris-HCl (pH 8.8), 6 M urea,
30% (v/v) glycerol, 2% (w/v) SDS and 2.5% (w/v) iodoacetamide. The IPG strip was removed
from the rehydration/equilibration tray and was dipped into the graduated cylinder containing 1X
Tris/glysine/SDS running buffer. Then an agarose solution (Bio-Rad) was poured into the top of
the SDS-PAGE gel as stacking layer and the IPG strip was placed within the agarose layer
(taking care not to introduce any air bubbles). The gel was run at a constant 200 V for 45
minutes.

3.8.13 Biotin Visualization
The biotin visualization was performed as described in Chapter 2, section 2.6.10.

3.8.14 Sypro Ruby Stain
The Sypro Ruby staining was performed as described in Chapter 2, section 2.6.12.

3.8.15 Pro-Q Staining
The Pro-Q staining was performed as described in Chapter 2, section 2.6.13.

3.8.16 Gel Image Quantification
Gel bands were quantified using ImageQuant 5.1 by drawing the same size rectangular
shape around comparable bands.

The percentage of phosphoproteins or biotinylated

phosphoproteins observed after phosphatase treatment was calculated by dividing the protein
signal after treatment to the protein signal before treatment. The percentages displayed in Figure
3.5 are average percentages and standard error of observed phosphoprotein or biotinylated
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phosphoprotein from three independent trials. To calculate phosphatase activity, the average
percentage of phosphoproteins or biotinylated phosphoproteins observed after phosphatase
treatment was subtracted from 100%.

Footnote: Portions of the text in this chapter were reprinted or adapted with permission from
Licensee: chamara senevirathne
License Date: Mar 11, 2013
License Number: 3106010371572
Publication: ChemBioChem
Title: Biotinylated Phosphoproteins from Kinase-Catalyzed Biotinylation are Stable to
Phosphatases: Implications for Phosphoproteomics
Type Of Use: Dissertation/Thesis
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Chapter 4
Phosphoproteomic Analysis using Kinase-Catalyzed Biotinylation
Protein phosphorylation plays a fundamental role in protein function, and aberrant
phosphorylation level and elevated kinase activity are responsible for the disease formation. Here
we report development of a new phosphoproteomic enrichment tool combining kinase-catalyzed
biotinylation with avidin affinity chromatography. Given the limitations of metal ion affinity
chromatography with full-length phosphoprotein enrichment, kinase-catalyzed biotinylation may
provide new opportunities for future proteomics research.
4.1 Current Methods Used to purify Phosphopeptides and Phosphoproteins
Since phosphorylation has a significant role in protein function, the detection and
isolation of phosphopeptides and phosphoproteins are important goals for proteomic
research.(117) Mass spectrometric (MS) analysis has been widely used to identify protein
phosphorylation.(116, 118, 161, 162) MS analysis can be coupled with different separation systems and
mass analyzers to increase sensitivity and accuracy.(120, 121) Despite many improvements, MS has
limitations. For example, the ion suppression of the charged phosphate in MS analysis results in
difficulty detecting phosphopeptides in complex mixtures.(122) To minimize the influence of ion
suppression, unphosphosphorylated peptides are often removed from the mixtures prior to MS
analysis. As a result, multiple phosphopeptide purification methods have been developed to
enhance phosphoproteomics analysis. Phosphoprotein and phosphopeptide enrichment
techniques can be grouped into four main classes: immunoprecipitation, chemical modification,
affinity chromatography, and modified ATP analogs (83, 106) (Figure 4.1).
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Figure 4.1: Overview of Phosphopeptide and Phosphoprotein Isolation Methods. Schematic
representation of current methods of phosphopeptide and phosphoprotein purification is shown
here. The purification methods are classified into four major groups; immunoprecipitation,
affinity chromatography, chemical modification and modified ATP analogs strategies.

4.1.1: Immunoprecipitation
Phosphoproteins can be immunoprecipitated by antibodies generated specifically against
phosphopeptides.(108) For phosphoproteomics applications, antibodies recognizing a single
phosphotyrosine amino acid have been used successfully, while the poor binding affinity of
antibodies recognizing phosphoserine or phosphothreonine has limited their use.(110,

115)

The

antibody is immobilized to solid phase resin through covalent bond before immunoprecipitation.
A mixture of protein sample is incubated with the immobilized antibody, and proteins containing
a phosphotyrosine will bind with the antibody (Figure 4.2). Unbound proteins are removed
during washing steps and only the phosphotyrosine containing proteins are retained. Then pure
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phosphoproteins are eluted from the resin by applying denaturing conditions. The isolated
phosphoproteins can be analyzed by MS after digestion.

Figure 4.2: Immobilized Antibody Purification of Phosphoproteins. Phosphotyrosine specific
antibodies are attached to a solid resin. Incubation of the sample results in the binding of
phosphotyrosine proteins only and unbound proteins can be washed away. The isolated proteins
are eluted, digested and analyzed with MS.

4.1.2: Affinity Chromatography
Affinity chromatography is the most popular and widely used method in phosphopeptide
isolation. Affinity chromatography can be subdivided in to two strategies; Immobilized Metal
Affinity Chromatography (IMAC) and Metal Oxide Chromatography (MOC). Various metal
ions (Ga3+, Fe3+ and Al3+) (105, 163-165) and, metal oxides (TiO2, ZrO2 and Al2O3) (166-168) facilitate
phosphopeptide enrichment for IMAC and MOC, respectively. In IMAC, the metal ion is usually
bound to the resin using iminodiacetic acid (IDA) or nitrilotriacetic acid (NTA) (Figure 4.3),
whereas MOC uses the metal oxide as the resin (Figure 4.4). Both methods purify
phosphopeptides using a similar type of mechanism. Application of peptide mixtures leads to
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binding through electrostatic interactions between the negatively charged phosphates and
positively charged metal. Unmodified peptides can be removed from the resin upon washing.
Then phosphopeptides can be eluted from the resin and analyzed by MS. However, it is widely
reported that metal ion chromatography is biased towards phosphopeptides containing negatively
charged aspartic and glutamic acid residues,(169) which enhance binding affinity to the positively
charged metal. In addition, full-length phosphoprotein enrichment remains technically
challenging with metal ion chromatography.

Figure 4.3: Immobilized Metal Affinity Chromatography (IMAC) Purification. Incubation
of peptide mixture with IMAC column results in binding of phosphopeptides to the resin.
Washing removes unphosphorylated peptides to elute pure phosphopeptides. Purified
phosphopeptides can be analyzed by MS.
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Figure 4.4: Immobilized Metal Oxide Chromatography (MOC) Purification. Incubation of
peptide mixture with MOC column results in binding of phosphopeptide to the resin. Washing
removes unphosphorylated peptides to elute pure phosphopeptides. Purified phosphopeptides can
be analyzed by MS.

4.1.3: Chemical Modification
In terms of chemical modification strategies, two examples include β-elimination of the
phosphate groups of phosphoserine and phosphothreonine(170,

171)

and covalent phosphate

modification methods (via a phosphoamidate).(172-174) For the β-elimination method (Figure 4.5),
alkali treatment of phosphorylated serine or threonine 1 formed dehydroalanine 2, which can be
treated with a biotin (path A) or bifunctional tagging groups (path B).(170) Introducing a biotin tag
facilitates direct affinity purification (path A, compound 3).(171) On the other hand, incubation
with ethanedithiol attaches a thiol group (path B, compound 4), which can be cross-linked with
NHS activated biotin for subsequent purification (path B, compound 5) or, the free thiol can be
directly attached to solid support resin via a disulfide linker (path A, compound 6), which will
release purified peptides upon reduction. Dehydroalanine intermediate (2) formation with Olinked sugars and alkylated cysteine under alkaline conditions is the major drawback of this
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method. In addition, because a thiol group is introduced, all the cysteines should be blocked by
oxidation initially. Finally, this method is suitable only for phosphoserine and phosphothreonine
as phosphotyrosine is resistance to β-elimination.

Figure 4.5: Purification of Phosphopeptide using Phosphate Elimination. Treatment of alkali
leads to formation of dehydroalanine intermediate (2). (A) Nucleophilic addition of a biotin-tag
to the intermediate (3) facilitates subsequent purification. (B) Addition of ethanedithiol
introduces free thiol on the peptide (4) which can be trapped by NHS-biotin (5) or solid support
disulfide (6) functionalities. Purified peptides can be analyzed by MS.
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Unlike the β-elimination method, the phosphoamidate methods (Figure 4.6) enriches all
the three type of phosphorylated peptides.(172) In this method all amino and carboxylic
functionality has to be protected (intermediate 8 and 9) to overcome intramolecular or
intermolecular reactions. Then a thiol containing linker is attached to the phosphate group
through a phosphoamidate bond (intermediate 11). The modified phosphopeptide can be attached
to solid resin upon incubation with immobilized iodoacetyl groups (intermediate 12) and
unmodified peptides are washed away. Finally, pure phosphopeptide (compound 13) can be
cleaved off from the solid resin.

Figure 4.6: Purification of Phosphopeptide using Phosphoamidate Chemistry. Amino and
carboxylic groups are first blocked to avoid any side reactions (intermediate 8 and 9). Then a
free thiol group is introduced on the phosphate via a phosphoamidate bond (11). The peptide is
attached to the solid resin (12) to remove unphosphorylated peptides. Phosphopeptides (13) can
be obtained upon TFA treatment which hydrolyze phosphoamidate bond. Purified
phosphopeptides can be analyzed by MS.
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4.1.4: Modified ATP Analog
A fourth strategy involves ATP analogs along with lysates containing analog-sensitive
kinase mutants to label phosphoproteins for subsequent identification.(83,

87)

Here, ATP-γS

modified on the base was used with a mutant kinase. Incubation of ATP analog and mutant
kinase with cell lysate lead to protein labeled with a thiophosphate. Then the mixture was reacted
with PNMB (para-nitrobenzylmethansulfonate, Figure 4.7 A). Both the thiophosphates, cysteines
react to form nitrobenzylated proteins. However, only the nitrobenzyl thiophosphorylated
proteins can be purified with a specific antibody that recognizes this modification. Enriched
proteins were then subjected to digestion and subsequent MS identification. As an alternative to
specific antibody purification, thiophosphoproteins are digested and bound on solid support by
reacting with immobilized iodoacteamide (Figure 4.7 B).(87) Washing removes all the unbound
peptides, whereas thiophosphopeptides and cysteine containing peptide remain on beads.
Phosphopeptides are released upon elution with oxidative conditions (HOOSO3H) and cysteine
containing peptides remain bound to the beads. This is a powerful method to identify substrates
for a particular kinase.
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Figure 4.7: Purification of Phosphopeptide using Modified ATP-γS and Mutant Kinases.
Incubation of cell lysates with mutant kinases and modified ATP-γS lead to formation of
thiophosphorylated proteins. (A) Reaction of thiophosphorylated proteins with PNMB facilitates
the purification of phosphproteins with specific antibody against this modification. (B)
Thiophosphorylated proteins are digested and bound to solid resin together with cysteine
containing peptides. Only the phosphopeptides are released from the resin upon oxidation with
HOOSO3H acid. Isolated peptides can be analyzed by MS.

4.1.5: Our Strategy with Modified ATP Analog
Enrichment strategies that complement these phosphopeptide purification strategies
would promote a deeper study of the phosphoproteome. As an alternative method for
phosphoprotein enrichment, we reported use of γ-modified ATP analogues for labeling kinase
substrates.(91-94) We demonstrated that an ATP analogue with biotin attached to the γ-phosphate
(ATP-biotin 2, Figure 2.2) acts as a cosubstrate for kinases and transfers biotin along with the
phosphate group (Figure 2.2 B) to substrate peptides and proteins. Specifically, cellular kinases
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accept the ATP-biotin as a cosubstrate. Based on these studies, we envisioned applying kinasecatalyzed biotinylation to the enrichment of phosphopeptides and/or phosphoproteins from cell
lysates.

4. 2: Purification of Phosphopeptides: β-casein Model Study
4.2.1: Avidin Purification with Regular Elution
We were interested in using kinase-catalyzed biotinylation for enrichment of
phosphopeptides from cell lysates to facilitate MS analysis. To develop a purification protocol
based on kinase-catalyzed biotinylation, bovine β-casein was modified by ATP-biotin in the
presence of CK2 (Figure 4.8). The reaction mixture was reduced and alkylated, and then digested
with trypsin to create a mixture of peptides containing biotinylated phosphopeptides. The
digested mixture was loaded onto a NeutrAvidin column (Thermo Fisher). The column was
washed, and biotinylated peptides were eluted with mild heating (45 °C for 5 minutes) in the
presence of 5 mM competitive biotin (Figure 4.8, condition a). Peptides were separated by
reverse phase chromatography and introduced into a Thermo Fisher LTQ-XL mass spectrometer.
After ionization, abundant species were fragmented with CID or ETD to produce MS2 spectra.
MS data analysis was performed using Proteome Discoverer 1.3 (Thermo Fisher) and searches
were conducted using Mascot (ver 2.3; Matrix Sciences) to score MS2 spectra simultaneously
against a bovine protein database. The presence of a phosphoryl biotin modification (+508 Da)
on serine, threonine, or tyrosine was included in the search as a dynamic modification. One
modified peptide containing a single phosphorylated amino acid was identified with high
confidence (Table 4.1 and 4.2, Table A 4.1 and Figure A 4.1).
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4.2.2: TiO2 Purification
At the same time we were interested in comparing our methodology with another
phosphopeptide enrichment technique. We selected TiO2 affinity chromatography because it is
widely used for phosphopeptide enrichment.(166-168) Full-length β-casein was incubated with ATP
and CK2 and the same digest protocol was followed. The peptide mixture was loaded onto a
TiO2 tip column, washed, eluted (5% ammonium hydroxide and 5% pyrrolidine, Figure 4.9) and
subjected to MS analysis. In this case we searched for the presence of a phosphate modification
(+80 Da) on serine, threonine, or tyrosine. A total of 253 MS2 spectra were scored as
phosphopeptides, which correspond to 12 different sequences (Table 4.1 and 4.2, Table A 4.2,
Figure A 4.2 and Figure A 4.3). Among these peptides, 11 unique sites of phosphorylation were
identified, which is similar to previous MS analyses of casein phosphopeptides using TiO 2
enrichment.(116, 117, 175)
4.2.3: Avidin Purification with Acidic Elution
Previous work established that biotin can interfere with MS analysis due to ion
suppression.(172) As a result, competitive biotin elution with avidin might not be suitable for high
efficiency phosphopeptide MS analysis. To avoid the biotin group during the MS analysis step,
we sought a different condition that would elute phosphopeptides from the avidin column,
instead of biotinylated phosphoproteins. We rationalized that a low pH elution would cleave the
acid-labile phosphoramidate bond (Figure 2.2 B and Figure 4.8, condition b) and release
phosphopeptides from the avidin bead, which would improve subsequent MS analysis.
To validate the use of acidic elution conditions, we explored whether TFA cleavage
would increase the number of observed β-casein phosphopeptides. As described, biotinylated βcasein peptides were loaded onto an avidin column. In this case, phosphopeptides were eluted

109

after cleavage with 50% TFA (Figure 4.8, condition b). MS was performed and analyzed
identically to the TiO2 sample, where serine, threonine, or tyrosine residues with a phosphate
group (+80 Da) were identified. This time, 14 spectral counts were identified corresponding to 3
different sequences and 3 unique sites of phosphorylation (Table 4.1 and 4.2, Table A 4.3, and
Figure A 4.4). While the acidic conditions improved enrichment, the number of phosphopeptides
identified was not comparable to TiO2 affinity purification.
One barrier to kinase-catalyzed biotinylation of β-casein may be that potential sites have
already been phosphorylated. To further enhance the biotin/avidin purification strategy, we
speculated that a greater number of phosphosites would be biotinylated, resulting in more
efficient enrichment, if we created conditions where kinases and phosphatases are in equilibrium.
To test this hypothesis, calf intestinal alkaline phosphatase (CIP) was added to the reaction
mixture during kinase-catalyzed biotinylation of β-casein. Phosphopeptide purification and MS
analysis were then performed. In this case, we observed 259 spectral counts corresponding to 10
different phosphopeptides (Table 4.1 and 4.2, Table A 4.4, Figure A 4.5 and Figure A 4.6). From
the peptides, 14 unique sites of phosphorylation were identified, which is similar to the results
with TiO2 purification. The data indicated that kinase-catalyzed biotinylation should be
performed under equilibrium conditions to expose all phosphorylation sites to biotinylation.
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Figure 4.8: Isolation of Phosphopeptide using ATP-biotin and Avidin Affinity Purification.
Kinase-catalyzed biotinylation generates biotinylated proteins, which were digested and loaded
onto an avidin affinity column. Biotinylated peptides were bound to the resin and all other
peptides were washed away. Phosphopeptides were eluted using two conditions: (a) Biotin
elution generated biotinylated peptides/proteins for MS analysis; (b) 50% TFA elution generated
phosphopeptides/proteins for MS analysis due to cleavage of the biotin group.

Figure 4.9: TiO2 Affinity Purification. Casein or cell lysates were incubated with ATP and
digested with trypsin. The mixture was loaded onto a TiO2 column and unphosphorylated
peptides were washed away. Elution with ammonium hydroxide and pyrrolidine resulted in
release of the resin bound phosphopeptides for MS analysis.
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4.2.4: β-Casein Model Study Analysis
β-casein was used as a model phosphoprotein to establish optimal conditions for the
biotinylation and subsequent MS analysis. We found that optimal biotinylation occurred only in
the presence of phosphatase activity. Because purified casein is naturally phosphorylated,
biotinylation cannot occur on sites already in the phosphorylated state. The presence of
phosphatase activity in the reaction ensures that biotinylation can occur on all phosphorylation
sites, even those previously phosphorylated. Because cell lysates naturally contain kinases and
phosphatases, the presence of phosphatases in the biotinylation reaction mimics the natural
environment of the cell,(1) leading to robust biotinylation and optimal enrichment. In chapter 3,
we found that the phosphorylbiotin group on peptide and protein substrates was relatively
insensitive to active phosphatases, which is critical for robust kinase-catalyzed labeling
demonstrated here.(1)
In addition to maintaining equilibrium phosphorylation conditions during the
biotinylation reaction, we found that removal of the biotin group prior to MS analysis was
essential. The biotin group likely leads to ion suppression in the MS instrument,(172) which would
reduce the number of modified peptides observed. Alternatively, the biotin group can be lost
during post-enrichment manipulations via hydrolysis of the acid-labile phosphoramidate,(171)
which would also reduce the number of observed biotinylated peptides. The optimized strategy
takes advantage of the acid-labile phosphoramidate bond where phosphopeptides are eluted from
avidin affinity resin after biotin cleavage. With biotin cleavage, phosphopeptides are recovered
after enrichment, making the MS analysis identical to that used with other methods, such as TiO2
chromatography.
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Table 4.1: Comparison of Casein phophopeptides identified using Avidin versus TiO2 affinity
chromatography.

Protein/Peptide

Avidin
biotin
elution

Avidin
acid
elution

α-S1-Casein
DIGsEsTEDQAMEDIK

Avidin
acid elution
CIP included

TiO2

13

1

DIGsEStEDQAMEDIK

2

DIGSEsTEDQAMEDIK

2

VNELsKDIGsEStEDQAMEDIK

1

VPQLEIVPNsAEER

1

17

VPQLEIVPNsAEERLHSMK

16
4

YKVPQLEIVPNsAEER

9

26

YKVPQLEIVPNsAEERLHSMK

16
1

α-S2-Casein
NANEEEYsIGsssEEsAEVATEEVK

2

NAVPITPTLNREQLsTsEENSKK

6

NAVPITPTLNREQLStsEENSKK

1

NAVPITPTLNREQLsTSEENSKK

1

KTVDMEsTEVFTKK

3

TVDMEsTEVFTK

3

TVDMEStEVFTK

10

TVDMEsTEVFTKK

11

6
7

TVDmEStEVFTKK

4

TVDMEsTEVFTKKTK

2

β-Casein
FQsEEQQQtEDELQDK
FQsEEQQQTEDELQDK

4

14

7

96

78

FQSEEQQQtEDELQDK

1

IEKFQsEEQQQtEDELQDK

4

IEKFQsEEQQQTEDELQDK

16

10

47

82

IEKFQSEEQQQtEDELQDK

1

KIEKFQsEEQQQTEDELQDK

4

κ-Casein
sPAQILQWQVLSNTVPAK
Total phosphopeptides

4

14

1
259

253

Number of different peptides

1

3

10

12

Number of multiply phosphorylated peptides

0

4

44

29

Number of singly phosphorylated peptides

4

10

215

224

Number of each phosphorylated amino acid

4(pS)

14(pS), 4(pT)

268(pS),40(pT)

257(pS)26(pT)

1

3

14

11

Number of unique phosphorylated sites
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To more thoroughly compare the biotin versus metal ion purification methods, we
searched for similarity between phosphopeptides identified in the two methods (Table 4.1). Eight
phosphorylated sites were found in common comparing both methods; these included S50 and
T56 of β-casein and S61, S63, T64, S130, S158 and T159 of α-casein (Figures A 4.2 and 4.5).
Interestingly, several additional phosphosites where identified in α-casein (S56, S68, S71, S72,
S73 and S76) and κ-casein (S90) using avidin purification, which were not observed with the
TiO2 method. Three phosphosites (S144, T145 and S146) were identified only with the TiO2
method. The ratio of singly to multiply phosphorylated peptides from TiO2 and avidin
enrichment were 8:1 and 4.5:1, respectively, which is similar to prior reports.(176, 177) Of the total
phosphorylated peptides recovered from the biotinylation method, 86% were phosphorylated at
serine while 14% were modified at threonine. Similarly, the TiO2 method identified 90% and
10% of phosphopeptides modified on serine and threonine, respectively.
To assess how accurately the biotinylation reaction reflects the endogenous
phosphorylation profile, we compared the casein phosphorylation sites observed here to those
identified in prior reports. Phosphorylated S50, T56 (β-casein), S56, S61, S63, S71, S72, S73,
S76, S130 and S158 (α-casein) were also identified in previous studies.(116-118)Biotin-avidin
purification identified 14 phosphorylated sites, including S50 and T56 of β-casein, S56, S61,
S63, T64, S68, S71, S72, S73, S76, S130, S158 and T159 of α-casein and S90 of κ-casein. The
biotinylation method identified eleven sites that were previously reported (S50, T56 (β-casein),
S56, S61, S63, S71, S72, S73, S76, S130 and S158 (α-casein)).(116-118,

175)

Three series of

adjacent sites were absent (S30, S32, S33, S34 (β-casein), 23, 24, 25, 28, and 79, 81, 82, 83 (αcasein)), which may suggest that biotinylation is less effective when a series of consecutive sites
exists. We note that TiO2 purification also did not identify these series of sites. In addition, prior
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reports observe similarly different profiles, which may reflect variance in experimental
conditions or casein samples. Three phosphorylated sites were only observed with avidin
purification (T64, S68 (α-casein) and S90 (κ-casein)). The κ- casein isoform is in low abundance
in milk, which made prior removal of α- and β-casein necessary for reported profiling.(178) It is
notable that a novel, presumably low abundance, serine phosphorylation site in κ-casein is
observed with biotin-avidin purification. The data with casein indicate that the biotinylation
strategy enriches for similar phosphorylation sites compared to other reports and reasonably
reflects the endogenous phosphorylation profile. In addition, the fact that a novel
phosphorylation site on the low abundance κ-casein protein is observed suggests the method
provides sensitive detection. In total, this study has established kinase-catalyzed biotinylation for
phosphopeptide enrichment and subsequent MS analysis.

4.3: Purification of Phosphopeptides: HeLa cell lysates
4.3.1: Avidin Purification
Having established a purification technique for biotin-labeled phosphopeptides, we
applied the method to phosphoproteomic analysis of cell lysates. Briefly, HeLa cell lysates were
incubated with ATP-biotin to label endogenous substrates with endogenous kinases. The
biotinylated phosphoproteins were reduced and alkylated, followed by digestion and purification
using avidin beads. After TFA cleavage and elution of phosphopeptides, MS data analysis was
performed with dynamic modification of +80 Da on serine, threonine, and tyrosine residues.
Overall, spectral counts of 447 located on 147 proteins were identified (Table 4.2 and Table A
4.5). While 153 different phosphopeptides were observed, 304 unique sites of phosphorylation
were characterized.
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4.3.2: TiO2 Purification
For comparison, the recovery of phosphopeptides from HeLa cell lysates using TiO2
affinity chromatography was also determined. Lysates were incubated with ATP, reduced,
alkylated, digested, and enriched using a TiO2 tip column. MS analysis was performed and
results indicated that 490 spectral counts were detected on 188 different proteins (Table 4.2 and
Table A 4.6). In this case, 220 different phosphopeptides and 309 unique sites of
phosphorylation were identified, similar to previous reports.(118) Comparing the avidin and TiO2
methods, both enriched similar number of phosphopeptides and unique phosphorylation sites.

Table 4.2: Summary of the phosphopeptides/proteins identified using avidin purification and
TiO2 purification
Peptide
FDRa

Total
Proteins

Modified
Proteins

Spectral
count

Unique
Peptides

Unique
Sites

TiO2
Avidin with
biotin elution
ATP-biotin
Avidin with
TFA elution
ATP-biotinb
Avidin with
TFA elution
HeLa cell lysate
ATP
TiO2

0.9

3

3

253

12

11

0.8

4

1

4

1

1

0.6

3

2

14

3

3

0.8

4

4

259

10

14

1.3

317

188

490

220

309

ATP-biotin

1.1

277

147

447

153

304

0.6

4

3

69

6

5

341

126

237

Sample

Enrichment

Peptide enrichment
Casein
ATP
ATP-biotin

Avidin

Protein enrichment
Casein
ATP-biotin

Avidin

HeLa cell lysate
ATP-biotin
Avidin
1.2
468
118
FDR = false discovery rate as a percentage
b
Casein + ATP-biotin = sample was treated in the presence of CIP
a
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4.3.3: HeLa Cell Lysate Study Analysis
The optimized conditions established with β-casein were used to enrich phosphopeptides
from HeLa cell lysates. These experiments were performed in duplicate to increase the number
of phosphoproteins identified. Comparing the identified peptides, each replicate resulted in the
identification of distinct phosphopeptides; 40 (26%) or 51 (23%) phosphoproteins were common
for the two trials using avidin or TiO2 enrichment, respectively (Figure 4.10 A). More
importantly, a comparison of the biotinylation and TiO2 methods indicated that only 2 peptides
(1.3 %) were identified in common (Figure 4.10 B). The enrichment of a distinct subset of
phosphopeptides is in contrast to a prior report showing 33-35% overlap between TiO2, Fe(III),
and covalent phosphate modification methods.(169) A 19% overlap was observed when comparing
TiO2 to SnO2 enrichment.(176) The data suggest that kinase-catalyzed biotinylation enriches a
distinct subset of phosphopeptides compared to other methods.
To explain the limited overlap between the biotinylation and TiO2 methods, the phosphorylated
amino acid residues on the observed peptides were analyzed. The percentage of singly versus
multiply phosphorylated peptides was quite similar, with biotinylation and TiO2 methods
showing preference for singly phosphorylated peptides (85% versus 70% singly phosphorylated
peptides from TiO2 versus avidin purification, respectively, Tables A 4.5 and A 4.6). On the
other hand, the percentage of phosphorylation at serine, threonine and tyrosine was different for
avidin and TiO2 enrichment (46, 42, and 12% compared to 86, 12, and 2%, respectively); both
methods enrich serine and threonine over tyrosine, although the biotinylation method enriched
for serine and threonine equally and was more effective at phosphotyrosine enrichment. The ratio
of singly to multiply phosphorylated peptides from TiO2 and avidin enrichment was 5.8:1 and
2.3:1, respectively. In total, the data show that kinase-catalyzed biotinylation in cell lysates has a
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comparable efficiency of phosphopeptide identification compared to the widely used TiO2
affinity chromatography method.

Figure 4.10: Peptide Data Analysis. (A) Venn diagrams showing the overlapping peptides
identified in duplicate from avidin purification (left) and TiO2 enrichment (right). (B) Venn
diagram showing the overlapping peptides identified in the avidin and TiO2 purification
strategies. Only 2 individual phosphopeptides are found in common (1.3%). (C) Venn diagram
showing the overlapping peptides identified using avidin purification and either peptide and
protein isolation. Only 21 individual phosphopeptides are found in common (17%).

We also compared the amino acid composition of the identified phosphopeptides (Figure
4.11). With TiO2 enrichment, a bias towards phosphopeptides containing the acidic amino acids,
Asp and Glu, was observed. The bias of metal ion affinity chromatography in favor of acidic
peptides is well documented in prior reports

(169)

and is likely derived from the nonspecific

interaction of the negatively charged acidic side chains with the positively charged metal ion.
Unlike the TiO2 method, avidin enrichment showed no acidic peptide bias. As a comparison, the
amino acid composition of all peptides derived from human proteins was analyzed (Figure 4.11,
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gray bars) using the UniProtKB database (http://www.uniprot.org). As expected, the TiO2
method enriches peptides with a higher percentage of aspartic and glutamic acid residues
compared to the human protein database. In addition, both methods showed an elevated
enrichment of alanine-containing peptides. However, the avidin method did not show a
significant bias towards any other amino acid, which distinguishes it from metal-based or
chemical phosphate modification methods.(169)

Figure 4.11: Amino Acid Analysis. Amino acid composition of the identified phosphopeptides
from HeLa cell lysates with TiO2 (closed bars, black) and avidin (open bars, white) enrichment,
respectively. For comparison, the amino acid composition of all human proteins obtained from
the UniProtKB database is shown (gray bars).
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Based on the amino acid analyses, one reason the two methods enrich distinct proteins
may be due to the slight bias of TiO2 enrichment toward singly modified peptides (85% versus
70%). However, previous reports showed that IMAC had a similar increase in multiply
phosphorylated peptides (9%), yet displayed 35% overlap in phosphopeptide population
compared to TiO2 enrichment.(169) Therefore, the limited overlap between the avidin and TiO2
purification strategies is likely independent of the multiplicity of phosphorylation. In contrast,
IMAC, TiO2, and chemical covalent phosphate modification methods showed a similar bias
toward Asp, Glu, Ser but against Tyr,(169) which suggests that amino acid bias is a contributor to
their 35% overlap. Therefore, the results suggest that kinase-catalyzed biotinylation enriches a
different subset of phosphopeptides from HeLa cell lysates compared to metal ion affinity due to
its effective purification of Thr and Tyr phosphorylated peptides and lack of obvious amino acid
bias. In addition, the biotinylation method isolates only dynamically phosphorylated proteins, but
TiO2 enriches both dynamically and statically phosphorylated proteins.
A necessary requirement of the avidin purification method is that ATP-biotin must be
added to cell lysates to generate biotinylated phosphoproteins. Others have used modified ATP
cosubstrates for labeling of lysates and detection of phosphopeptides and phosphoproteins.(81)
Most notably, Shokat and colleagues have developed a chemical modification strategy using
ATP analog-sensitive kinase mutants to label phosphoproteins.(82,

83, 179)

Substrates identified

using ATP-analog sensitive kinases were confirmed in secondary cell biology studies,
demonstrating their biological relevance.(180, 181) Because kinase-catalyzed biotinylation utilizes a
similar lysate-labeling reaction to these prior successful strategies, the avidin purification method
described here is expected to isolate biologically relevant substrates.
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4.4: Purification of Full-Length Proteins
Having established phosphopeptide enrichment using kinase-catalyzed biotinylation, we
were interested in

extending our methodology towards purification of full-length

phosphoproteins. To enable MS analysis of intact proteins (for example, top-down or mediumdown proteomics),(182, 183) a method to purify phosphoproteins from complex mixtures is needed.
Metal affinity chromatography has been used exclusively for phosphopeptide enrichment,
presumably because full length proteins interact with TiO2 independent of phosphorylation
state.(184) On the other hand, avidin affinity chromatography is established to enrich full-length
proteins from cellular mixtures.(171, 185)
4.4.1: Avidin Purification with β-Casein Model Study
To initially test compatibility with full-length phosphoprotein enrichment, ATP-biotin
was incubated with full-length β-casein and CK2. The biotinylation reaction mixture was then
loaded onto an avidin affinity column, washed, eluted, and separated by SDS-PAGE (Figure 4.12
and Figure A 4.7). Biotinylated casein was visualized using Western blot analysis and an antibiotin antibody, indicating that β-casein was labeled with biotin (Figure 4.12, lane 2, bottom gel).
The flow through (Figure 4.12, lane 3) and final washing steps (Figure 4.12, lanes 4 and 5) did
not show the presence of protein, which indicates biotinylated casein bound to the beads. Finally,
phosphorylated caseins were obtained after cleavage of the biotin tag with TFA (Figure 4.12,
lane 6). The peptides resulting from in-gel digestion of the purified phosphoproteins (Figure
4.12, lane 6, top gel) were analyzed by LC/MS/MS. Sixty-nine spectral counts were observed
with 6 different peptides and 5 unique phosphorylation sites (Table 4.2 and Table A 4.7). Of the
total phosphorylated peptides recovered, 80% were phosphorylated at serine, and 20% at
threonine. The ratio of singly to multiply phosphorylated peptides from protein enrichment was
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3:1. Given that these casein experiments were performed without phosphatase incubation, the
phosphoprotein enrichment identified a similar number of unique phosphorylated sites (5 unique
sites, Table 4.1 and 4.2) compared to phosphopeptide enrichment (3 unique sites, Table 4.1 and
4.2). These results establish a protocol for enzymatic biotinylation as a means to purify intact
phosphoproteins from protein mixtures.

Figure 4.12: Capturing Biotinylated Proteins from β-Casein (A) β-casein (lane 1) was
biotinylated with CK2 and ATP-biotin (lane 2), loaded onto an avidin column (flow through,
lane 3), washed (lane 4 and 5) and eluted using 50% TFA (lane 6). The proteins were visualized
with SYPRO ruby stain (top) and a biotin-specific antibody (α- biotin, bottom). Two trials are
shown in Figure A 4.7.

4.4.2: Avidin Purification with HeLa Cell Lysates
The phosphoprotein enrichment method was then applied towards HeLa cell lysates to
confirm that the biotinylation reaction is appropriate to a proteomic application. HeLa cell
lysates were incubated with ATP-biotin and biotinylated proteins were purified using avidin
beads. As a control, lysates incubated with ATP did not show significant enrichment of proteins
(Figure A 4.9), indicating that ATP-biotin and kinase-catalyzed biotinylation are required.
Biotinylated proteins in the lysates were separated and visualized by SDS-PAGE (Figure 4.13
and Figure A 4.8). While many protein bands were observed by SYPRO Ruby stain (Figure 4.13,
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lanes 1 and 2, top), only a subset of proteins were biotinylated (Figure 4.13, lane 2, bottom).
Phosphoproteins obtained after TFA cleavage of the biotin tag (Figure 4.13, lane 6) were
subjected to in-gel digestion and LC/MS/MS analysis. The analysis indicated that 118 proteins
were phosphorylated with 341 spectral counts (Table 4.2 and Table A 4.8). From 126 different
phosphopeptides, 237 unique phosphorylation sites were identified. The protein purification
method identified 43%, 36% and 21% of phosphopeptides modified on serine, threonine and
tyrosine, respectively and the ratio of singly to multiply phosphorylated peptides was 1.4:1.
These results establish that kinase-catalyzed biotinylation followed by avidin purification is able
to enrich full-length phosphoproteins for MS analysis of intact proteins.

Figure 4.13: Capturing Biotinylated Proteins from HeLa cell Lysates: HeLa cell lysates (lane
1) were biotinylated with ATP-biotin (lane 2), loaded onto an avidin column (flow through, lane
3), washed (lane 4 and 5) and eluted with 50% TFA (lane 6). The proteins were visualized with
sypro ruby stain (top) and a biotin-specific antibody (α- biotin, bottom).

4.4.3: Full-Length Proteins Analysis
While enrichment of phosphopeptides from complex mixtures is widely reported,
particularly using metal ion affinity chromatography, the isolation of intact phosphoproteins is
poorly documented. Metal ion chromatography is not compatible with full-length protein
purification. However, intact phosphoproteins have been enriched using a chemical approach
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involving β-elimination/Micheal addition to attach biotin to phosphoproteins, followed by avidin
purification and gel analysis.(186) Unfortunately, this strategy has not been combined with MSbased phosphoproteomic analysis. To facilitate analysis of full-length phosphoproteins, the
kinase-catalyzed biotinylation method was applied to the enrichment of intact casein as well as
proteins from HeLa cell lysates. Like with phosphopeptide enrichment, the presence of
phosphatases and elution using biotin cleavage provided optimal results. We found that a similar
number of phosphoproteins were observed using full-length protein enrichment compared to
phosphopeptide enrichment; 118 phosphoproteins were identified with full-length protein
enrichment compared to 147 and 188 phosphoproteins identified with avidin and TiO2
phosphopeptide enrichment, respectively. A comparison of the avidin-based peptide and protein
enrichment experiments revealed that 21 peptides (17%, Figure 4.10 C) were in common, which
is similar to the overlap of the two peptide purification trials (26 %, Figure 4.10 A). Additionally,
the peptide and intact protein enrichment data are very similar in their Ser/Thr/Tyr
phosphorylation percentages (46, 42, and 12% versus 43, 36 and 21%) and singly to multiply
phosphorylated peptide ratios (2.3:1 versus 1.4:1). These comparisons reveal that the peptide and
protein enrichment strategies are performing consistently. With the availability of a
phosphoprotein purification strategy, studies relying on intact proteins, such as 2-D gel analysis
or top-down proteomics, can be readily applied to analysis of the phosphoproteome.

4.5: Conclusions and Future Direction
In conclusion, we have established kinase-catalyzed biotinylation for phosphoproteomic
analysis. This avidin-based purification method provides a useful alternative to metal ion affinity
chromatography by maintaining the same efficiency of enrichment. The fact that distinct
phosphopeptides were identified using avidin and TiO2 enrichment strongly suggests that the two
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methods can be coupled to more fully characterize the phosphoproteome. We also utilized the
biotinylation method to isolate intact phosphoproteins from complex mixtures. The ability to
enrich either phosphopeptides or phosphoproteins using kinase-catalyzed biotinylation will
expand the studies possible for phosphoproteomics research.
As a future direction of this method, dynamic regulation of the phosphorylation can be
study with

the

purification

method.

In

addition,

protein

purification

coupled

to

immunoprecipitation can be used to identification of intact protein using top-down MS analysis.
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4.6: Experimental
4.6.1 Materials
ATP-biotin was synthesized as explained in Chapter 2, section 2.6.3 and 2.6.4. Adenosine
5’-triphosphate disodium (ATP), glycerol, sodium hydroxide (NaOH), potassium chloride (KCl),
magnesium chloride (MgCl2), sodium chloride (NaCl), sodium dodecyl sulfate (SDS), glacial
acetic acid, and acetonitrile were purchased from Fisher. Proteomics grade trypsin, monoclonal
Anti-Biotin-Peroxidase antibody produce in mouse (A0185), ammonium bicarbonate, β-casein,
tris (2-carboxyethyl) phosphine (TCEP), and iodoacetamide (IAM) were bought from Sigma.
CK2 and CIP enzymes were purchased from New England Biolabs. Triton X-100 was purchased
from Fluka. HeLa cells were obtained from the National Cell Culture Center. Protease inhibitor
cocktail was purchased from Calbiochem, and Bovin serum albumin (BSA) was obtained from
Santa Cruz Biotechnology. PierceR detergent removal spin columns (cat. number 87777) and
ICAT-TM catridge-cation exchange column was purchased from Thermo Scientific and Applied
Biosystems, respectively. Immobilion P PVDF membrane was purchased from Millipore.
SYPRO Ruby stain was obtained from Invitrogen. Biotinylated phosphopeptides/ proteins were
enriched using NeutraAvidin Agarose Resin (Thermo Scientific) or Phos-TiO kit (GL Sciences).

4.6.2 Instrumentation
The purified final product was lyophilized using VirTis BT 3.3 EL Benchtop lyophilizer.
A SPD131 DDA ThermoSavant speed vac was used to evaporate solvents in vacuo. Quantitative
mass spectrometric analysis was performed on MALDI-TOF MS (Bruker Ultraflex). The
absorbance values for Bradford assay was measured with a fluorimeter (GENios Plus Tecan).
Microcentrifuges and mini vortex mixer was purchased from VWR and Eppendorf respectively.
The SDS-PAGE apparatus was purchased from BioRad (Protean III) and a mini-gel setup was
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used. Western blotting was carried out using the Mini-Transblot Electrophoretic Transfer Cell
apparatus from BioRad. Peptides were ionized with the ADVANCE ion source (Michrom) and
introduced into an LTQ-XL mass spectrometer (Thermo Fisher Scientific). The separated
proteins were visualized using a Typhoon 9210 scanner (Amersham Biosciences).

4.6.3 HeLa Cell Lysis Procedure
The HeLa cell lysis was performed as described in Chapter 3, section 3.7.9.

4.6.4 Bradford Assay
The Bradford assay was performed as described in Chapter 3, section 3.7.10.

4.6.5 Kinase-catalyzed Phosphorylation or Biotinylation
Phosphorylated or biotinylated proteins were prepared as follows. β-casein (0.2 mM) was
mixed with CK2 (20 units/μL) and either ATP or ATP-biotin (2 mM) in the manufacturer
supplied kinase reaction buffer for 2 hours at 30 °C with or without calf intestinal phosphatase
(CIP, 20 units/μL). The total reaction volume was 10 μL. For HeLa cell lysates, 25 μg of total
protein was incubated with either ATP or ATP-biotin (2 mM) in the manufacturer supplied 1X
CK2 buffer for 2 hours at 30 °C in a total 20 μL volume. To generate a peptide digest for MS
analysis, the sample was reduced, alkylated and trypsin digested (see section 4.6.6 for details).
The protein or peptide samples were used immediately.

4.6.6 Trypsin Digestion Procedure
SDS (dissolved in H2O, 0.1% final concentration) was added to the protein sample
(section 4.6.5) and the mixture was vortexed and spun down. Then, TCEP (dissolved in 50 mM
ammonium bicarbonate) was added to the sample to a final concentration of 5 mM, and the
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sample was vortexed, spun down, and incubated at room temperature for 45 minutes.
Iodoacetamide (dissolved in 50 mM ammonium bicarbonate) was added to the sample to a final
concentration of 15 mM and vortexd, spun down, and incubated in the dark for 30 minutes.
Trypsin (dissolved in 1 mM hydrochloric acid, 1:20 w/w ratio trypsin:protein) was then added to
the sample and vortexed, spun down, and incubated for 16 hours at 37 °C for optimum
enzymatic digestion.

4.6.7 Isolation of Biotinylated Peptides/Proteins
A NeutrAvidin bead slurry (250-300μL) was centrifuged (1000 x g, 1 min, RT) to collect
the beads. The beads were then washed five times with 200 μL of wash buffer (0.025 M TrisHCl, pH 7.4, 0.15 M NaCl, 0.0001 M EDTA, 5% glycerol). Biotinylated peptides or proteins
(section 4.8.5) were diluted with wash buffer (0.025 M Tris-HCl, pH 7.4, 0.15 M NaCl, 0.0001
M EDTA, 5% glycerol), up to 200 μL. Then the samples were incubated with the washed
NeutrAvidin beads for 2 hours at 4 ºC with rocking. The beads were collected (1000 x g, 1 min,
RT) and washed five times with 200 μL of wash buffer prior to elution.
To elute the phosphopeptides/proteins using biotin competition, elution buffer (40 μL,
0.025 M Tris-HCl, pH 7.4, 1% SDS, 0.005 M biotin) was added to the beads and the mixture was
heated to 45 ºC for 5 minutes. Eluted biotinylated phosphopeptide samples were passed through
an ICATTM cation exchange column (Applied Biosystems) using the manufacturer protocol prior
to MS analysis.
To elute phosphopeptides/proteins using acidic cleavage conditions, 50% TFA in water
(40 μL) was added to the beads and the mixture was heated to 45 ºC for 5 minutes. The
supernatant containing phosphopeptides/phosphoproteins was collected after centrifugation
(1000 x g, 2 min, RT). The TFA was evaporated using a Speedvac and then used for gel analysis
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after neutralizing with 1.5 M Tris-base (pH 8.8). Or, the remaining solution was passed through a
detergent removal column (Thermo Fisher) using the manufacturer’s protocol prior to MS
analysis.

4.6.8 TiO2 Isolation of Phospho Peptides
Phosphopeptide isolation was performed using a Phos-TiO kit (GL Sciences) using the
manufacturer recommended protocol. Peptides were generated after phosphorylation and trypsin
digestion as described in section 4.6.5 and 4.6.6 respectively. The peptide sample (total protein
mass for casein and HeLa lysate was 48 μg and 25 μg, respectively, before trypsin digest) was
mixed with 100 μL of buffer B (1 mL of 100% lactic acid) and 3 mL of buffer A (1 mL of 2%
TFA solution and 4 mL of acetonitrile), and loaded onto the TiO2 Spin Tip. The Spin Tip was
centrifuged (1000 x g, 10 min, RT). The sample in the tube was reapplied to the Spin Tip again
to assure complete binding. The Spin Tip was rinsed (3000 x g, 2min, RT) with 20 μL of buffer
B followed by 20 μL of buffer A. The peptides were eluted (1000 x g, 5min, RT) with 5%
ammonium hydroxide solution in water (50 μL), followed by 5% pyrrolidine solution in water
(50 μL). The combined, eluted sample was evaporated using a Speedvac prior to MS analysis.

4.6.9 Western Blotting
The biotin visualization was performed as described in Chapter 2, section 2.6.10. Here,
the membrane was western blotted with anti-biotin IgG (Sigma) in a 1:500 dilution.

4.6.10 Sypro Ruby Stain
The Sypro Ruby staining was performed as described in Chapter 2, section 2.6.12.
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4.6.11 In-Gel Protein Digestion
Gel slices were excised and cut into 1 mm3 cubes. Gel pieces were washed with a 1:1
mixture of 50 mM ammonium bicarbonate and acetonitrile (250 μL). Proteins were reduced with
10 mM TCEP in 25 mM ammonium bicarbonate buffer (200 μL, to cover gel pieces) for 40
minutes at room temperature, and the solution was discarsted. Then the cysteine residues were
subsequently alkylated by adding 50 mM iodoacetamide in 25 mM ammonium bicarbonate
buffer (200 μL, to cover gel pieces) for 10 minutes at room temperature in dark, and the solution
was removed. In-gel digestion was performed overnight at 37 °C after the addition of sequencing
grade trypsin (dissolved in 1 mM hydrochloric acid, 1:20 w/w ratio trypsin: protein, Promega) in
25 mM ammonium bicarbonate and 10% acetonitrile (200 μL, to cover gel pieces). The digestion
solution was also collected. Peptides were sequentially extracted from the gel using 0.1% formic
acid and acetonitrile (1:1 mixture, 200 μL) for 10 minutes at room temperature, followed by
acetonitrile (200 μL) alone for 10 minutes at room temperature. Volatile buffers and salts were
removed by desiccation using a Speedvac concentrator.

4.6.12 Mass Spectrometric Analysis
(Analysis was performed by Joseph Caruso at the Institute of Environmental Health)
Digested samples (secion 4.6.7 and 4.6.8) not separated by SDS-PAGE were either
purified using a Pierce Detergent Removal Spin column (Thermo Fisher) or manually desalted
by reverse phase chromatography using a Michrom peptide cap-trap (Thermo Fisher Scientific),
and dried in a Speedvac. For LC/MS/MS, peptides were re-suspended in 5% acetonitrile, 0.1%
formic acid and 0.005% trifluoroacetic acid (TFA). Reverse phase chromatographic separation of
peptides was performed with a Paradigm MS4 HPLC (Michrom Bioresources) at 500 nL/min
over a Magic C18AQ column (Michrom; 0.1x150 mm, 3μm, 200 Å). The gradient started at 95%
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Buffer A [2% acetonitrile, 0.1% formic acid] and 5% Buffer B [95% acetonitrile, 0.1% formic
acid], and increased to 10% Buffer B over 2 min, and then 35% Buffer B over 45 min. Mass
analysis was performed using a LTQ-XL linear ion trap mass spectrometer (Thermo Fisher).
Abundant peptides were selected for fragmentation in either collision-induced dissociation (CID)
or electron transfer dissociation (ETD) mode. For CID, the seven most abundant ions in the MS1
scan (m/z 400-1800) were selected for fragmentation, and for ETD the top five ions in the MS1
scan (m/z 400-2000) were selected. Settings for CID and ETD included an isolation width of 2
Da, normalized collision energy of 35, activation Q of 0.25 and an activation time of 30 ms
(CID) or 100 ms (ETD). Dynamic exclusion was turned on (repeat count = 1; repeat duration = 5
s; list size = 500; exclusion duration = 20 s). When samples were run in CID mode, a MS3 scan
was triggered if a neutral loss of a phosphate group was detected within the top 3 fragment ions
of the MS2 scan. The neutral loss list consisted of 49.0, 32.7 and 24.5 for doubly-, triply- and
quadruply-charged phosphopeptides, respectively. Peak lists were generated from the RAW files
using Proteome Discoverer (ver 1.3; Thermo Fisher) and exported into Mascot (ver 2.3; Matrix
Science). Search criteria included static modification of cysteine (carbamidomethylation,
+57.02), and dynamic modifications of Met (oxidation, +15.99), protein N-terminus (acetylation,
+42.01), and Ser, Thr and Tyr (phosphorylation, +79.97). MS2 and MS3 spectra were searched
against tryptic peptide sequences (up to 1 missed cleavage) within the latest bovine (NCBI) or
human (UniProtKB) databases. Charge states of +2, +3 and +4 were assigned for CID MS2
spectra, and the ETD Spectrum Charger node within Proteome Discoverer was used to determine
the charge state of peptides analyzed by ETD. A simultaneous search was performed against a
scrambled database to estimate the false discovery rate (FDR). Reported peptides scored above a
1.3% FDR threshold. Mascot search results were exported to Scaffold (ver 3.6; Proteome
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Software) and a subset database was researched using the X! Tandem algorithm. Phosphosite
localization probabilities were generated using ScaffoldPTM (ver 2.0; Proteome Software).

4.6.13 Data Analysis
Peptide and proteins cutoffs used for Scaffold are listed in each supplementary table. 99%
protein and 90% (Table A 4.7), 80% (Table A 4.1, A 4.2 and A 4.3) and 55% (Table A 4.4)
peptide probability cutoffs were used with casein samples in Scaffold. For HeLa lysates, 90%
protein and 55% peptide probability cutoffs (Table A 4.8) and 50% protein and 80% (Table A
4.5) or 79% (Table A 4.6) peptide probability cutoffs were used for full length and peptide
enrichment experiments, respectively.
Frequency of amino acid composition (Figure 4.11) was calculated by dividing the times
a particular amino acid was observed by the total number of amino acids.
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APPENDIX A
2.1 Compound Characterization

Figure A 2.1: HRMS of biotin-PEG amine 8

Figure A 2.2: The IR spectrum (4000-650 cm-1) of biotin-PEG amine 8
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Figure A 2.3: 1H-NMR of biotin-PEG amine 8 recorded in D2O solvent

Figure A 2.4: 13C-NMR of biotin-PEG amine 8 recorded in D2O solvent
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Figure A 2.5: HRMS of ATP-biotin 2

Figure A 2.6: The UV absorbance spectrum (200-600 nm) of ATP-biotin 2
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Figure A 2.7: 1H-NMR of ATP-biotin 2 recorded in D2O solvent

Figure A 2.8: 13C-NMR of ATP-biotin 2 recorded in D2O solvent
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Figure A 2.9: 31P-NMR of ATP-biotin 2 recorded in D2O solvent

2.2 Complete Gel Images for Peptide Labeling
(A) Reaction with AKT

137
(B) Reaction with CAMK4

(C) Reaction with CHK1

138
(D) Reaction with FLT1

(E) Reaction with GSK3β

139
(F) Reaction with MARK1

(G) Reaction with MST1

140
(H) Reaction with PAK1

(I) Reaction with RSK1

141
(J) Reaction with SRC

Figure A 2.10: Full gel images for peptide labeling experiment with 10 different kinases.
Phosphorylated peptides or biotinylated phosphopeptides were created by incubating ATP or
ATP-biotin with AKT1 and AKT(PKB) substrate (CKRPRAASFAE) (A), CAMK4 and
Autocamtide

(KKALRRQETVDAL-amide)

(B),

CHK1

and

CHKtide

(KKKVSRSGLYRSPSMPENLNRPR) (C), FLT1 and IGF1Rtide (KKKSPGEYVNIEFG) (D),
GSK3β and GSK3 substrate (YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE) (E), MARK1 and
CHKtide (KKKVSRSGLYRSPSMPENLNRPR) (F), MST1 and Axltide (KKSRGDYMTMQIG)
(G), PAK1 and PAKtide (RRRLSFAEPG) (H), RSK1 and S6K substrate (KRRRLASLR) (I), or
SRC and SRC substrate (KVEKIGEGTYGVVYK-amide) (J), in the manufacturer provide buffer
(1X, Promega). Crude reaction mixtures were separated on a 16% Tris-tricine peptide gel and
transferred to a PVDF membrane. Peptides are visualized with Coomassie Brilliant Blue (top
gel) and biotinylated peptides with SA-Cy5 conjugate (bottom gel) with reaction contents
indicated above each lane. Trials 1, 2, and 3 represent three independent trials. Reaction with
CAMK4 labeling was seen only with single trial.
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2.3 Complete Gel Images for Protein Labeling
(A) Reaction with ASK1

(B) Reaction with Aurora A

143
(C) Reaction with CDK1

(D) Reaction with CK1

144
(E) Reaction with DAPK1

(F) Reaction with ERK1

145
(G) Reaction with GRK5

(H) Reaction with HIPK1

146
(I) Reaction with JAK3

(J) Reaction with MLK1

147
(K) Reaction with NEK2

(L) Reaction with TGFβR2

148
(M) Reaction with TRKA

Figure A 2.11: Full gel images for protein labeling experiment with 13 different kinases.
Phosphorylated proteins or biotinylated phosphoproteins were created by incubating ATP or
ATP-biotin with ASK1 and MBP (A), Aurora A and MBP (B), CDK1 and Histone H1 protein
(C), CK1 and dephosphorylated Casein protein (D), DAPK1 and MBP (E), ERK1 and MBP (F),
GRK5 and Casein protein (G), HIPK1 and MBP (H), JAK3 and poly (Glu4, Tyr1) peptide
substrate (I), MLK1 and MBP (J), NEK2 and MBP (K), TGFβR2 and MBP (L), or TRKA and
poly (Glu4, Tyr1) peptide substrate (M) in the manufacturer provide buffer (1X, Promega). Crude
reaction mixtures were separated on 16% SDS-PAGE and transferred in to PVDF membrane.
Proteins are visualized with Sypro Ruby Stain (top gel) and biotinylated proteins with SA-Cy5
conjugate (bottom gel) with reaction contents indicated above each lane. Trial 1, 2, and 3
represented three independent trials. MBP stand for Myelin Basic Protein. Complete gel images
for remaining three kinases (Abl, CK2, and PKA) can be found on Appendix 3.2. The
experiments with ASK1, CDK1, CK1, GRK5, HIPK1, and MLK1 were performed by graduate
student Maheeka Embogama. The experiment with CDK1, CK1, GRK5, MLK1 western blots
indicate biotin labeling of BSA, which is a component in the buffer used in kinase reaction. Both
JAK3 and TRKA labeling was seen only in a single trial. Molecular weight of protein as follows:
MBP (~18 kDa), Casein (~24 kDa), and Histone H1 (~22 kDa).
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2.4 Complete HPLC Traces
(A) Reaction with Abl
i

ii

150
iii

Figure A 2.12: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or
biotinylation (panel 3). Reactions were performed using Abl enzyme and the Abl peptide
substrate (EAIYAAPFAKKK). i, ii, and iii are three independent trials.
(B) Reaction with AKT1
i

151
ii

iii

Figure A 2.13: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or
biotinylation (panel 3). Reactions were performed using AKT1 enzyme and the AKT (PKB)
substrate (CKRPRAASFAE). i, ii, and iii are three independent trials.
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(C) Reaction with CAMK4
i

ii
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iii

Figure A 2.14: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or
biotinylation (panel 3). Reactions were performed using CAMK4 enzyme and the Autocamtide
(KKALRRQETVDAL-amide). i, ii, and iii are three independent trials.
(D) Reaction with CK2
i
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ii

iii

Figure A 2.15: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or
biotinylation (panel 3). Reactions were performed using CK2 enzyme and the CK2 peptide
substrate (RRREEETEEE). i, ii, and iii are three independent trials.
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(E) Reaction with FLT1
i

ii
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iii

Figure A 2.16: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or
biotinylation (panel 3). Reactions were performed using FLT1 enzyme and the IGF1Rtide
(KKKSPGEYVNIEFG). i, ii, and iii are three independent trials.
(F) Reaction with GSK3β
i
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ii

iii

Figure A 2.17: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or
biotinylation (panel 3). Reactions were performed using GSK3β enzyme and the GSK3 substrate
(YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE). i, ii, and iii are three independent trials. Note:
Because the starting peptide was already phosphorylated, the separation of mono and diphosphorylated peptides was poor.
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(G) Reaction with PAK1
i

ii
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iii

Figure A 2.18: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or
biotinylation (panel 3). Reactions were performed using PAK1 enzyme and the PAKtide
(RRRLSFAEPG). i, ii, and iii are three independent trials.
(H) Reaction with PKA
i
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ii

iii

Figure A 2.19: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or
biotinylation (panel 3). Reactions were performed using PKA enzyme and the kemptide
(LRRASLG). i, ii, and iii are three independent trials.

161
(I) Reaction with RSK1
i

ii

162
iii

Figure A 2.20: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or
biotinylation (panel 3). Reactions were performed using RSK1 enzyme and the S6K substrate
(KRRRLASLR). i, ii, and iii are three independent trials. Note: phodphopeptide was eluted after
the unphosphorylated starting peptide.
(J) Reaction with SRC
i
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ii

iii

Figure A 2.21: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or
biotinylation (panel 3). Reactions were performed using SRC enzyme and the SRC peptide
substrate (KVEKIGEGTYGVVYK-amide). i, ii, and iii are the three independent trials. Note:
biotin-amine peak (tR~12.6 min) was not observed in the biotinylation reaction (panel 3).

164

2.5 Complete Gel Images for Protein Quantification
(A) Reaction with ASK1

(B) Reaction with Aurora A

165
(C) Reaction with CAMK4

(D) Reaction with CDK1

166
(E) Reaction with CHK1

(F) Reaction with CK1

167
(G) Reaction with DAPK1

(H) Reaction with ERK1
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(I) Reaction with GRK5

(J) Reaction with HIPK1
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(K) Reaction with JAK3

(L) Reaction with MARK1
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(M) Reaction with MLK1

(N) Reaction with MST1

171
(O) Reaction with NEK2

(P) Reaction with TGFβR2
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(Q) Reaction with TRKA

Figure A 2.22: Full gel images for protein quantification experiment with 16 different kinases.
Phosphorylated proteins or biotinylated phosphoproteins were created by incubating ATP or
ATP-biotin with ASK1 and MBP (A), Aurora A and MBP (B), CAMK4 and MBP (C), CHK1
and MBP (D), CDK1 and Histone H1 protein (E), CK1 and dephosphorylated Casein protein (F),
DAPK1 and MBP (G), ERK1 and MBP (H), GRK5 and Casein protein (I), HIPK1 and MBP (J),
JAK3 and poly (Glu4, Tyr1) peptide substrate (K), MARK1 and MBP (L), MLK1 and MBP (M),
MST1 and MBP (N), NEK2 and MBP (O), TGFβR2 and MBP (P), or TRKA and poly (Glu4,
Tyr1) (Q) peptide substrate in the manufacturer provide buffer (1X, Promega). Reaction products
were treated with 50% TFA to obtain phosphoproteins for quantification. Crude reaction
mixtures were separated on 16% SDS-PAGE. Proteins were visualized with Sypro Ruby Stain
(top gel) and phosphoproteins with Pro-Q diamond stain (bottom gel) with reaction contents
indicated above each lane. Trial 1, 2, and 3 represent three independent trials. MBP stands for
Myelin Basic Protein. Quantification of ERK1 and TGFβR2 was done with only two trials as the
other one was outlier. The experiment with CAMK4 was performed by Maheeka Embogama.
Sypro Ruby and Pro-Q stains are independent gels load from same crude reaction mixtures.
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2.6 Michaelis-Menten Kinetics Plots
(A) Reaction with Abl

Figure A 2.23: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with Abl and Abl peptide (EAIYAAPFAKKK). Average of three independent trials with
standard error is shown here. m1=Vmax and m2=KM.
(B) Reaction with AKT1

Figure A 2.24: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with AKT1 and AKT (PKB) peptide substrate (CKRPRAASFAE). Average of three independent
trials with standard error is shown here. m1=Vmax and m2=KM.

174
(C) Reaction with ASK1

Figure A 2.25: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with ASK1 and MBP. Average of three independent trials with standard error is shown here.
m1=Vmax and m2=KM.

(D) Reaction with Aurora A

Figure A 2.26: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with Aurora A and MBP. Average of three independent trials with standard error is shown here.
m1=Vmax and m2=KM.
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(E) Reaction with CAMK4

Figure A 2.27: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with CAMK4 and Autocamtide (KKALRRQETVDAL-amide). Average of three independent
trials with standard error is shown here. m1=Vmax and m2=KM.
(F) Reaction with CDK1

Figure A 2.28: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with CDK1 and Histone H1 protein. Average of three independent trials with standard error is
shown here. m1=Vmax and m2=KM.
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(G) Reaction with CHK1

Figure A 2.29: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with CHK1 and CHKtide (KKKVSRSGLYRSPSMPENLNRPR). Average of three independent
trials with standard error is shown here. m1=Vmax and m2=KM.
(H) Reaction with CK1

Figure A 2.30: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with CK1 and dephosphorylated Casein protein. Average of three independent trials with
standard error is shown here. m1=Vmax and m2=KM.
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(I) Reaction with CK2

Figure A 2.31: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with CK2 and CK2 peptide (RRREEETEEE). Average of three independent trials with standard
error is shown here. m1=Vmax and m2=KM.
(J) Reaction with DAPK1

Figure A 2.32: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with DAPK1 and MBP. Average of three independent trials with standard error is shown here.
m1=Vmax and m2=KM.
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(K) Reaction with ERK1

Figure A 2.33: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with ERK1 and MBP. Average of three independent trials with standard error is shown here.
m1=Vmax and m2=KM.
(L) Reaction with FLT1

Figure A 2.34: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with FLT1 and IGF1Rtide (KKKSPGEYVNIEFG). Average of three independent trials with
standard error is shown here. m1=Vmax and m2=KM.
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(M) Reaction with GRK5

Figure A 2.35: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with GRK5 and Casein protein. Average of three independent trials with standard error is shown
here. m1=Vmax and m2=KM.
(N) Reaction with GSK3β

Figure A 2.36: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with GSK3β and GSK3 substrate (YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE). Average of three
independent trials with standard error is shown here. m1=Vmax and m2=KM.
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(O) Reaction with HIPK1

Figure A 2.37: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with HIPK1 and MBP. Average of three independent trials with standard error is shown here.
m1=Vmax and m2=KM.
(P) Reaction with JAK3

Figure A 2.38: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with JAK3 and poly (Glu4, Tyr1) peptide substrate. Average of three independent trials with
standard error is shown here. m1=Vmax and m2=KM.
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(Q) Reaction with MARK1

Figure A 2.39: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with MARK1 and CHKtide (KKKVSRSGLYRSPSMPENLNRPR). Average of three
independent trials with standard error is shown here. m1=Vmax and m2=KM.
(R) Reaction with MLK1

Figure A 2.40: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with MLK1 and MBP. Average of three independent trials with standard error is shown here.
m1=Vmax and m2=KM.
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(S) Reaction with MST1

Figure A 2.41: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with MST1 and Axltide (KKSRGDYMTMQIG). Average of three independent trials with
standard error is shown here. m1=Vmax and m2=KM.
(T) Reaction with NEK2

Figure A 2.42: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with NEK2 and MBP. Average of three independent trials with standard error is shown here.
m1=Vmax and m2=KM.
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(U) Reaction with PAK1

Figure A 2.43: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with PAK1 and PAKtide (RRRLSFAEPG). Average of three independent trials with standard
error is shown here. m1=Vmax and m2=KM.
(V) Reaction with PKA

Figure A 2.44: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with PKA and kemptide (LRRASLG). Average of three independent trials with standard error is
shown here. m1=Vmax and m2=KM.
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(W) Reaction with RSK1

Figure A 2.45: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with RSK1 and S6K substrate (KRRRLASLR). Average of three independent trials with
standard error is shown here. m1=Vmax and m2=KM.
(X) Reaction with SRC

Figure A 2.46: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with SRC and SRC substrate (KVEKIGEGTYGVVYK-amide). Average of three independent
trials with standard error is shown here. m1=Vmax and m2=KM.
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(Y) Reaction with TGFβR2

Figure A 2.47: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with TGFβR2 and MBP. Average of three independent trials with standard error is shown here.
m1=Vmax and m2=KM.
(Z) Reaction with TRKA

Figure A 2.48: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right)
with TRKA and poly (Glu4, Tyr1) peptide substrate. Average of three independent trials with
standard error is shown here. m1=Vmax and m2=KM.
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2.7 Supporting HPLC Traces for Biotinylation

Figure A 2.49: HPLC traces for the CK2 peptides after biotinylation. Reactions were performed
using CK2 enzyme and the CK2 peptide substrate (RRREEETEEE) and subjected to HPLC
analysis with (top spectra) or without (bottom spectra) heat deactivation and pre-equlibration
with buffer. Without these treatments, ATP-biotin remained intact (tR=10.3), where the biotinamine linker (tR=12.6) attached to phosphate on peptide was removed. The peptide appears at 7.6
min, while the phosphopeptide appears at 7.1 min.

2.8 Mechanism for Biotin-amine Cleavage

Figure A 2.50: Release of biotin-amine linker attached to phosphate on peptides during preequilibration and HPLC analysis at low pH and high pressure. The cleavage is facilitate by
neighboring group participating.
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2.9 ADP-Glo Assay Controls-HPLC Data

A

B

C

D

Figure A 2.51: HPLC traces for the ATP (A, tR=42.1 min) ADP (A, tR=38.2 min), AMP (A,
tR=32.6 min), ATP-biotin (B, tR=28.0 min), adenine (C, tR=6.9 min), and adenosine (D, tR=7.1
min).
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2.10 ADP-Glo Assay Controls-Time dependent Luminescence Data

Figure A 2.52: ATP ( ) or ATP-biotin (

) incubated with kinase detection reagent and

luminescence signal was measure every 2.5 min with five different concentration (1 µM, 3 µM,
10 µM, 30 µM, and 100 µM). Mean of the three independent trials is shown with standard errors.
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APPENDIX B
3.1 Complete HPLC Traces
(A) Reaction with PKA and PP1
HPLC trace for reactions performed using PKA and PP1 (Trial 1).

HPLC trace for reactions performed using PKA and PP1 (Trial 2).

190
HPLC trace for reactions performed using PKA and PP1 (Trial 3).

Figure A 3.1: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2),
phosphorylation followed by phosphatase treatment (panel 3), biotinylation (panel 4) or
biotinylation followed by phosphatase treatment (panel 5). Reactions were performed using
PKA, the PKA substrate peptide (LRRASLG), and PP1. All the three independent trials are
shown here with the percentage of phosphopeptide in the reaction.
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(B) Reaction with CK2 and CIP
HPLC trace for reactions performed using CK2 and CIP (Trial 1).

HPLC trace for reactions performed using CK2 and CIP (Trial 2).

192
HPLC trace for reactions performed using CK2 and CIP (Trial 3).

Figure A 3.2: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2),
phosphorylation followed by phosphatase treatment (panel 3), biotinylation (panel 4) or
biotinylation followed by phosphatase treatment (panel 5). Reactions were performed using
CK2, the CK2 peptide (RRREEETEEE), and CIP. A, B, and C are the three independent trials
with the percentage of phosphopeptide in the reaction.

193
(C) Reaction with Abl and TCPTP
HPLC trace for reactions performed using Abl and TCPTP (Trial 1).

HPLC trace for reactions performed using Abl and TCPTP (Trial 2).

194
HPLC trace for reactions performed using Abl and TCPTP (Trial 3).

Figure A 3.3: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2),
phosphorylation followed by phosphatase treatment (panel 3), biotinylation (panel 4) or
biotinylation followed by phosphatase treatment (panel 5). Reactions were performed using Abl,
the Abl substrate peptide (EAIYAAPFAKKK), and TC PTP. A, B, and C are the three
independent trials with the percentage of phosphopeptide in the reaction.
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3.2 Complete Gel Images
(A) Reaction with PKA and PP1
Gel images for reactions performed using PKA and PP1 (Trial 1).

Gel images for reactions performed using PKA and PP1 (Trial 2).

196
Gel images for reactions performed using PKA and PP1 (Trial 3).

Figure A 3.4: Full gel images for full length protein experiments containing PKA, MBP
substrate, and PP1, with reaction contents indicated under each lane. The three independent
trials, showing 2%, 5%, and 12% phosphoproteins remain (Pro-Q, lane 7), and 74%, 63%, and
79% biotinylated phosphoproteins remain (SA-Cy5, lane 9) after phosphatase treatment. The
ATP kinase reaction (lane 6) is set to 100% in Pro-Q, while the ATP-biotin kinase reaction (lane
8) is set to 100% SA-Cy5.
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(B) Reaction with CK2 and CIP
Gel images reactions performed using CK2 and CIP (Trial 1).

Gel images reactions performed using CK2 and CIP (Trial 2).

198
Gel images reactions performed using CK2 and CIP (Trial 3).

Figure A 3.5: Full gel images for full length protein experiments containing CK2, β-casein
substrate, and CIP, with reaction contents indicated under each lane. The three independent
trials, showing 9%, 4%, and 5% phosphoproteins remain (Pro-Q, lane 7), and 70%, 108%, and
66% biotinylated phosphoproteins remain (SA-Cy5, lane 9) after phosphatase treatment. The
ATP kinase reaction (lane 6) is set to 100% in Pro-Q, while the ATP-biotin kinase reaction (lane
8) is set to 100% SA-Cy5.
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(C) Reaction with Abl and TCPTP
Gel images for reactions performed using Abl and TC PTP (Trial 1).

Gel images for reactions performed using Abl and TC PTP (Trial 2).

200
Gel images for reactions performed using Abl and TC PTP (Trial 3).

Figure A 3.6: Full gel images for full length protein experiments containing Abl, MBP substrate,
and TC PTP, with reaction contents indicated under each lane. The three independent trials,
showing 11%, 7%, and 2% phosphoproteins remain (Pro-Q, lane 7), and 70%, 68%, and 111%
biotinylated phosphoproteins remain (SA-Cy5, lane 9) after phosphatase treatment. The ATP
kinase reaction (lane 6) is set to 100% in Pro-Q, while the ATP-biotin kinase reaction (lane 8) is
set to 100% SA-Cy5.
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3.3 Gel Images Related to Inhibitors Studies.
Gel images for reactions performed using presence of kinase or phosphatase inhibitors (Trial 1).

Gel images for reactions performed using presence of kinase or phosphatase inhibitors (Trial 2).

202
Gel images for reactions performed using presence of kinase or phosphatase inhibitors (Trial 3).

Figure A 3.7: Gel analysis of phosphoproteins (ProQ, top) or biotinylated phosphoproteins (SACy5, bottom) from HeLa cell lysates incubated with ATP or ATP-biotin in the absence or
presence of kinase or phosphatase inhibitors. The contents of each reaction are indicated below
each lane. Addition of kinase inhibitor showed 15%, 18%, and 22% phosphopeptides (Pro-Q,
lane 3), and 31%, 33%, and 16% biotinylated phosphoproteins (SA-Cy5, lane 6). Addition of
phosphatase inhibitors showed 136%, 109%, and 110% phosphopeptides (Pro-Q, lane 4), and
83%, 90%, and 69% biotinylated phosphoproteins (SA-Cy5, lane 7). The ATP kinase reaction
(lane 2) is set to 100% in Pro-Q, while the ATP-biotin kinase reaction (lane 5) is set to 100%
SA-Cy5.
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3.4 Quantification of Gel Images Related to Inhibitors Studies

Figure A 3.8: Gel bands were quantified using ImageQuant 5.1 by drawing the same size
rectangular shape around comparable bands. The percentage of phosphoproteins or biotinylated
phosphoproteins observed after kinase or phosphatase inhibitor treatment was calculated by
dividing the protein signal after treatment (Pro-Q, lane 3 or 4 and SA-Cy5, lane 6 or 7) to the
protein signal before treatment (Pro-Q, lane 2 and SA-Cy-5, lane 5). The contents of each
reaction are indicated below each lane. The ATP kinase reaction (lane 2) is set to 100% in part
A, while the ATP-biotin kinase reaction (lane 5) is set to 100% in part B.
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3.4 Two-Dimension Gel Images
(A) Gel images for reactions performed using ATP in the presence of phosphatase inhibitors

Trial 1

Trial 2

Trial 3

Figure A 3.9: Reaction of HeLa cell lysates and ATP with phosphatase inhibitors (phosphatase
inhibitor treated). Proteins were visualized with Pro-Q diamond phosphoprotein stain. All the
three independent trials are displayed here.
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(B) Gel images for reactions performed using ATP in the absence of phosphatase inhibitors

Trial 1

Trial 2

Trial 3

Figure A 3.10: Reaction of HeLa cell lysates and ATP without phosphatase inhibitors
(untreated). Proteins were visualized with Pro-Q diamond phosphoprotein stain. All the three
independent trials are displayed here.
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(C) Gel images for reactions performed using ATP-biotin in the presence of phosphatase inhibitors

Trial 1

Trial 2

Trial 3

Figure A 3.11: Reaction of HeLa cell lysates and ATP-biotin with phosphatase inhibitors
(phosphatase inhibitor treated). Biotinylated proteins were visualized with SA-Cy5. All the three
independent trials are displayed here.
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(D) Gel images for reactions performed using ATP-biotin in the absence of phosphatase inhibitors

Trial 1

Trial 2

Trial 3

Figure A 3.12: Reaction of HeLa cell lysates and ATP-biotin without phosphatase inhibitors
(untreated). Biotinylated proteins were visualized with SA-Cy5. All the three independent trials
are displayed here.

208

APPENDIX C
Table A 4.1: Phosphopeptides identified by MS analysis after kinase-catalyzed biotinylation of
casein, followed by purification of the trypsin digestion using NeutrAvidin affinity
chromatography and elution with biotina
Accession
number

Protein name
Peptide sequence

gi|30794310

Casein, beta

MW (Da)

SCb

PPc

ISd/IDSe

LPf

IMg

4

80

34/44

100

CID

25,000

FQsEEQQQTEDELQDK

a

Peptides identified by MS were searched for serine, threonine, or tyrosine residues containing a
+508 m/z modification, which is consistent with the presence of a biotinylated phosphate. 99%
protein and 80% peptides cutoffs were used to generate the Scaffold coverage which scored
above 0.8% FDR threshold. bSC=Spectral Count. c PP= Peptide probability (written as
percentage). d IS= Ion Score. e IDS= Identity Score. fLP= Localization Probability(written as a
percentage). gIM= Ionization Method. CID=Collision Induced Dissociation.

Annotated spectra from Scaffold
Peptide sequence: FQsEEQQQTEDELQDK

Figure A 4.1: The annotated spectrum of casein proteins identified by MS/MS analysis after
ATP-biotin treatment, followed by avidin purification and biotin elution. Only one peptide was
observed.
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Table A 4.2: Phosphopeptides identified by MS analysis after purification of a trypsin digestion
of casein using TiO2 affinity chromatographya
Accession
number

Proteins/peptides name

gi|30794348

Casein, alpha s1

gi|27806963

SCb

PPc

ISd/IDSe

LPf

IMg

DIGsEStEDQAMEDIK

2

95

44/46

100,14

CID

DIGsEsTEDQAMEDIK

1

75

31/46

100,92

CID

VPQLEIVPNsAEER

16

95

87/48

100

both

VPQLEIVPNsAEERLHSMK

4

95

88/49

100

both

YKVPQLEIVPNsAEER

16

95

121/49

100

both

YKVPQLEIVPNsAEERLHSMK

1

95

53/49

99

ETD

KTVDMEsTEVFTKK

3

95

111/49

100

ETD

NAVPITPTLNREQLsTsEENSKK

6

95

74/49

93,87

ETD

NAVPITPTLNREQLStsEENSKK

1

93

59/49

31,70

ETD

NAVPITPTLNREQLsTSEENsKK

1

95

65/49

64,94

ETD

TVDMEsTEVFTK

6

95

77/49

90

both

TVDMEsTEVFTKK

7

95

91/49

99

both

TVDmEStEVFTKK

4

95

61/49

33

ETD

2

92

43/49

83

ETD

FQsEEQQQTEDELQDK

78

95

108/49

100

both

FQsEEQQQtEDELQDK

7

94

88/49

100,100

both

FQSEEQQQtEDELQDK

1

82

34/46

99

CID

IEKFQsEEQQQTEDELQDK

82

95

77/46

100

both

IEKFQsEEQQQtEDELQDK

10

95

51/46

100,100

CID

IEKFQSEEQQQtEDELQDK

1

94

48/49

100

CID

KIEKFQsEEQQQTEDELQDK

4

95

112/49

100

ETD

Casein, alpha-S2

MW (Da)
24 500

26 000

TVDMEsTEVFTKKTK
gi|30794310

a

Casein, beta

25 000

Peptides identified by MS were searched for serine, threonine, or tyrosine residues containing a
+80 m/z modification, which is consistent with the presence of a phosphate group. 99% protein
and 80% peptides cutoffs were used to generate the Scaffold coverage which scored above 0.9%
FDR threshold. b SC=Spectral Count. c PP= Peptide probability (written as percentage). d IS= Ion
Score. e IDS= Identity Score. fLP= Localization Probability (written as a percentage, multiple
numbers corresponding to the value of each site). gIM= Ionization Method. CID=Collision
Induced Dissociation, ETD= Electron Transfer Disscociation, both=CID and ETD.
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Sequence of Casein Protein

Figure A 4.2: Primary sequences of casein proteins identified in the TiO2 purification after ATP
treatment. Amino acids highlighted in yellow represent peptides observed in the MS/MS
analysis, while amino acids in green were modified through either phosphorylation (S or T) or
oxidation (M). 99% protein and 80% peptides cutoffs were used to generate the Scaffold
coverage, which scored above 0.9% FDR threshold.

Annotated spectra from Scaffold
Peptide sequence: DIGsEsTEDQAMEDIK
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Peptide sequence: DIGsEStEDQAMEDIK

Peptide sequence: VPQLEIVPNsAEER

Peptide sequence: VPQLEIVPNsAEERLHSMK

Peptide sequence: YKVPQLEIVPNsAEER
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Peptide sequence: YKVPQLEIVPNsAEERLHSMK

Peptide sequence: NAVPITPTLNREQLsTsEENSKK

Peptide sequence: NAVPITPTLNREQLStsEENSKK

Peptide sequence: NAVPITPTLNREQLsTSEENsKK
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Peptide sequence: KTVDMEsTEVFTKK

Peptide sequence: TVDMEsTEVFTKK

Peptide sequence: TVDmEStEVFTKK

Peptide sequence: TVDMEsTEVFTK
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Peptide sequence: TVDMEsTEVFTKKTK

Peptide sequence: FQsEEQQQTEDELQDK

Peptide sequence: FQsEEQQQtEDELQDK

Peptide sequence: FQSEEQQQtEDELQDK
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Peptide sequence: IEKFQSEEQQQtEDELQDK

Peptide sequence: IEKFQsEEQQQtEDELQDK

Peptide sequence: IEKFQsEEQQQTEDELQDK

Peptide sequence: KIEKFQsEEQQQTEDELQDK

Figure A 4.3: The annotated spectrum of casein proteins identified by MS/MS analysis after
ATP treatment, followed by TiO2 purification. While twelve unique peptide spectra were
observed, several had variable phosphorylation states. All 21 spectra representing the observed
phosphorylated states are shown.
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Table A 4.3: Phosphopeptides identified by MS analysis after kinase-catalyzed biotinylation of
casein, followed by purification of the trypsin digestion using NeutrAvidin affinity
chromatography and acidic elutiona
Accession
number

Proteins/Peptides name

gi|30794348

Casein, alpha s1

gi|30794310

SCb

PPc

ISd/IDSe

LPf

IMg

VPQLEIVPNsAEER

1

94

42/46

100

CID

YKVPQLEIVPNsAEER

9

95

62/48

100

both

4

81

37/46

100,100

CID

MW (Da)

Casein, beta
IEKFQsEEQQQtEDELQDK

a

24,500

25,000

Peptides identified by MS were searched for serine, threonine, or tyrosine residues containing a
+80 m/z modification, which is consistent with the presence of a phosphate group. 99% protein
and 80% peptides cutoffs were used to generate the Scaffold coverage which scored above 0.6%
FDR threshold. b SC=Spectral Count. c PP= Peptide probability (written as percentage). d IS=
Ion Score. e IDS= Identity Score. f LP= Localization Probability (written as a percentage,
multiple numbers corresponding to the value of each site). g IM= Ionization Method.
CID=Collision Induced Dissociation, ETD= Electron Transfer Disscociation, both=CID and
ETD.

Annotated spectra from Scaffold
Peptide sequence: YKVPQLEIVPNsAEER
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Peptide sequence: VPQLEIVPNsAEER

Peptide sequence: IEKFQsEEQQQtEDELQDK

Figure A 4.4: The annotated spectrum of casein proteins identified by MS/MS analysis after
ATP-biotin treatment, followed by avidin purification and acidic elution. Three peptides were
observed
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Table A 4.4: Phosphopeptides identified by MS analysis after kinase-catalyzed biotinylation of
casein in the presence of calf intestinal phosphatase, followed by purification of the trypsin
digestion using NeutrAvidin affinity chromatography and acidic elutiona
Accession
numbers

Proteins/Peptides name

gi|30794348

Casein, alpha s1

gi|27806963

gi|30794310

gi|27881412

SCb

PPc

ISd/IDSe

LPf

IMg

DIGSEsTEDQAMEDIK

2

95

50/46

85

CID

DIGsEsTEDQAMEDIK

13

95

52/46

100,99

CID

VNELsKDIGsEStEDQAMEDIK

1

56

29/46

100,100,29

CID

VPQLEIVPNsAEER

17

95

71/46

100

CID

YKVPQLEIVPNsAEER

26

95

113/46

100

CID

NANEEEYsIGsssEEsAEVATEEVK

2

55

28/46

72,83,87,
79,57

CID

TVDMEsTEVFTK

3

95

64/46

99

CID

TVDMEStEVFTK

10

95

64/46

81

CID

TVDMEsTEVFTKK

11

95

71/46

99

CID

FQsEEQQQTEDELQDK

96

95

81/46

100

CID

FQsEEQQQtEDELQDK

14

95

51/46

100,100

CID

IEKFQsEEQQQTEDELQDK

47

95

62/46

100

CID

IEKFQsEEQQQtEDELQDK

16

94

48/46

100,100

CID

1

80

37/46

100

CID

Casein, alpha-S2

Casein, beta

Casein, kappa
sPAQILQWQVLSNTVPAK

a

MW
(Da)
24,500

26,000

25,000

21,252

Peptides identified by MS were searched for serine, threonine, or tyrosine residues containing a
+80 m/z modification, which is consistent with the presence of a phosphate group. 99% protein
and 55% peptides cutoffs were used to generate the Scaffold coverage which scored above 0.8%
FDR threshold. b SC=Spectral Count. c PP= Peptide probability (written as percentage). d IS= Ion
Score. e IDS= Identity Score. f LP= Localization Probability (written as a percentage, multiple
numbers corresponding to the value of each site). g IM= Ionization Method. CID=Collision
Induced Dissociation.
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Sequence of Casein Protein

Figure A 4.5: Primary sequences of casein proteins identified in the Avidin purification after
ATP-biotin treatment in the presence of CIP. Amino acids highlighted in yellow represent
peptides observed in the MS/MS analysis, while amino acids in green were modified through
either phosphorylation (S or T) or oxidation (M). 99% protein and 55% peptides cutoffs were
used to generate the Scaffold coverage, which scored above 0.8% FDR threshold.
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Annotated spectra from Scaffold
Peptide sequence: DIGsEsTEDQAMEDIK

Peptide sequence: DIGSEsTEDQAMEDIK

Peptide sequence: VNELsKDIGsEStEDQAMEDIK

Peptide sequence: VPQLEIVPNsAEER
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Peptide sequence: YKVPQLEIVPNsAEER

Peptide sequence: NANEEEYsIGsssEEsAEVATEEVK

Peptide sequence: TVDMEsTEVFTKK

Peptide sequence: TVDMEStEVFTK
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Peptide sequence: TVDMEsTEVFTK

Peptide sequence: sPAQILQWQVLSNTVPAK

Peptide sequence: FQsEEQQQTEDELQDK

Peptide sequence: FQsEEQQQtEDELQDK
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Peptide sequence: IEKFQsEEQQQTEDELQDK

Peptide sequence: IEKFQsEEQQQtEDELQDK

Figure A 4.6: The annotated spectrum of casein proteins identified by MS/MS analysis after
ATP-biotin treatment in the presence of CIP, followed by avidin purification and acidic elution.
While ten unique peptide spectra were observed, several had variable phosphorylation states. All
14 spectra representing the observed phosphorylated states are shown.
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Table A 4.5: Phosphopeptides identified by MS analysis after kinase-catylzed biotinylation of
HeLa cell lysates and subsequent purification of the trypsin digestion using NeutrAvidin affinity
chromatography and acidic elutiona

Accession
numbers

Proteins/peptides name

DECR_HUMAN

2,4-dienoyl-CoA reductase, mitochondrial

MW
(Da)

26S protease regulatory subunit 4

28S ribosomal protein S28, mitochondrial

40S ribosomal protein S12

40S ribosomal protein S15a

40S ribosomal protein S17

40S ribosomal protein S24

60S acidic ribosomal protein P0

60S acidic ribosomal protein P2

60S ribosomal protein L11

60S ribosomal protein L12

60S ribosomal protein L14

6-phosphogluconate dehydrogenase,
decarboxylating

Actin, alpha skeletal muscle

Adenylate kinase 2, mitochondrial
AtMDAGKLVSDEMVVELIEK

CID

2

95

43/43

100

CID

13

95

82/43

100

CID

1

95

43/43

100

CID

1

95

40/43

100

CID

6

95

57/43

97,70

CID

1

93

45/43

49

CID

2

95

58/43

100

CID

1

95

37/43

100

CID

23

95

71/43

99

CID

7

90

59/43

100, 100

CID

2

95

51/43

81

CID

3

95

33/43

100

CID

5

95

65/43

99

CID

42,052

KDLYANNVmsGGTTmYPGIADR
KAD2_HUMAN

98

53,142

ALYAsKIISYAQGFmLLR
ACTS_HUMAN

22/43

23,432

APGtKGtAAAAAAAAAAK

6PGD_HUMAN

91

17,819

VVYLRctGGEVGATSALAPK
RL14_HUMAN

1

20,253

YDPSIGIYGLDFYVVLGRPGFsIADKK
RL12_HUMAN

CID

11,666

YVASYLLAALGGNSsPSAK
RL11_HUMAN

15

34,274

NVASVcLQIGYPTVASVPHsIINGYKR
RLA2_HUMAN

69/43

15,424

tHFGGGKTtGFGMIYDSLDYAK
RLA0_HUMAN

95

15,551

DNYVPEVSALDQEIIEVDPDtKEMLK
RS24_HUMAN

1

14,840

QFGFIVLtTSAGImDHEEAR
RS17L_HUMAN

IMg

14,515

aEEGIAAGGVMDVNTALQEVLKtALIHDGLAR
RS15A_HUMAN

LPf

20,843

NVEsFASmLR
RS12_HUMAN

ISd/IDSe

49,186

MGQsQSGGHGPGGGK
RT28_HUMAN

PPc

36,069

GAAFLSITTIYAETGSGFVVPSASAKAGVEAMsK
PRS4_HUMAN

SCb

26,479
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AKA12_HUMAN

A-kinase anchor protein 12

191,474

GsVEEPKPEEPK
AKP8L_HUMAN

1

95

47/43

100

CID

3

95

39/43

87

CID

1

95

41/43

45

CID

2

95

53/43

91

CID

3

95

44/43

100

CID

1

95

51/43

100, 100

CID

3

94

56/42

42,92

CID

1

95

56/43

89

CID

9

95

72/43

55,90

CID

1

91

43/43

43

CID

MTQIMFEAFNTPAMyVAIQAVLSLYASGR

38

95

57/43

100

CID

cPEAIFQPSFLGIEsSGIHETTFNSImK

1

95

30/43

100

CID

EKMTQIMFEAFNtPAMYVAIQAVLSLYASGR

9

95

43/43

99

CID

1

95

40/43

98

CID

3

93

43/42

100

CID

1

93

49/42

11

CID

1

95

46/43

63

CID

1

95

32/43

57,34,72

CID

1

95

33/43

43,27,39

CID

A-kinase anchor protein 8-like

71,650

AVLsERDLYR
APLP1_HUMAN

Amyloid-like protein 1

72,176

EAVsGLLImGAGGGSLIVLSMLLLRR

ANR16_HUMAN

Ankyrin repeat domain-containing protein
16

39,284

FLLQsGLK
ANXA1_HUMAN

Annexin A1

38,716

amVsEFLKQAWFIENEEQEYVQTVK
ANXA2_HUMAN

Annexin A2

38,606

ELAsALKsALSGHLETVILGLLK
ANXA3_HUMAN

Annexin A3

36,377

HYGYSLysAIKSDTSGDYEITLLK
AP2A2_HUMAN

AP-2 complex subunit alpha-2

103,963

QLsNPQQEVQNIFK
AATM_HUMAN

Aspartate aminotransferase, mitochondrial

47,519

YyDPKtcGFDFTGAVEDISK

ABCE1_HUMAN

ATP-binding cassette sub-family E member
1

67,316

NTVANsPQTLLAGmNKFLSQLEITFR
ACTBL_HUMAN

BMP4_HUMAN

Beta-actin-like protein 2

Bone morphogenetic protein 4

42,004

46,555

FLFNLsSIPENEVISSAELR

KCC4_HUMAN

Calcium/calmodulin-dependent protein
kinase type IV

51,926

tEIGVLLR
CATB_HUMAN

Cathepsin B

37,821

NGPVEGAFSVYSDFLLYKsGVYQHVTGEmMGGHAIR
CIDEA_HUMAN

Cell death activator CIDE-A

24,688

GVmASsLQELISK

CENP1_HUMAN

CENPB DNA-binding domain-containing
protein 1

21,053

SIIEEGEytPQVSLt
CE350_HUMAN

Centrosome-associated protein 350
DNKAtSPGPtDLEtR

350,933
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CHKB_HUMAN

Choline/ethanolamine kinase

45,272

EPVLsAAIATK
COPE_HUMAN

2

95

46/43

71

CID

1

90

40/43

95

CID

2

95

51/43

100

CID

95

56/43

42

CID

1

95

42/42

100

CID

2

95

30/43

29

CID

1

95

33/43

34

CID

MAAAFNTTVAALEDELTQLILEGLIsAR

1

95

53/43

76

CID

IPPAIKsANsELGGIWSVGQR

3

92

48/43

100,100

CID

1

95

38/43

100,100

CID

1

91

39/42

100

CID

1

94

30/43

100,100,100

CID

2

95

76/42

34,37.39

CID

1

94

53/43

35

CID

1

95

30/43

32

CID

1

95

32/43

43

CID

4

95

39/42

23,21

CID

1

95

49/43

76

CID

Coatomer subunit epsilon

34,483

LVLQYAPsA
COF1_HUMAN

Cofilin-1

18,503

asGVAVSDGVIK
COF2_HUMAN

Cofilin-2

18,737

StLGEKLGGNVVVSLEGKPL
CO9A2_HUMAN

Collagen alpha-2(IX) chain

65,131

AAAtASPR
CO6A6_HUMAN

Collagen alpha-6(VI) chain

247,178

mIsAGLPGEMGSPGEPGPPGR

C1T9A_HUMAN

Complement C1q and tumor necrosis factorrelated protein 9A

34,682

DAYMSsEDQASGGIVLQLK
CSN1_HUMAN

KCRB_HUMAN

COP9 signalosome complex subunit 1

Creatine kinase B-type

55,538

42,645

LAVEALSSLDGDLAGRyyALK
CD11A_HUMAN

Cyclin-dependent kinase 11A

91,363

EYGsPLK
CDK12_HUMAN

Cyclin-dependent kinase 12

164,159

WSDSSKQDDSPSGASYGQDyDLsPsR

UCRI_HUMAN

Cytochrome b-c1 complex subunit Rieske,
mitochondrial

29,668

GFSYLVtGVttVGVAYAAKNAVTQFVSSmSASADVLALAK
CCHL_HUMAN

Cytochrome c-type heme lyase

30,602

DYQFtILDVRPALDSLSAVWDR
ERCC6_HUMAN

DNA excision repair protein ERCC-6

168,419

VPVQEIDDDFFPSsGEEAEAASVGEGGGGGRK
DUS4_HUMAN

Dual specificity protein phosphatase 4

42,954

LmNRDENGGGAGGSGSHGTLGLPsGGK
DYM_HUMAN

Dymeclin

75,939

AAAsPELsSPLANQSLLLLLVLANLTDASDAPNPYRQAImSFK
TRI23_HUMAN

E3 ubiquitin-protein ligase TRIM23
QDEFMQPIPtIGFNVETVEYK

64,066
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EXOS1_HUMAN

Exosome complex component CSL4

21,452

LcNLEEGSPGSGTYTRHGyIFsSLAGcLmK
GNA1_HUMAN

Glucosamine 6-phosphate N-acetyltransferase

Glyceraldehyde-3-phosphate dehydrogenase

GRIP1-associated protein 1

Heat shock-related 70 kDa protein 2

Helicase POLQ-like

Heterogeneous nuclear ribonucleoproteins
A2/B1

Heterogeneous nuclear ribonucleoproteins
C1/C2

Histone H1.4

Histone H1x

Histone-lysine N-methyltransferase SETD2

Hydroxysteroid dehydrogenase-like protein 2

Keratin, type I cytoskeletal 17

Keratin, type I cytoskeletal 18

Keratin, type II cytoskeletal 1

Keratin, type II cytoskeletal 6A

Keratin, type II cytoskeletal 7

Keratin, type II cytoskeletal 79
QTYSTKGGFSSNSASGGsGsQAR

95

50/43

45,63

CID

1

95

29/43

77,80

CID

1

95

57/43

100

CID

3

92

52/43

93,99

CID

2

95

51/43

78

CID

1

95

40/43

100, 100

CID

6

95

62/43

21

CID

1

95

48/42

45

CID

5

95

75/43

99, 100

CID

15

95

56/43

98

CID

5

93

44/43

100

CID

2

95

31/43

43

CID

2

93

56/43

42,57,57,81

CID

17

95

61/43

99,87

CID

1

95

28/43

78,83

CID

51,387

TLNETELtELQsQISDTSVVLSmDNSR
K2C79_HUMAN

1

60,046

AIGGGLSSVGGGSSTIKyTTtSSssR
K2C7_HUMAN

CID

66,040

MsGEcAPNVSVSVSTSHTTISGGGSR
K2C6A_HUMAN

99

48,059

NHEEEVKGLQAQIAsSGLTVEVDAPK
K2C1_HUMAN

72/43

48,107

TIEELQNKILtATVDNANILLQIDNAR
K1C18_HUMAN

95

45,397

tAQPHPKLLGtIYTAAEEIEAVGGK
K1C17_HUMAN

8

287,597

KsSEFLK
HSDL2_HUMAN

CID

22,488

NQPGKYsQLVVETIR
SETD2_HUMAN

100,100

21,867

sEtAPAAPAAPAPAEK
H1X_HUMAN

36/43

33,671

SMNsRVFIGNLNTLVVK
H14_HUMAN

95

37,430

DyFEEyGKIDTIEIITDR

HNRPC_HUMAN

3

124,136

LyLSFVLYTLLK

ROA2_HUMAN

CID

70,023

SENVQDLLLLDVTPLSLGIEtAGGVmtPLIK
HELQ_HUMAN

31,38

95,991

SGLEELVLSEMNsPsR
HSP72_HUMAN

50/43

36,053

LtGMAFRVPTANVSVVDLTcR
GRAP1_HUMAN

91

20,749

LNcyKItLEcLPQNVGFYK
G3P_HUMAN

1

57,836

228

LARP1_HUMAN

La-related protein 1

123,513

GEGSDsKESPK
LIPM_HUMAN

1

95

35/43

100

CID

1

90

40/43

76

CID

1

95

91/43

18

CID

GytNWAIGLSVADLIESMLK

2

95

43/43

100,100

CID

IHPVstMVKGMYGIENEVFLSLPcILNAR

5

95

66/43

79,73

CID

1

95

49/43

67,63

CID

1

95

34/43

77

CID

1

95

28/43

43,21

CID

1

95

33/43

45

CID

1

95

46/42

99,99

CID

1

95

54/42

41,23

CID

1

95

25/43

54,62

CID

1

95

45/43

98

CID

1

95

46/43

71,73

CID

1

95

56/43

99,99

CID

3

95

46/43

100,50

CID

1

95

31/43

100

CID

1

95

29/43

43

CID

Lipase member M

48,234

EFLyQTR
LDH6B_HUMAN

L-lactate dehydrogenase A-like 6B

41,944

LMISSIVQYsPHcKLIIVSNPVDILTYVAWK
LDHB_HUMAN

LONF1_HUMAN

L-lactate dehydrogenase B chain

LON peptidase N-terminal domain and RING
finger protein 1

36,639

86,726

mSsPAVARTsPGGSR

L12R1_HUMAN

Loss of heterozygosity 12 chromosomal
region 1 protein

22,223

MGsEQSSEAESRPNDLNSSVTPSPAK
GMPPB_HUMAN

Mannose-1-phosphate guanyltransferase beta

39,834

ALILVGGyGtR
MA7D3_HUMAN

MAP7 domain-containing protein 3

98,431

ESMEAsPEAmVK
MALD1_HUMAN

MARVEL domain-containing protein 1

18,915

WLmVNVAHDVLAAALYGAATGImSDQmQRHsycNLK

MARE1_HUMAN

Microtubule-associated protein RP/EB family
member 1

30,000

mAVNVYStsVTSDNLSRHDmLAWINESLQLNLTK

M4K2_HUMAN

Mitogen-activated protein kinase kinase kinase
kinase 2

91,558

VVRNPYtGATFLLAALPTSLLLLQWyEPLQK
MYL6_HUMAN

Myosin light polypeptide 6

16,930

HVLVTLGEKmtEEEVEmLVAGHEDSNGcINYEAFVR
ML12B_HUMAN

Myosin regulatory light chain 12B

19,780

NAFAcFDEEATGTIQEDYLRELLttMGDR
MTMRC_HUMAN

Myotubularin-related protein 12

86,150

LINssDELQDNFR
MTMR8_HUMAN

Myotubularin-related protein 8

78,921

SVTLGtVVGSsK
NAA10_HUMAN

N-alpha-acetyltransferase 10

26,459

GLAAEDSGGDsK
NPHP3_HUMAN

Nephrocystin-3
NLAVLSyEGGDFEK

150,870

229

AHNK_HUMAN

Neuroblast differentiation-associated protein
AHNAK

629,104

AGAISASGPELQGAGHsKLQVTMPGIK
NPM_HUMAN

1

95

30/43

100

CID

3

95

51/43

100,100,100

CID

ymNSGPVVAmVWEGLNVVK

2

95

41/43

88

CID

YmNsGPVVAmVWEGLNVVK

1

95

69/43

13

CID

1

95

33/43

21

CID

3

91

46/43

44

CID

8

95

48/43

100

CID

1

92

45/43

88

CID

3

95

72/43

78

CID

2

95

51/43

60,83

CID

AsLsKLGDVYVNDAFGTAHR

13

95

58/43

100,100

CID

TGQATVASGIPAGWMGLDcGPEsSK

5

95

34/43

83

CID

1

95

35/43

25

CID

1

95

48/43

28

CID

1

95

66/43

47,47

CID

20

95

46/43

100

CID

1

95

53/43

100

CID

2

95

59/43

41,84,45

CID

1

90

49/43

100

CID

Nucleophosmin

32,576

VtLATLKmsVQPTVsLGGFEITPPVVLR
NDKB_HUMAN

O10P1_HUMAN

Nucleoside diphosphate kinase B

Olfactory receptor 10P1

17,298

34,743

mAGENHTTLPEFLLLGFsDLK
OR6B1_HUMAN

Olfactory receptor 6B1

35,301

LALGSWAIGFGIsLAK
PPIA_HUMAN

Peptidyl-prolyl cis-trans isomerase A

18,013

MVNPtVFFDIAVDGEPLGR
PAL4G_HUMAN

Peptidyl-prolyl cis-trans isomerase A-like 4G

18,166

HtGSGILSMANAGPNTNGSQFFIcTAK

PPIF_HUMAN

Peptidyl-prolyl cis-trans isomerase F,
mitochondrial

22,040

AcSKGsGDPSSSSSSGNPLVYLDVDANGKPLGR
PEX19_HUMAN

Peroxisomal biogenesis factor 19

32,807

ETLsGLAKNAtDLQNSSmSEEELTK
PGK1_HUMAN

PFD2_HUMAN

Phosphoglycerate kinase 1

Prefoldin subunit 2

44,615

16,648

SSGsGAGKGAVSAEQVIAGFNR
PFD3_HUMAN

Prefoldin subunit 3

22,659

NLSTAtKNLDSLEEDLDFLR
PAWR_HUMAN

PRKC apoptosis WT1 regulator protein

36,568

mATGGYRtsSGLGGSTTDFLEEWK
PROF1_HUMAN

Profilin-1

15,054

mAGWNAyIDNLmADGTcQDAAIVGYK
PDCD5_HUMAN

Programmed cell death protein 5

14,285

EAEmRNsILAQVLDQSAR
PHB2_HUMAN

Prohibitin-2

33,298

TIAtsQNRIYLtADNLVLNLQDESFTR
PSME2_HUMAN

Proteasome activator complex subunit 2
AFYAELYHIISsNLEKIVNPK

27,402
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PSA2_HUMAN

Proteasome subunit alpha type-2

25,899

GysFsLttFSPSGKLVQIEYALAAVAGGAPSVGIK
PSA5_HUMAN

1

95

53/43

92,86,84,73

CID

1

95

60/43

95,95

CID

6

95

89/42

43

CID

VEVTSPNLDVsLPSmEVDIQAPGAKLDStR

1

91

22/43

82

CID

smEASVDVtAPK

1

95

53/43

100100

CID

1

95

22/43

100

CID

1

95

31/43

63,90,85

CID

1

95

33/43

99,99

CID

3

95

42/43

23

CID

1

90

43/43

100

CID

18

95

60/43

100100

CID

1

95

56/43

100

CID

1

95

31/43

23,27,67

CID

1

94

27/43

100,

CID

1

95

25/43

19

CID

1

95

36/43

31

CID

4

95

63/43

94,83

CID

1

95

58/43

32

CID

Proteasome subunit alpha type-5

26,411

LFQVEYAIEAIKLGSTAIGIQtsEGVcLAVEK
PSB7_HUMAN

Proteasome subunit beta type-7

29,966

FRPDMEEEEAKNLVsEAIAAGIFNDLGSGSNIDLcVISK
AHNK2_HUMAN

DPY30_HUMAN

Protein AHNAK2

Protein dpy-30 homolog

616,628

11,250

MEPEQMLEGQtQVAENPHSEYGLTDNVER
MIDA_HUMAN

Protein midA homolog, mitochondrial

49,239

DHVEVcPDAGVIIEELSQRIALtGGAALVADyGHDGtK
MUTED_HUMAN

Protein Muted homolog

21,610

msGGGTETPVGcEAAPGGGsK
PPR29_HUMAN

Protein phosphatase 1 regulatory subunit 29

89,689

RDSTYsQLSPR
VPRBP_HUMAN

Protein VPRBP

169,011

DENsQLVAIVLR
PLP2_HUMAN

Proteolipid protein 2

16,691

MADsERLsAPGcWAAcTNFSR
PSYR_HUMAN

Psychosine receptor

39,335

yLAVVYPLK
ASXL3_HUMAN

Putative Polycomb group protein ASXL3

241,919

EAAAAAAVAAAASIVsGAmGsPGEGGKtR
CAF17_HUMAN

Putative transferase CAF17, mitochondrial

38,156

yLQGVPEGVRDLPPGVALPLESNLAFMNGVSFTK
CX069_HUMAN

Putative uncharacterized protein CXorf69

9,236

EALGSGHYVGGsIRSMAAAALSGLAVR

VSIG7_HUMAN

Putative V-set and immunoglobulin domaincontaining protein 7

13,301

ILFLVVIAAGAQSQVQLmQsGAEVKKPGASVR
RB11B_HUMAN

Ras-related protein Rab-11B

24,489

NNLSFIETSALDSTNVEEAFKNILtEIyR
RAB21_HUMAN

Ras-related protein Rab-21
HVSIQEAESYAESVGAKHyHTSAK

24,348

231

RFC2_HUMAN

Replication factor C subunit 2

39,158

yRPVKLNEIVGNEDTVSR
RTBDN_HUMAN

1

95

51/43

100

CID

1

95

32/42

80,96

CID

1

95

35/43

78

CID

1

93

44/43

73,78

CID

2

95

42/43

86,58

CID

1

95

41/43

47

CID

2

95

52/43

100,100

CID

1

95

28/43

82,80

CID

1

95

53/42

21,19

CID

95

51/43

100,100

CID

2

95

54/43

100

CID

YVVKTSFYsNK

2

95

32/43

100

CID

YVVKTSFySNK

4

95

29/43

81

CID

1

95

57/43

91

CID

1

95

39/43

100

CID

1

95

30/43

100

CID

9

95

63/43

79

CID

mDGEEKtYGGcEGPDAmYVK

2

95

51/43

29

CID

EHALtSGTIKAmLSGPGQFAENETNEVNFR

2

95

65/43

24

CID

Retbindin

24,615

mDcRVHmRPIGLTWVLQLtLAWILLEAcGGsRPLQAR
RHG23_HUMAN

Rho GTPase-activating protein 23

162,197

LsPPAAPEERPAADTRSIVSGYSTLSTmDR
ARHGI_HUMAN

Rho guanine nucleotide exchange factor 18

130,784

GTLLsDGsPALSR
PRPS2_HUMAN

Ribose-phosphate pyrophosphokinase 2

34,770

LLsAGAtKVYAILTHGIFSGPAISR
RYR2_HUMAN

Ryanodine receptor 2

564,570

SSTLQQLIsETmVR
SALL4_HUMAN

Sal-like protein 4

112,231

SSLPstFIR

PP1RA_HUMAN

Serine/threonine-protein phosphatase 1
regulatory subunit 10

99,059

LSHDNmEEKVPWVcPRPLVLPSPLVTPGsNsQER
SPB6_HUMAN

Serpin B6

42,623

TYIGEIFTQILVLPYVGKELNMIImLPDEttDLR
MTAP_HUMAN

S-methyl-5'-thioadenosine phosphorylase

31,236

AEsFMFRtWGADVINmTTVPEVVLAK
STMN1_HUMAN

Stathmin

17,303

ASGQAFELILsPR

SMC5_HUMAN

SODC_HUMAN

Structural maintenance of chromosomes
protein 5

Superoxide dismutase [Cu-Zn]

128,810

15,935

DGVADVSIEDSVISLSGDHcIIGRtLVVHEK
TCPH_HUMAN

T-complex protein 1 subunit eta

59,368

QQLLIGAyAKALEIIPR
THEM5_HUMAN

Thioesterase superfamily member 5

27,678

GLKLPSGLAVsSDK
THIO_HUMAN

Thioredoxin

11,737

QIESKtAFQEALDAAGDK

ELOC_HUMAN

Transcription elongation factor B polypeptide
1

12,473

232

BTF3_HUMAN

Transcription factor BTF3

22,168

VQAsLAANTFTLTGHAEtKQLtEmLPSILNQLGADSLTSLR
TFR1_HUMAN

Transferrin receptor protein 1

Transgelin-2

Transmembrane protein 200A

Triosephosphate isomerase

Ubiquitin carboxyl-terminal hydrolase 36

Ubiquitin-conjugating enzyme E2 D2

Uncharacterized protein C12orf43

Unconventional myosin-If

Vesicle-trafficking protein SEC22b

Wee1-like protein kinase 2

Zinc finger and BTB domain-containing protein
7A
aGGVDGPIGIPFPDHsSDILSGLNEQR

2

95

51/43

100

CID

1

95

31/43

100

CID

2

90

51/43

96,86

CID

2

95

37/43

100

CID

1

95

33/43

30,30

CID

1

95

50/43

100

CID

1

95

33/43

100

CID

4

95

48/43

100

CID

2

93

43/42

100

CID

1

95

32/43

72

CID

62,926

LFLQsGGK

ZBT7A_HUMAN

CID

24,594

VLLtmIARVADGLPLAASmQEDEQSGR
WEE2_HUMAN

65

124,847

SSQAPtRAAPAPPR
SC22B_HUMAN

45/43

28,171

LFFtSVPGGREK
MYO1F_HUMAN

95

16,736

SQWSPALTISKVLLsIcsLLcDPNPDDPLVPEIAR
CL043_HUMAN

2

122,653

tGSSSLPGRPSVIPDHSKK
UB2D2_HUMAN

CID

30,791

VVLAYEPVWAIGTGKtAtPQQAQEVHEK
UBP36_HUMAN

100,64,69

54,358

SsMALGPGAGQLLSPGAARR
TPIS_HUMAN

80/42

22,392

ENFQNWLKDGtVLcELINALYPEGQAPVK
T200A_HUMAN

95

84,874

mmDQARsAFSNLFGGEPLSYTR
TAGL2_HUMAN

3

61,440
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Total phosphoproteins
Spectral count
Number of different phosphopeptides
Number of multiply phosphorylated peptides
Number of singly phosphorylated peptides
Number of each phosphorylated amino acid observed
Number of unique phosphorylated amino acids
a

147
447
153
135
312
256(pS), 234(pT), 66(pY)
304

Peptides identified by MS were searched for serine, threonine, or tyrosine residues containing a
+80 m/z modification, which is consistent with the presence of a phosphate group. 50% protein
and 80% peptides cutoffs were used to generate the Scaffold coverage which scored above 1.1%
FDR threshold. b SC=Spectral Count. c PP= Peptide probability (written as percentage). d IS=
Ion Score. e IDS= Identity Score. f LP= Localization Probability (written as a percentage,
multiple numbers corresponding to the value of each site). g IM= Ionization Method.
CID=Collision Induced Dissociation.
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Table A 4.6: Phosphopeptides identified by MS analysis after purification of a HeLa cell lysate
trypsin digestion using TiO2 affinity chromatography a
Accession
U5S1_HUMAN

MW
(Da)

SCb

PPc

ISd/IDSe

LPf

IMg

3

95

82/46

51

CID

1

87

49/48

100

ETD

9

95

65/46

100

CID

EESEEsDDDMGFGLFD

4

95

68/46

100

CID

KEESEEsDDDMGFGLFD

34

95

7846

100

CID

VRYsLDPENPTK

3

95

63/48

100

both

VRySLDPENPTK

1

88

49/48

100

ETD

1

89

33/45

100

CID

1

84

50/48

92,71,
81,82

ETD

1

89

50/48

29

ETD

EMNDAAMFyTNR

1

86

35/46

100

CID

SGPKPFSAPKPQTsPSPK

6

95

63/48

92

ETD

1

95

58/48

32

ETD

1

79

46/47

100,100

CID

1

94

63/49

22,32,
22

ETD

1

84

47/48

100

ETD

3

95

56/48

99

both

Protein/peptide name
116 kDa U5 small nuclear
ribonucleoprotein component

109,420

mDTDLYDEFGNYIGPELDsDEDDDELGRETK
RS27_HUMAN

40S ribosomal protein S27

9,443

PLAKDLLHPsPEEEK
RLA0L_HUMAN

60S acidic ribosomal protein P0-like

34,347

EESEEsDEDmGFGLFD
RLA2_HUMAN

RL17_HUMAN

RL3_HUMAN

60S acidic ribosomal protein P2

60S ribosomal protein L17

60S ribosomal protein L3

11,647

21,379

46,092

HGsLGFLPR

MEPCE_HUMAN

7SK snRNA methylphosphate capping
enzyme

74,338

tsSKsEAGARGGGQGsK
ANLN_HUMAN

Actin-binding protein anillin

124,184

TPIsPLKTGVSKPIVK
CAP1_HUMAN

AK1C1_HUMAN

Adenylyl cyclase-associated protein 1

Aldo-keto reductase family 1 member C1

51,838

36,771

dAGLAKSIGVsNFNR

ANR53_HUMAN

Ankyrin repeat domain-containing
protein 53

59,514

AtALsKTPEQR

AGAP2_HUMAN

Arf-GAP with GTPase, ANK repeat and
PH domain-containing protein 2

124,659

gSKSSAGTGAsVsAAAtAAAAGGGGSTASTSGGVGAGAGAR
ARGL1_HUMAN

Arginine and glutamate-rich protein 1

33,199

ASsPPDRIDIFGR

ABCF1_HUMAN

ATP-binding cassette sub-family F
member 1

95,910

LSVPTsDEEDEVPAPKPR
ACLY_HUMAN

ATP-citrate synthase

120,825

235

AKPAMPQDSVPsPR
ATN1_HUMAN

Atrophin-1

Bifunctional aminoacyl-tRNA synthetase

BRCA1-A complex subunit RAP80

Bromodomain-containing protein 4

Calcium-activated chloride channel regulator 4

cAMP-dependent protein kinase type I-alpha
regulatory subunit PE=1 SV=1

cAMP-dependent protein kinase type II-alpha
regulatory subunit

Caskin-2

Catenin alpha-1

Chromodomain-helicase-DNA-binding protein
8

Chromosome transmission fidelity protein 18
homolog

Coiled-coil domain-containing protein 46

Collagen alpha-1(XVII) chain

Contactin-associated protein-like 4

Coronin-7

CXXC-type zinc finger protein 5

Cyclic nucleotide-gated cation channel beta-3
LFKtLLGGTGKASLAR

82

52/48

50

ETD

1

95

6048

94

ETD

1

82

46/48

63,67

ETD

1

83

36/46

99

CID

1

79

46/48

26

CID

1

84

47/48

100

ETD

2

95

76/46

45

ETD

1

86

68/48

27,26,65

ETD

1

95

51/48

83,84,76,65

ETD

1

95

58/46

57,66,23

ETD

1

85

57/49

54,41,67,29

ETD

1

83

53/46

100

ETD

1

92

54/48

100

ETD

1

86

70/49

48,37

ETD

1

79

45/48

99

ETD

32,960

sLRRSRPLSHYSSFGSSGGSGGGsMmGGEsADK
CNGB3_HUMAN

1

100,588

DGALVGtAcKDKQLR
CXXC5_HUMAN

CID

145,259

GsVTGAVLK
CORO7_HUMAN

26

150,404

rGSSySSsmsTGGGGAGsLGAGGAFGEAAGDR
CNTP4_HUMAN

36

112,733

SSQIIAELQttIsSLK
COHA1_HUMAN

84

107,366

GDAAssPAPAAsVGsSQGGARK
CCD46_HUMAN

1

290,503

SQEILSQGNPFmGVSATAVSsssAGGQPPQSAPK

CTF18_HUMAN

ETD

100,055

TPEELDDsDFETEDFDVR

CHD8_HUMAN

12

126,768

GLLQGEALsEGGRR
CTNA1_HUMAN

49/48

45,501

AATIVATSEGsLWGLDR
CSKI2_HUMAN

86

42,964

TDSREDEIsPPPPNPVVK

KAP2_HUMAN

1

101,267

KIEAtRcSAGIsGR

KAP0_HUMAN

ETD

152,199

LNLPDYyKIIK
CLCA4_HUMAN

100

79,709

vKEVSEsRNLEK
BRD4_HUMAN

48/48

170,575

EYIPGQPPLSQSSDSsPTRNSEPAGLETPEAK
UIMC1_HUMAN

86

124,756

ASPGGVStSSSDGKAEK
SYEP_HUMAN

1

92,235

236

DC1L1_HUMAN

Cytoplasmic dynein 1 light intermediate chain
1

56,562

DFQEYVEPGEDFPAsPQRR
CYTSA_HUMAN

1

95

39/46

99

ETD

1

95

44/49

62,63,60,60

ETD

1

84

48/48

81

ETD

1

79

47/48

17

ETD

AIPELDAYEAEGLALDDEDVEELTAsQR

1

93

40/46

98

CID

GLLYDsDEEDEERPARK

1

80

36/46

89

CID

GLLYDsDEEDEERPAR

1

81

32/46

99

CID

RGLLYDsDEEDEERPAR

1

95

55/46

23

CID

1

95

75/49

13

ETD

1

95

49/46

100

CID

8

95

98/45

99

CID

2

95

57/46

95

both

EEsDDEAAVEEEEEEKKPK

2

95

45/46

100

CID

VEEEPEEEPEETAEDTTEDTEQDEDEEMDVGtDEEEETAK

1

95

102/45

27

CID

4

89

51/48

92

both

5

95

55/46

78, 100

CID

1

94

56/48

100

ETD

2

95

48/46

71

CID

15

95

115/46

100

CID

Cytospin-A

124,587

StcPsAAPsASAPAMTTVENKsK
DSC3_HUMAN

Desmocollin-3

99,953

gWITIDEIsGSIITSK
DNMT1_HUMAN

DNA (cytosine-5)-methyltransferase 1

183,151

LVMAGETtNSRGQR
MCM2_HUMAN

DMRT1_HUMAN

DNA replication licensing factor MCM2

Doublesex- and mab-3-related transcription
factor 1

101,880

39,455

AGGFGKASGALVGAASGSSAGGsSRGGGSGSGASDLGAGSK
HUWE1_HUMAN

E3 ubiquitin-protein ligase HUWE1

481,874

GSGTAsDDEFENLR
EF1B_HUMAN

Elongation factor 1-beta

24,746

YGPADVEDTTGSGATDSKDDDDIDLFGsDDEEESEEAK
EF1D_HUMAN

Elongation factor 1-delta

31,104

KPATPAEDDEDDDIDLFGsDNEEEDKEAAQLR
ENPL_HUMAN

EIF2A_HUMAN

Endoplasmin

Eukaryotic translation initiation factor 2A

92,454

64,973

SDKsPDLAPTPAPQSTPR

EIF3B_HUMAN

Eukaryotic translation initiation factor 3
subunit B

92,465

ALENGDADEPSFsDPEDFVDDVsEEELLGDVLK

EIF3C_HUMAN

Eukaryotic translation initiation factor 3
subunit C

105,329

QPLLLsEDEEDTKR

EIF3G_HUMAN

Eukaryotic translation initiation factor 3
subunit G

35,594

GIPLATGDtSPEPELLPGAPLPPPKEVINGNIK

EIF3J_HUMAN

Eukaryotic translation initiation factor 3
subunit J

29,045

aAAAAAAGDSDsWDADAFSVEDPVR
IF4G3_HUMAN

Eukaryotic translation initiation factor 4

176,638
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gamma 3
DITEEIMSGGGsR
IF2P_HUMAN

1

92

53/48

39

ETD

2

93

39/46

100

CID

2

95

60/49

79,95

ETD

1

86

71/49

38,42

ETD

1

81

45/48

100

ETD

1

95

65/49

96

ETD

1

90

52/49

45,37,66

ETD

1

80

47/49

68,88,78,57

ETD

1

89

50/47

95, 100

ETD

1

88

38/46

100,100,100

CID

1

95

60/48

88,65

ETD

1

81

50/48

96,46

ETD

ESEDKPEIEDVGsDEEEEK

2

95

49/46

100

CID

ESEDKPEIEDVGsDEEEEKK

2

95

49/46

100

both

EEKESEDKPEIEDVGsDEEEEKK

2

92

76/46

100

both

ESEDKPEIEDVGsDEEEEKKDGDK

1

95

48/46

100

ETD

1

95

64/49

85,98,97,99

ETD

8

95

66/46

100

both

5

95

54/46

100

CID

Eukaryotic translation initiation factor 5B

138,813

NKPGPNIEsGNEDDDASFK
FAS_HUMAN

Fatty acid synthase

273,409

QGVQVQVstSNISSLEGAR
FBSP1_HUMAN

F-box/SPRY domain-containing protein 1

30,615

aAPAPGAGAAsGGAGcSGGGAGAGAGSGsGAAGAGGR
FOXK1_HUMAN

Forkhead box protein K1

75,439

EGsPIPHDPEFGSK
FREM2_HUMAN

FRAS1-related extracellular matrix protein 2

351,137

TGTDLsK
F16A2_HUMAN

FTS and Hook-interacting protein

105,552

DGAGLGLSGGsPGAstPVLLTR

GRIN3_HUMAN

G protein-regulated inducer of neurite
outgrowth 3

82,420

LsDscGsIsKADHSGSLDPTNK
CXA3_HUMAN

Gap junction alpha-3 protein

47,411

asKASRASsGR
GLYG2_HUMAN

Glycogenin-2

55,166

lVVLItPQVssLLR

GCC2_HUMAN

GRIP and coiled-coil domain-containing
protein 2

184,642

KtVETLQQQLsK
RAD_HUMAN

GTP-binding protein RAD

33,227

MtLNGGGSGAGGsR
HS90A_HUMAN

HSP72_HUMAN

Heat shock protein HSP 90-alpha

Heat shock-related 70 kDa protein 2

84,645

70,005

lyQGGPGGGsGGGGSGAsGGPtIEEVD
HDGF_HUMAN

Hepatoma-derived growth factor

26,771

AGDLLEDsPKRPK
HNRPU_HUMAN

Heterogeneous nuclear ribonucleoprotein U

90,567

LQAALDDEEAGGRPAMEPGNGsLDLGGDSAGR

HNRL2_HUMAN

Heterogeneous nuclear ribonucleoprotein Ulike protein 2

85,087

238

sGDETPGSEVPGDKAAEEQGDDQDSEK
H1X_HUMAN

Histone H1x

Histone-binding protein RBBP7

Homeobox protein cut-like 1

Homeobox protein Hox-A3

Homeobox protein Hox-B3

Hsp90 co-chaperone Cdc37

Ig lambda chain V region 4A

Immunoglobulin superfamily member 10

Integrator complex subunit 3

Intracellular hyaluronan-binding protein 4

Kelch domain-containing protein 10

Keratin, type II cytoskeletal 1

Keratin, type II cytoskeletal 2 epidermal

Keratin, type II cytoskeletal 6A

Krueppel-like factor 3

Lamin-A/C

La-related protein 1

Large proline-rich protein BAT2

49/49

92,16

ETD

1

79

45/48

100

CID

1

79

45/47

43

CID

1

85

37/46

73

CID

2

95

44/45

38

CID

1

81

49/49

70,82,70,93

ETD

1

85

49/49

25

ETD

1

89

50/48

99

ETD

1

95

63/48

44

ETD

1

95

47/49

20

ETD

1

82

46/48

96,100,100

ETD

1

95

55/49

62,26,25

ETD

1

81

48/48

34,38

ETD

3

95

88/48

100

both

4

95

48/46

82

CID

123,495

GLSAsLPDLDSENWIEVK
BAT2_HUMAN

81

74,123

SGAQASSTPLSPtRITR
LARP1_HUMAN

1

38,811

RASPGLSMPssSPPIK
LMNA_HUMAN

CID

60,028

sLyGLGGSKRISIGGGScAIsGGYGsR
KLF3_HUMAN

100

65,416

GGSIsGGGyGsGGGK
K2C6A_HUMAN

58/46

66,022

GGGGGGYGSGGSSYGSGGGsYGsGGGGGGGR
K22E_HUMAN

95

49,081

RGGGAAGAGGGGSGAGGGsGGSGGR
K2C1_HUMAN

4

45,767

GGRsPAGASGHRAGAGGR
KLD10_HUMAN

CID

118,056

GAAAAAAASGAAGGGGGGAGAGAPGGGRLLLSTsLDAK
HABP4_HUMAN

100

290,823

TSALMEAEVGKHTsstsKR
INT3_HUMAN

96/46

12,362

ALIYSTsNK
IGS10_HUMAN

95

44,450

vDYSVWDHIEVsDDEDETHPNIDTASLFR
LV001_HUMAN

6

44,323

ESRQTsK
CDC37_HUMAN

CID

46,351

vEmANLLNLtER
HXB3_HUMAN

100

164,172

TSAScSPAPESPMSSsEsVK
HXA3_HUMAN

51/46

47,802

asKEMFEDTVEER
CUX1_HUMAN

95

22,470

sVELEEALPVTTAEGMAK
RBBP7_HUMAN

1

228,848

239

GGGtGGPNHPPAPRGR
LSG1_HUMAN

1

92

53/48

100

ETD

1

81

51/48

100,100,100

ETD

1

91

37/45

93,91,84,83

CID

1

80

47/48

50

ETD

2

95

98/49

100

ETD

1

86

68/49

63,53,79,66

ETD

2

93

54/47

100

ETD

2

95

54/46

100

CID

1

83

81/49

34,34,21

ETD

9

95

78/46

100

CID

1

95

62/46

99

CID

DMEsPTKLDVTLAK

5

95

100/48

96

both

DMSPLSETEMALGKDVtPPPETEVVLIK

1

95

43/46

93

CID

1

79

45/47

97

CID

1

90

55/49

13

ETD

1

82

46/49

70,66,41

ETD

1

79

45/47

50

CID

1

91

57/49

90

ETD

Large subunit GTPase 1 homolog

75,208

yILKDyVsGK
LMBL3_HUMAN

Lethal(3)malignant brain tumor-like protein 3

88,319

MtESASstSGQEFDVFSVmDWKDGVGtLPGSDLK

LRFN2_HUMAN

Leucine-rich repeat and fibronectin type-III
domain-containing protein 2

84,715

NELLDFtASLAR
LA_HUMAN

Lupus La protein

46,821

FAsDDEHDEHDENGATGPVKR
KDM2B_HUMAN

Lysine-specific demethylase 2B

152,599

ESDHSRsssPtAGPSTEGAEGPEEK
KDM3B_HUMAN

Lysine-specific demethylase 3B

191,594

GGNAsGEPGLDQR

MISSL_HUMAN

MAPK-interacting and spindle-stabilizing
protein-like

24,251

sDEFSLADALPEHsPAK

MED1_HUMAN

Mediator of RNA polymerase II transcription
subunit 1

168,464

LAsPmKPVPGtPPSSKAKSPISSGSGGSHmSGTSSSsGMK
ICLN_HUMAN

Methylosome subunit pICln

26,197

FEEESKEPVADEEEEDsDDDVEPITEFR
MFAP1_HUMAN

Microfibrillar-associated protein 1

51,941

SLAALDALNtDDENDEEEYEAWKVR
MAP4_HUMAN

MTUS2_HUMAN

Microtubule-associated protein 4

Microtubule-associated tumor suppressor
candidate 2

120,988

150,178

IDQNtVVTR
MUC16_HUMAN

Mucin-16

2,353,421

IEmEStFSVAHGLKGTSTSQDPIVSTEK
MBNL1_HUMAN

Muscleblind-like protein 1

41,799

AAQYQVNQAAAAQAAATAAAMtQsAVKsLK
MEF2A_HUMAN

Myocyte-specific enhancer factor 2A

54,794

NRQVTFtK
NAT10_HUMAN

N-acetyltransferase 10

115,690

aIEEQmVAAKDVVMEPTMKTLsDDLDEAAK
SIRT1_HUMAN

NAD-dependent deacetylase sirtuin-1

81,665

240

aDEAALALQPGGsPSAAGADR

NACA_HUMAN

1

95

66/46

99

CID

4

95

96/45

98

CID

1

95

56/47

16

ETD

1

90

51/48

100,100,99,
99

ETD

GGVTGsPEASISGSKGDLK

2

90

52/48

86

ETD

GKGGVTGsPEASISGSKGDLK

2

95

59/48

38

ETD

LKsEDGVEGDLGETQSR

2

95

62/48

100

ETD

DIDISsPEFK

1

95

37/46

100

CID

GKGGVTGSPEAsISGSKGDLK

1

83

36/46

24

CID

AAPEAsSPPASPLQHLLPGK

1

85

48/48

29

ETD

AKQVVSVVQDEEVGLPFEASPEsPPPASPDGVTEIR

1

88

37/45

21

ETD

1

82

47/48

79

ETD

3

95

49/46

100

CID

KEDsDEEEDDDsEEDEEDDEDEDEDEDEIEPAAmK

7

95

96/48

100,100

CID

AAAAAPAsEDEDDEDDEDDEDDDDDEEDDsEEEAMETTPAK

1

95

76/45

100,100

CID

AIRLELQGPRGsPNAR

4

95

85/48

100

ETD

LELQGPRGsPNAR

3

95

78/45

100

ETD

9

95

61/46

100

CID

6

95

72/46

100

CID

1

95

43/46

53

CID

1

95

56/49

46,46,31,82

ETD

1

82

51/47

99

ETD

1

83

46/47

85,81

ETD

Nascent polypeptide-associated complex
subunit alpha

23,365

VQGEAVSNIQENTQTPTVQEEsEEEEVDETGVEVK
NEO1_HUMAN

Neogenin

159,999

sGSAPQSPGAsIR
CHL1_HUMAN

Neural cell adhesion molecule L1-like protein

135,042

LtVNssNsIK

AHNK_HUMAN

NIBL1_HUMAN

NCOA1_HUMAN

Neuroblast differentiation-associated protein
AHNAK

Niban-like protein 1

Nuclear receptor coactivator 1

629,086

82,666

156,739

VNPsVNPSISPAHGVAR

NUCKS_HUMAN

Nuclear ubiquitous casein and cyclindependent kinases substrate

27,279

EMLMEDVGsEEEQEEEDEAPFQEK
NUCL_HUMAN

NPM_HUMAN

Nucleolin

Nucleophosmin

76,598

32,557

cGSGPVHISGQHLVAVEEDAEsEDEEEEDVK
NPM3_HUMAN

Nucleoplasmin-3

19,325

aAGTAAALAFLsQESR
NP1L4_HUMAN

Nucleosome assembly protein 1-like 4

42,806

EFITGDVEPTDAESEWHsENEEEEK
OSB10_HUMAN

Oxysterol-binding protein-related protein 10

83,953

GVSSRSAAAGLGGGGSRssPGsVAAsPSGGGGR
OSBL8_HUMAN

Oxysterol-binding protein-related protein 8

101,181

tPMVSVPKmK
PHAR3_HUMAN

Phosphatase and actin regulator 3
tSsVERGKER

62,536
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PAIRB_HUMAN

DDX46_HUMAN

Plasminogen activator inhibitor 1 RNA-binding
protein

44,948

TDKSSAsAPDVDDPEAFPALA

3

95

53/46

100

CID

SSAsAPDVDDPEAFPALA

1

82

32/46

76

CID

1

79

35/46

100

ETD

1

93

54/47

14

ETD

8

95

86/49

100

both

6

95

78/46

100

CID

EEsEEEEDEDDEEEEEEEKEK

2

95

43/46

100

CID

sAsAPAAEGEGTPTQPASEKEPEMPGPR

1

79

36/46

43

CID

8

95

79/46

100

CID

1

84

50/49

18

ETD

1

80

46/48

77

ETD

1

95

44/49

100,99,99,99

ETD

1

81

46/48

100,27,66

ETD

1

90

51/49

73,58

ETD

1

80

44/47

99

ETD

1

89

35/45

100

CID

2

95

46/46

100

CID

2

95

101/49

100

ETD

1

91

52/48

54

ETD

Probable ATP-dependent RNA helicase DDX46

117,348

AALGLQDsDDEDAAVDIDEQIESMFNSK

SYTC2_HUMAN

Probable threonyl-tRNA synthetase 2,
cytoplasmic

92,631

NELSGTLsGLTR
PA2G4_HUMAN

Proliferation-associated protein 2G4

43,769

sGEDEQQEQTIAEDLVVTK
TEBP_HUMAN

Prostaglandin E synthase 3

18,680

DWEDDsDEDMSNFDR
DEK_HUMAN

PDIA6_HUMAN

Protein DEK

Protein disulfide-isomerase A6

42,658

48,104

DGELPVEDDIDLsDVELDDLGKDEL
DOP1_HUMAN

Protein dopey-1

277,342

MTIAASAsLTTINLGATKNLR
DPY30_HUMAN

Protein dpy-30 homolog

11,232

iVENEKINAEKsSK
MUTED_HUMAN

Protein Muted homolog

21,592

MsGGGtEtPVGcEAAPGGGsKKR
PP14C_HUMAN

Protein phosphatase 1 regulatory subunit 14C

17,825

MsVAtGsSETAGGASGGGAR
PP1R7_HUMAN

Protein phosphatase 1 regulatory subunit 7

41,548

IRAIENIDtLTNLEsLFLGKNK
SHSA7_HUMAN

Protein shisa-7

56,197

sPALPPDPtAR
SYS1_HUMAN

Protein SYS1 homolog

17,598

EIPLNsAPK
PTMA_HUMAN

Prothymosin alpha

12,185

sDAAVDTSSEITTK
HS902_HUMAN

Putative heat shock protein HSP 90-alpha A2

39,348

ESKDKPEIEDVGsDEEEEKK

PSG7_HUMAN

Putative pregnancy-specific beta-1glycoprotein 7
ENKDVSTFtcEPK

46,984
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RBM15_HUMAN

Putative RNA-binding protein 15

107,175

GGEDSTsR
RB15B_HUMAN

1

79

45/46

33

CID

1

85

50/48

100,100,100

ETD

1

95

61/49

23

ETD

1

79

45/48

26

CID

SSsPAPADIAQTVQEDLR

18

95

113/48

96

both

YQDEVFGGFVTEPQEEsEEEVEEPEER

6

95

84/48

100

both

1

81

47/48

34

ETD

1

88

50/48

74,71,82

ETD

6

95

81/46

100

CID

1

95

55/49

37

ETD

1

95

43/46

23

CID

1

82

32/45

100

CID

3

95

63/49

100

both

KETEsEAEDNLDDLEK

3

95

68/48

100

ETD

EKtPELPEPSVK

3

95

57/46

100

both

MALPPQEDATAsPPRQK

1

79

45/48

96

CID

VKPEtPPRQSHSGSIsPYPK

3

95

7049

99,64

ETD

SATRPsPsPERSSTGPEPPAPTPLLAER

2

95

60/46

99,98

CID

VSGRTsPPLLDR

1

86

48/47

100

ETD

1

95

57/49

37,37,49,97

ETD

1

86

36/46

33,41

CID

Putative RNA-binding protein 15B

97,190

GGKAsGDPGAsGmsPR

S22AX_HUMAN

Putative solute carrier family 22 member
ENSG00000182157

58,972

gPALLDAAIPRLGPTRAPAEALGVLsPSYLAPLTR
CE060_HUMAN

Putative uncharacterized protein C5orf60

39,233

GKASPTsFHVSPR

G3BP1_HUMAN

RL3R1_HUMAN

Ras GTPase-activating protein-binding protein
1

Relaxin-3 receptor 1

52,145

51,107

mQMADAATIAtmNKAAGGDK
RTN2_HUMAN

Reticulon-2

59,247

IPGTGALAsAAAAVsGsK
RTN4_HUMAN

Reticulon-4

129,917

mEDLDQSPLVSSSDsPPRPQPAFK
RTL1_HUMAN

Retrotransposon-like protein 1

155,161

kEPPSGPLQEMEELPtDLLQDmEEPSSGPR
RBM14_HUMAN

RNA-binding protein 14

69,474

sPPRASYVAPLTAQPATYR
SEPR_HUMAN

Seprase

87,697

TINIPyPK
SEPT2_HUMAN

Septin-2

41,470

IYHLPDAEsDEDEDFKEQTR
SRRM1_HUMAN

SRRM2_HUMAN

DCLK1_HUMAN

Serine/arginine repetitive matrix protein 1

Serine/arginine repetitive matrix protein 2

Serine/threonine-protein kinase DCLK1

102,319

299,604

82,208

KHFNtGPKPNStAAGVsVIAtTALDK
ICK_HUMAN

Serine/threonine-protein kinase ICK
SSGtMSVIsK

71,412
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OXSR1_HUMAN

Serine/threonine-protein kinase OSR1

58,005

LHKTEDGGWEWsDDEFDEESEEGK
TAOK2_HUMAN

Serine/threonine-protein kinase TAO2

Serologically defined colon cancer antigen 1

Small acidic protein

Small subunit processome component 20
homolog

Sodium- and chloride-dependent creatine
transporter 1

Spindle and kinetochore-associated protein 3

Splicing factor 3A subunit 1

Splicing factor, arginine/serine-rich 19

Stathmin

STIP1 homology and U box-containing protein
1

Striated muscle preferentially expressed
protein kinase

Structural maintenance of chromosomes
protein 4

SUN domain-containing protein 2

SMCE1_HUMAN

Tau-tubulin kinase 2

TFIIH basal transcription factor complex
helicase subunit

15

95

117/46

58

CID

1

95

40/46

71

CID

1

87

49/48

73

ETD

1

92

53/47

91

ETD

1

95

48/46

100

CID

1

84

46/47

17

ETD

1

95

68/46

100

CID

1

94

59/48

92

ETD

1

88

49/48

88

ETD

7

95

77/46

47

both

1

81

50/49

100,100

ETD

1

95

52/49

64

ETD

1

95

56/49

100,35

ETD

137,397

fLEtcLEKMQKDTsAGK

ERCC2_HUMAN

ETD

46,632

eAAEQAERSQSsIVPEEEQAANK
TTBK2_HUMAN

29,71

80,294

VDQMEGGAAGPsAsVR
SWI/SNF-related matrix-associated actindependent regulator of chromatin subfamily E
member 1

51/48

147,170

TEsPATAAETASEELDNR
SUN2_HUMAN

91

354,268

DmGALTctARNR

SMC4_HUMAN

1

34,839

LGAGGGsPEKSPSAQELK

SPEG_HUMAN

CID

17,285

ASGQAFELILsPR

STUB1_HUMAN

100

139,255

RRSGAASSSSsSR
STMN1_HUMAN

49/46

88,868

FGESEEVEMEVEsDEEDDKQEK
SFR19_HUMAN

95

46,343

yNSNLATPIAIK
SF3A1_HUMAN

1

70,506

sAENGIYSVSGDEKK
SKA3_HUMAN

CID

318,378

aAPPTAGsmAIEK

SC6A8_HUMAN

100

20,315

SAsPDDDLGSSNWEAADLGNEER

UTP20_HUMAN

38/46

122,940

lASKEEsSNSSDsK
SMAP_HUMAN

90

138,237

MLLARHsLDQDLLR
SDCG1_HUMAN

1

86,894
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GFtIIIEPFDDR
SMCA4_HUMAN

1

87

49/48

100

ETD

1

79

45/48

25,25

CID

1

83

82/49

19

ETD

aASAAAASAAAASAASGsPGPGEGSAGGEKR

22

95

146/46

98

both

FSAVLVEPPPMSLPGAGLSsQELSGGPGDGP

2

95

51/46

32

CID

1

87

49/48

14

ETD

1

87

37/46

93

CID

1

91

52/48

96

ETD

1

89

52/48

91

ETD

1

84

48/48

50,59

ETD

1

79

45/47

100,100

CID

1

95

66/46

99,99

CID

DYEEVGVDsVEGEGEEEGEEY

2

95

83/46

100

CID

TIGGGDDsFNTFFSETGAGK

1

95

41/46

99

CID

TIGGGDDsFNTFFSETGAGKHVPR

1

95

55/46

66

CID

1

93

53/48

74

ETD

2

95

65/46

100

CID

3

95

77/49

99

ETD

1

81

46/48

66,46

ETD

1

91

34/46

100 100

CID

Transcription activator BRG1

184,632

DSDAGssTPTTSTR
SOX11_HUMAN

Transcription factor SOX-11

46,663

MDPSAKPSASQsPEKSAAGGGGGSAGGGAGGAK
TIF1B_HUMAN

P66A_HUMAN

Transcription intermediary factor 1-beta

Transcriptional repressor p66-alpha

88,531

68,045

TVSAGKGSATsNWKK
TYY1_HUMAN

Transcriptional repressor protein YY1

44,694

DIDHETVVEEQIIGENsPPDYSEYMTGK
TLE3_HUMAN

Transducin-like enhancer protein 3

83,399

VSPAHsPPENGLDK

TMCO7_HUMAN

Transmembrane and coiled-coil domaincontaining protein 7

120,731

AARQAVGsGAQETcGLDR

TMCC1_HUMAN

Transmembrane and coiled-coil domains
protein 1

72,035

SGQEMtAVMQsGRPR
TRIO_HUMAN

Triple functional domain protein

346,885

lssGKADGHVK
NSUN2_HUMAN

tRNA (cytosine-5-)-methyltransferase NSUN2

86,455

AGEPNsPDAEEANsPDVTAGcDPAGVHPPR
TBA1B_HUMAN

PTN18_HUMAN

Tubulin alpha-1B chain

Tyrosine-protein phosphatase non-receptor
type 18

50,134

50,465

TLSAsAAEVAPR

U520_HUMAN

U5 small nuclear ribonucleoprotein 200 kDa
helicase

244,496

EEAsDDDMEGDEAVVR
UBP2L_HUMAN

Ubiquitin-associated protein 2-like

114,516

RYPSSISSsPQKDLTQAK
CF174_HUMAN

Uncharacterized protein C6orf174

103,184

NSGSGVAGGGSGGGGsyWK
K0753_HUMAN

Uncharacterized protein KIAA0753
LsyAVHLAR

109,390
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AQRVNsTTEANIHLKDGssVNtAK
CF035_HUMAN

1

95

51/49

87,40,40,55

ETD

1

84

50/49

15

ETD

1

95

69/49

28,28

ETD

1

95

58/48

100

ETD

1

95

49/46

100

CID

1

89

50/48

21

ETD

2

84

33/45

22

CID

1

81

47/49

65,65,54

ETD

1

91

51/48

14

ETD

EEsDGEYDEFGR

1

95

42/46

100

CID

EVEDKEsEGEEEDEDEDLSK

1

95

41/46

100

CID

UPF0463 transmembrane protein C6orf35

14,741

GGIFLGTVAAAGmLAGFITTLsLAKKK
CB029_HUMAN

UPF0760 protein C2orf29

55,200

GGAsGPGSGSGGPGGPAGRmsLTPK
YRDC_HUMAN

YrdC domain-containing protein, mitochondrial

29,310

LFRPPsPAPAAPGAR

ZC3HF_HUMAN

Zinc finger CCCH domain-containing protein
15

48,586

DVDETGITVAsLER

Z512B_HUMAN

Zinc finger protein 512B

97,246

LPGSSKsGPGKDGSR
Z804A_HUMAN

Zinc finger protein 804A

136,872

StTVTVR

ZKSC2_HUMAN

Zinc finger protein with KRAB and SCAN
domains 2

110,922

KENVGNVVSLGSAVStsNKItR
ZXDC_HUMAN

Zinc finger protein ZXDC

89,970

GAGSNAGASQStQR

ZRAB2_HUMAN

Zinc finger Ran-binding domain-containing
protein 2

Total phosphoproteins
Spectral count
Number of different phosphopeptides
Number of multiply phosphorylated peptides
Number of singly phosphorylated peptides
Number of each phosphorylated amino acid observed
Number of unique phosphorylated amino acids
a

37,387

188
490
220
72
418
521(pS), 68(pT), 9(pY)
309

Peptides identified by MS were searched for serine, threonine, or tyrosine residues containing a
+80 m/z modification, which is consistent with the presence of a phosphate group. 50% protein
and 79% peptides cutoffs were used to generate the Scaffold coverage which scored above 1.3%
FDR threshold. b SC=Spectral Count. c PP= Peptide probability (written as percentage). d IS= Ion
Score. e IDS= Identity Score. f LP= Localization Probability (written as a percentage, multiple
numbers corresponding to the value of each site). g IM= Ionization Method. CID=Collision
Induced Dissociation, ETD= Electron Transfer Disscociation, both=CID and ETD.
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Gel image for Avidin Purification with Casein Model Study
A
B

Figure A 4.7: ATP-biotin reaction. Β-casein (lane 1) were biotinylated with CK2 and ATPbiotin (lane 2), load onto an avidin column (lane 3), washed (lane 4 and 5) and eluted with acid
(lane 6). All proteins were visualized with sypro ruby stain (top) and anti-biotin (bottom). Two
trials are shown here.
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Table A 4.7: Phosphopeptides identified by MS analysis after kinase-catylzed biotinylation of
casein and subsequent purification of the full-length proteins using NeutrAvidin affinity
chromatography and acidic elutiona
Accession
number

Proteins/peptides name

gi|30794348

casein alpha s1

gi|27806963

gi|30794310

SPb

PPc

ISd/IDSe

LPf

IMg

VPQLEIVPNsAEER

8

95

58/46

100

CID

YKVPQLEIVPNsAEER

11

95

69/46

100

CID

NmAINPsKENLcSTFcK

9

95

67/46

100

CID

TVDmEsTEVFTK

5

95

54/46

99

CID

FQsEEQQQTEDELQDK

11

95

88/46

100

CID

FQsEEQQQtEDELQDK

9

95

53/46

100,100

CID

IEKFQsEEQQQTEDELQDK

8

95

65/46

100

CID

IEKFQsEEQQQtEDELQDK

8

95

55/46

100,100

CID

casein alpha-S2

casein beta

MW (Da)

24,500

26,000

25,000

Total phosphoproteins
Total phosphopeptides
Number of different phosphopeptides
Number of multiply phosphorylated peptides
Number of singly phosphorylated peptides
Number of each phosphorylated amino acid
observed
Number of unique phosphorylated amino acids
a

3
69
6
17
52
69(pS),17(pT)
5

The full length proteins isolated after affinity chromatography were digested with trypsin prior
to MS analysis. Peptides identified by MS were searched for serine, threonine, or tyrosine
residues containing a +80 m/z modification, which is consistent with the presence of a phosphate
group. 99% protein and 90% peptides cutoffs were used to generate the Scaffold coverage which
scored above 0.6% FDR threshold. b SC=Spectral Count. c PP= Peptide probability (written as
percentage). d IS= Ion Score. e IDS= Identity Score. f LP= Localization Probability (written as a
percentage). g IM= Ionization Method.

248

Gel image for Avidin Purification with HeLa Cell Lysates
A

B

C

Figure A 4.8: ATP-biotin reaction. HeLa cell lysates (lane 1) were biotinylated with ATP-biotin
(lane 2), load onto an avidin column (lane 3), washed (lane 4 and 5) and eluted with acid (lane
6). All proteins were visualized with sypro ruby stain (top) and anti-biotin (bottom). All the three
trials are shown here.
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Table A 4.8: Phosphopeptides identified by MS analysis after kinase-cataylzed biotinylation of
HeLa cell lysates and subsequent purification of the full length proteins using NeutrAvidin
affinity chromatography and acidic elutiona
Accession
numbers

Proteins/peptides name

RS3_HUMAN

40S ribosomal protein S3

MW
(Da)

60S ribosomal protein L12

60S ribosomal protein L14

60S ribosomal protein L18

6-phosphofructo-2-kinase/fructose-2,6biphosphatase 3

6-phosphogluconate dehydrogenase,
decarboxylating

Acetyl-CoA carboxylase 2

Actin-related protein 2/3 complex subunit 5

Alpha-enolase

AN13A_HUMAN

Alstrom syndrome protein 1
SSLDFQVVQPSLPDSNTITQDL
KTIPSQNSQIVtsR
Ankyrin repeat domain-containing protein
13A

AP-1 complex subunit beta-1

Apolipoprotein C-III

Arrestin domain-containing protein 1

Baculoviral IAP repeat-containing protein 6

Band 4.1-like protein 1

CID

1

82

34/43

100,100

CID

1

82

34/43

98,14

CID

1

95

44/43

100

CID

4

95

46/43

59

CID

1

65

30/43

92,100,100

CID

1

82

36/43

96

CID

56

95

43/43

100,100

CID

1

93

38/42

18,18

CID

1

87

36/43

51,51,51

CID

1

54

17/43

100

CID

1

71

31/43

98,79,86

CID

1

90

37/43

100

CID

1

95

41/42

100

CID

45,963

530,237

VALGAsRK
E41L1_HUMAN

100

10,834

VtcIGScGVSNK
BIRC6_HUMAN

52/43

104,621

AsEAEDAsLLsFmQGYMK
ARRD1_HUMAN

95

67,602

AAMIWIVGEyAER
APOC3_HUMAN

11

460,940

QGWTVLHEAVstGDPEMVYtVLQHR
AP1B1_HUMAN

CID

47,152

AGytDKVVIGMDVAASEFFR
ALMS1_HUMAN

100,99

16,303

ALAAGGVGSIVRVLtAR
ENOA_HUMAN

39/43

276,526

GSGmIAGESSLAyEEIVTIsLVtcR
ARPC5_HUMAN

93

53,124

ALYAsKIISYAQGFmLLR
ACACB_HUMAN

1

59,592

IGGDSGLSsR

6PGD_HUMAN

IMg

21,617

tNRPPLsLSRMIR

F263_HUMAN

LPf

23,414

APGtKGtAAAAAAAAAAK
RL18_HUMAN

ISd/IDSe

17,801

VVyLRcTGGEVGATSALAPK
RL14_HUMAN

PPc

26,671

ELAEDGYSGVEVRVtPtR
RL12_HUMAN

SCb

98,487

250

mTtETGPDSEVKK
E41L3_HUMAN

Band 4.1-like protein 3

Beta-actin-like protein 2

Calcium-activated potassium channel
subunit alpha-1

Calponin-1

Carbamoyl-phosphate synthase
[ammonia], mitochondrial

Chromobox protein homolog 3

Cofilin-2

Collagen alpha-1(XII) chain

Creatine kinase B-type

C-type lectin domain family 5 member A

Cyclin-D1-binding protein 1

Cytoplasmic dynein 1 heavy chain 1

D-3-phosphoglycerate dehydrogenase

DNA-directed RNA polymerase I subunit
RPA2

Dolichyl pyrophosphate Man9GlcNAc2
alpha-1,3-glucosyltransferase

DPY30 domain-containing protein 2

E3 ubiquitin-protein ligase MARCH7
sNFSSRESEssR

92

38/43

90

CID

1

92

40/43

100,85

CID

4

95

41/43

99,100,100

CID

1

55

28/43

33

CID

7

95

46/43

36

CID

1

95

41/43

29

CID

1

95

40/43

100,100

CID

1

85

36/43

100,100,100

CID

1

93

38/43

47

CID

2

90

38/43

45

CID

2

55

28/43

100

CID

1

95

45/43

11,98

CID

1

86

35/43

67,67,67,67

CID

2

95

45/43

100

CID

1

58

17/43

97,51,51

CID

20,569

EMEmtEMLK
MARH7_HUMAN

2

58,166

IIQYLFLIsVItmVLLTLmtVtLDPPQK
DYDC2_HUMAN

CID

128,215

ISFtILDAVISPPtVPK

ALG6_HUMAN

92,99

56,633

ILQDGGLQVVEKQNLsK

RPA2_HUMAN

42/43

532,388

LVEAISRDLSsQLLK
SERA_HUMAN

95

40,244

LNEAAVTVSREATtLTIVFSQLPLPSPQETQK
DYHC1_HUMAN

10

21,504

GKGstLAIVNtPEK
CCDB1_HUMAN

CID

42,627

LAVEALSSLDGDLAGRyyALK
CLC5A_HUMAN

21,58

333,127

GmTsSEPISImEK
KCRB_HUMAN

40/43

18,719

StLGEKLGGNVVVSLEGKPL
COCA1_HUMAN

94

20,794

GLDPERIIGATDSsGELMFLmK
COF2_HUMAN

1

164,925

EyGVKVLGtsVESImATEDR
CBX3_HUMAN

CID

33,153

GAsQAGmTAPGtK

CPSM_HUMAN

25

137,546

mANGGGGGGGSsGGGGGGGGSSLR
CNN1_HUMAN

40/43

41,986

TTGIVmDSGDGVtHIVPIyEGYALPHAILR

KCMA1_HUMAN

93

120,662

yTMSRSLDGEVGTGQyATTK
ACTBL_HUMAN

1

78,035

251

EF2_HUMAN

Elongation factor 2

95,322

cLyAsVLTAQPR
IF4A1_HUMAN

Eukaryotic initiation factor 4A-I

Eukaryotic translation elongation factor 1
epsilon-1

Eukaryotic translation initiation factor 3
subunit A

Eukaryotic translation initiation factor 4B

Exportin-7

Filamin-A

Fructose-bisphosphate aldolase C

Gamma-synuclein

Glucosamine-6-phosphate isomerase 1

Glucose-6-phosphate isomerase

Glyceraldehyde-3-phosphate
dehydrogenase

H(+)/Cl(-) exchange transporter 7

Heat shock cognate 71 kDa protein

High mobility group protein B3

Hydroxysteroid dehydrogenase-like protein
2

Integrator complex subunit 9

1

89

36/43

71,71,71,97

CID

28/43

80,80,80,80

CID

55

1

55

28/43

99,61,61

CID

1

72

31/43

100,100,100

CID

1

62

31/43

21

CID

1

60

30/43

52

CID

1

58

29/43

30

CID

1

58

29/43

13

CID

5

95

44/43

98

CID

1

88

35/42

86,86

CID

4

95

42/43

100,100,100

CID

5

78

33/42

49

CID

1

82

34/43

63,86

CID

1

90

38/42

29,29

CID

22,963

45,379

tAQPHPKLLGtIYTAAEEIEAVGGK
INT9_HUMAN

CID

70,882

IKsTNPGISIGDVAK

HSDL2_HUMAN

65

88,663

VssKNsLESYAFNmK
HMGB3_HUMAN

40/43

36,035

FDSEKMAYTIHEIPVFIAmGVVGGVLGAVFNALNyWLtMFR
HSP7C_HUMAN

90

63,130

LtGMAFRVPTANVSVVDLTcR
CLCN7_HUMAN

6

32,651

TITDVINIGIGGSDLGPLMVTEALKPySSGGPR

G3P_HUMAN

CID

13,312

VPtMALTVGVGTVmDAR
G6PI_HUMAN

24

39,438

EQANAVSEAVVsSVNTVATK
GNPI1_HUMAN

37/43

280,711

VLAAVYKALSDHHVYLEGTLLKPNmVtPGHAcPIK
SYUG_HUMAN

88

123,895

sQGDAsKVtAQGPGLEPSGNIANK
ALDOC_HUMAN

3

1

AtEPHmLETytPEVTK
FLNA_HUMAN

CID

69,136

GFGyAEFEDLDSLLsALsLNEEsLGNR
XPO7_HUMAN

100,100

166,557

mstRVLLAtLsIPITPER
IF4B_HUMAN

31/43

19,793

aAAAELSLLEKsLGLSK

EIF3A_HUMAN

71

46,137

SGSsRVLITTDLLAR

MCA3_HUMAN

1

73,798

FGDVVHFmELWGKSSLNTVIFTEPDFsyLEALAPYQPLAMK

252

K1C16_HUMAN

Keratin, type I cytoskeletal 16

51,251

ISSVLAGGscR
K2C1_HUMAN

Keratin, type II cytoskeletal 1

Keratin, type II cytoskeletal 2 epidermal

Keratin, type II cytoskeletal 7

Keratin, type II cytoskeletal 8

Large proline-rich protein BAG6

Leucine-rich repeat-containing protein 59

Lipase member M

Mucin-16

Nucleophosmin

Nucleoside diphosphate kinase B

Olfactory receptor 2A5

PACRG-like protein

PDZ domain-containing protein 2

Peptidylprolyl cis-trans isomerase A-like
4G

Peroxiredoxin-2

Peroxiredoxin-5, mitochondrial

Phosducin-like protein

95

44/43

22,74

CID

4

81

33/43

100

CID

1

91

36/43

100

CID

1

95

39/42

100

CID

4

95

41/42

100

CID

2

91

37/43

23,23

CID

6

95

45/43

100,100,100

CID

12

95

52/43

82

CID

1

93

41/43

29,29

CID

1

95

54/43

100,100,100

CID

1

87

36/43

93,98,18

CID

2

95

48/43

78

CID

4

89

38/43

100,100

CID

1

92

38/43

94

CID

22,068

ETDLLLDDsLVSIFGNR
PHLP_HUMAN

2

21,874

LsEDyGVLKTDEGIAYR
PRDX5_HUMAN

CID

18,148

HTGSGILsMANAGPNTNGSQFFIcTAK
PRDX2_HUMAN

80,93,100

301,623

AEYsQGKsSLMSDsR

PAL4G_HUMAN

30/43

27,135

MQKsEGsGGtQLK
PDZD2_HUMAN

62

35,191

AFSTcSsHLcmVGLFFGSAIVMymAPKSR
PACRL_HUMAN

2

17,280

YmNsGPVVAmVWEGLNVVK
OR2A5_HUMAN

CID

32,557

VTLATLKmsVQPtVsLGGFEITPPVVLR
NDKB_HUMAN

100,100

2,353,421

SQSSVLADSsPMcttsTmGDTSVLTSTPAFLETR
NPM_HUMAN

29/43

48,216

EFLyQTR
MUC16_HUMAN

61

34,913

AGsKGGNLR
LIPM_HUMAN

1

119,389

LINLVGEsLR
LRC59_HUMAN

CID

53,688

sLDmDSIIAEVK
BAG6_HUMAN

100

51,369

TLNETELtELQsQISDTSVVLSmDNSR
K2C8_HUMAN

29/43

65,416

yGSGGGSKGGSISGGGyGsGGGK
K2C7_HUMAN

55

66,022

GGSGGGGGGssGGR
K22E_HUMAN

1

34,264

253

ttLDDKLLGEK

P3C2G_HUMAN

1

95

38/43

100,100

CID

1

93

39/43

54

CID

1

95

41/43

100,100

CID

AESSDKLyR

1

62

29/43

100,100

CID

LTVNPGtK

1

61

33/43

100

CID

1

87

37/43

100,98,85

CID

13

95

47/43

54

CID

1

90

37/43

46

CID

2

95

38/43

100,100

CID

NStKQEILAALEK

2

75

33/43

51

CID

HEVPAKsDVycEVcEFLVK

1

95

42/43

100,100

CID

1

95

42/42

20

CID

1

95

39/43

100,100

CID

1

95

46/43

100

CID

5

95

50/43

100

CID

1

62

30/43

57

CID

HSSGGGGGGAGGGGGSmGGGGSGFIsGRR

4

76

32/43

55

CID

TSRHssGGGGGGAGGGGGsmGGGGsGFISGR

3

87

36/43

87,87,95,41

CID

1

95

56/43

100

CID

Phosphatidylinositol-4-phosphate 3-kinase
C2 domain-containing subunit gamma

165,701

SKtVFVGAINIR

PKHO2_HUMAN

Pleckstrin homology domain-containing
family O member 2

53,332

EVAsAAsDGLLR
PARP1_HUMAN

PK1L2_HUMAN

Poly [ADP-ribose] polymerase 1

Polycystic kidney disease protein 1-like 2

113,070

272,556

WLIsmAVsFVESmFVtQPLK
PFD2_HUMAN

Prefoldin subunit 2

16,630

SsGSGAGKGAVSAEQVIAGFNR
PR40A_HUMAN

Pre-mRNA-processing factor 40 homolog A

108,789

YsALAKLSEK

PRP16_HUMAN

Pre-mRNA-splicing factor ATP-dependent
RNA helicase PRP16

140,488

ymtDGILLR
SAP_HUMAN

NSD2_HUMAN

Proactivator polypeptide

Probable histone-lysine Nmethyltransferase NSD2

58,094

152,241

TTVsMPR

AT8B2_HUMAN

Probable phospholipid-transporting
ATPase ID

137,426

LNLKPDLsDtVR

PDC6I_HUMAN

Programmed cell death 6-interacting
protein

96,007

LALAsLGYEK
PDCD5_HUMAN

Programmed cell death protein 5

14,267

EAEmRNsILAQVLDQSAR
PSB1_HUMAN

Proteasome subunit beta type-1

26,473

AMtTGAIAAmLSTILYSR
AF17_HUMAN

PSYR_HUMAN

Protein AF-17

Psychosine receptor

112,059

39,317

yLAVVYPLK
MGAL1_HUMAN

Putative maltase-glucoamylase-like protein

73,914

254
FLJ16351
NMNNTGmFAHDEPPAyK
GDIB_HUMAN

Rab GDP dissociation inhibitor beta

Radixin

Ran-binding protein 3

Retinal-specific ATP-binding cassette
transporter

Retrotransposon gag domain-containing
protein 1

Ribose-phosphate pyrophosphokinase 2

Serine/arginine-rich splicing factor 2

Serpin A9

SH2B adapter protein 3

Small subunit processome component 20
homolog

Spermidine synthase

Stress-70 protein, mitochondrial

Superoxide dismutase [Mn], mitochondrial

Talin-1

T-complex protein 1 subunit alpha

T-complex protein 1 subunit beta

Thioredoxin

66

31/43

91,92,59

CID

1

95

48/43

100

CID

2

74

17/43

100,100,100

CID

1

95

53/43

94,83

CID

3

92

39/43

100

CID

1

85

35/43

32,93

CID

1

95

44/43

65

CID

1

84

34/43

17

CID

1

79

32/43

14

CID

1

63

29/43

49

CID

1

51

28/43

84

CID

1

73

17/43

25

CID

1

95

40/43

44

CID

1

85

35/43

94,15

CID

57,472

ILLSsGRDAsLMVTNDGATILK
THIO_HUMAN

1

60,327

sQmESmLISGYALNcVVGSQGmPKR
TCPB_HUMAN

CID

269,747

GISmSSsKLLLAAK
TCPA_HUMAN

54

24,705

yQEALAKGDVTAQIALQPALK
TLN1_HUMAN

51/43

73,663

EGSGSSGtGEQKEDQK
SODM_HUMAN

95

33,807

QNQDAFDVIITDSSDPMGPAESLFKEsYYQLmK
GRP75_HUMAN

5

318,378

DmSSIYsmYSTLLAHK
SPEE_HUMAN

CID

63,208

mNGPALQPSSPsSAPSASPAAAPR

UTP20_HUMAN

100

46,540

STPAsQVySLNTDFAFR
SH2B3_HUMAN

32/43

25,459

yGRVGDVYIPR
SPA9_HUMAN

71

34,752

LLsAGAtKVYAILTHGIFSGPAISR
SRSF2_HUMAN

1

144,263

APIsGAmsmPLtR
PRPS2_HUMAN

CID

255,933

tHPERIAGR

RGAG1_HUMAN

74

60,192

LNDMAstDDGTLQsR

ABCA4_HUMAN

39/43

68,548

mPKPINVRVTtMDAELEFAIQPNTTGK
RANB3_HUMAN

91

50,648

mLLYTEVtR
RADI_HUMAN

1

11,719

255

ELOC_HUMAN

QIEsKTAFQEALDAAGDK

7

95

61/43

73

CID

QIESKtAFQEALDAAGDK

8

95

56/43

77

CID

1

95

41/43

23

CID

6

95

44/43

92,90,90,70

CID

1

88

37/43

26,26

CID

1

95

40/43

100

CID

3

95

44/43

58

CID

1

75

31/43

42,48

CID

1

89

36/43

21

CID

2

67

30/43

100,100

CID

1

95

42/43

21,100

CID

5

95

43/43

82

CID

1

88

36/43

100,100

CID

1

93

38/43

25

CID

2

91

37/43

100

CID

1

91

37/43

100,100,100

CID

28

95

57/43

100

CID

1

50

27/43

87,87,89,69

CID

Transcription elongation factor B
polypeptide 1

12,455

EHALtSGTIKAmLSGPGQFAENETNEVNFR

TAF4B_HUMAN

Transcription initiation factor TFIID subunit
4B

91,072

DNLLASGTssLtAtK
TIF1A_HUMAN

Transcription intermediary factor 1-alpha

116,813

QLEHVMHFSKWAVSSGSSTALLysK
TIF1B_HUMAN

Transcription intermediary factor 1-beta

88,531

HQEHILRFAsWALESDNNTALLLSK
TFR1_HUMAN

Transferrin receptor protein 1

84,856

mmDQARsAFSNLFGGEPLSYTR
TKT_HUMAN

Transketolase

67,861

QAFtDVATGSLGQGLGAAcGmAYtGK
TM14C_HUMAN

Transmembrane protein 14C

11,547

NVWVFLATSGTLAGImGmRFYHsGK
TPD54_HUMAN

Tumor protein D54

22,220

LGLstLGELKQNLSR
UBN2_HUMAN

Ubinuclein-2

146,074

LTNSSsTGtVGK
UBP36_HUMAN

Ubiquitin carboxyl-terminal hydrolase 36

122,635

tGSSSLPGRPSVIPDHSKK
UBP42_HUMAN

Ubiquitin carboxyl-terminal hydrolase 42

145,211

ssNVLTLSLKR
CF062_HUMAN

Uncharacterized protein C6orf62

27,066

DSsYSLESSLELLQK
CI066_HUMAN

Uncharacterized protein C9orf66

31,167

sALETSAFPPSKPK

URB2_HUMAN

Unhealthy ribosome biogenesis protein 2
homolog

170,531

SLDsstPLPIVR
CA227_HUMAN

UPF0732 protein C1orf227

11,338

mAsINRTIEImK
WBP11_HUMAN

WW domain-binding protein 11

69,982

tsAyGPPTRAVsILPLLGHGVPR
ZNF90_HUMAN

Zinc finger protein 90

69,041

256

AFISSsLLYKHK

1

Total phosphoproteins
Total phosphopeptides
Number of different phosphopeptides
Number of multiply phosphorylated peptides
Number of singly phosphorylated peptides
Number of each phosphorylated amino acid observed
Number of unique phosphorylated amino acids

90

36/43

27

CID

118
341
126
131
182
223(S), 185(T), 109(Y)
237

a

The full length proteins isolated after affinity chromatography were digested with trypsin prior
to MS analysis. Peptides identified by MS were searched for serine, threonine, or tyrosine
residues containing a +80 m/z modification, which is consistent with the presence of a phosphate
group. 90% protein and 55% peptides cutoffs were used to generate the Scaffold coverage which
scored above 0.8% FDR threshold. b SC=Spectral Count. c PP= Peptide probability(written as
percentage). d IS= Ion Score. e IDS= Identity Score. f LP= Localization Probability (written as a
percentage, multiple numbers corresponding to the value of each site). g IM= Ionization Method.
CID=Collision Induced Dissociation, ETD= Electron Transfer Disscociation, both=CID and
ETD.
Gel image for ATP control reaction
A

B

Figure A 4.9: (A) Control experiment with ATP. Hela cell lysates (lane 1) were phosphorylated
with ATP, load onto an avidin column (lane 2), washed (lane 3, 4 and 5) and eluted with acid
(lane 6). All proteins were visualized with sypro ruby stain. (B) Quantification of elution lanes
(lane 6) of ATP reactions and ATP-biotin (images shown in Figure A 4.8, lane 6), showing that
13% protein signal was observed in the ATP control reaction compared to the ATP-biotin
reaction (Figure A 4.8, lane 6 set to 100%).
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Kinase-catalyzed protein phosphorylation is involved in a wide variety of cellular events.
Development of methods to identify phosphoproteins in normal and diseased states is critical to
fully characterize cell biology. Our lab recently discovered kinase-catalyzed biotinylation, where
ATP-biotin is utilized by kinases to label phosphopeptides or phosphoproteins with a biotin tag.
To explore kinase-catalyzed biotinylation, kinetic measurements were obtained with various
kinases and the data indicated that kinase-catalyzed biotinylation occurs with catalytic efficiency
appropriate for phosphoproteomics application. Next, the susceptibility of the biotin tag to
phosphatases was characterized and found that the phosphorylbiotin group was relatively
insensitive to protein phosphatases. Importantly, robust kinase-catalyzed biotinylation occurs
without the need for phosphatase inhibitor treatment. The results suggest that kinase-catalyzed
biotinylation is well suited for phosphoproteomics studies, with particular utility towards
monitoring low abundance phosphoproteins. Finally, we report application of kinase-catalyzed
biotinylation to the enrichment of the phosphopeptides in cell lysates for mass spectrometrybased phosphoproteomics analysis. Significantly, the biotinylation strategy was used to enrich
full-length phosphoprotein, which is challenging using metal ion purification. With the utility of
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ATP-biotin labeling for phosphoproteomics analysis established, kinase-catalyzed biotinylation
can be applied to characterizing and understanding of the role of phosphorylation in various
biological events.
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